```
=> d his

     (FILE 'HOME' ENTERED AT 15:27:13 ON 08 MAR 2006)

     FILE 'REGISTRY' ENTERED AT 15:28:34 ON 08 MAR 2006
L1            1 S PYRIDINE/CN
L2      1365174 S 46.156.30/RID

     FILE 'CAPLUS' ENTERED AT 15:31:09 ON 08 MAR 2006

     FILE 'REGISTRY' ENTERED AT 15:31:29 ON 08 MAR 2006
L3        19032 S L2 AND (4(W)AMINO)

     FILE 'CAPLUS' ENTERED AT 15:32:08 ON 08 MAR 2006
L4        24236 S L3
L5           92 S L4(L)SPIN?
L6            6 S L3(L)(NERV?(L)(INJUR? OR DAMAG?))

     FILE 'REGISTRY' ENTERED AT 15:36:05 ON 08 MAR 2006

=> s l2 and amino
       6021455 AMINO
L7      407740 L2 AND AMINO

=> s l2 and (amino(5a)(pyrid? or pyridin?))
       6021455 AMINO
       2249228 PYRID?
       1893814 PYRIDIN?
        394889 AMINO(5A)(PYRID? OR PYRIDIN?)
L8      297977 L2 AND (AMINO(5A)(PYRID? OR PYRIDIN?))

=> s l8 not l3
L9      283724 L8 NOT L3

=> fil caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    20.36      92.59

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -5.25

FILE 'CAPLUS' ENTERED AT 15:37:43 ON 08 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```


FILE COVERS 1907 - 8 Mar 2006 VOL 144 ISS 11
FILE LAST UPDATED: 7 Mar 2006 (20060307/ED)

They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> s l9
L10       99286 L9

=> s l9(l)(nerv?(l)(injur? or damag?))
          99286 L9
         393107 NERV?
         150728 INJUR?
         378616 DAMAG?
L11          21 L9(L)(NERV?(L)(INJUR? OR DAMAG?))
```

AN 2003:319714 CAPLUS
DN 138:338157
TI Preparation of 1,4-disubstituted benzo-fused ureas as cytokine inhibitors
IN Cirillo, Pier F.; Hammach, Abdelhakim; Regan, John R.
PA Boehringer Ingelheim Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 100 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003032989	A1	20030424	WO 2002-US32809	20021011
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2462441	AA	20030424	CA 2002-2462441	20021011
	US 2003162968	A1	20030828	US 2002-269173	20021011
	US 6825184	B2	20041130		
	EP 1438048	A1	20040721	EP 2002-801703	20021011
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005506350	T2	20050303	JP 2003-535792	20021011
PRAI	US 2001-330254P	P	20011018		
	WO 2002-US32809	W	20021011		

OS MARPAT 138:338157
IT **272-97-9**, 5-Azabenzimidazole
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 1,4-disubstituted benzo-fused ureas as cytokine inhibitors)
RN 272-97-9 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine (7CI, 8CI, 9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
      (FILE 'HOME' ENTERED AT 15:27:13 ON 08 MAR 2006)

      FILE 'REGISTRY' ENTERED AT 15:28:34 ON 08 MAR 2006
L1             1 S PYRIDINE/CN
L2       1365174 S 46.156.30/RID

      FILE 'CAPLUS' ENTERED AT 15:31:09 ON 08 MAR 2006

      FILE 'REGISTRY' ENTERED AT 15:31:29 ON 08 MAR 2006
L3         19032 S L2 AND (4(W)AMINO)

      FILE 'CAPLUS' ENTERED AT 15:32:08 ON 08 MAR 2006
L4         24236 S L3
L5            92 S L4(L)SPIN?
L6             6 S L3(L)(NERV?(L)(INJUR? OR DAMAG?))
```

L6 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:513486 CAPLUS
DN 141:47362
TI Pyridines for treating injured mammalian nerve tissue
IN Borgens, Richard B.; Shi, Riyi; Byrn, Stephen R.; Smith, Daniel T.
PA Purdue Research Foundation, USA
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004052291	A2	20040624	WO 2003-US38834	20031205
	WO 2004052291	A3	20041014		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2508165	AA	20040624	CA 2003-2508165	20031205
	US 2004171587	A1	20040902	US 2003-730495	20031205
	EP 1567497	A2	20050831	EP 2003-796756	20031205
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	US 2002-431637P	P	20021206		
	WO 2003-US38834	W	20031205		

OS MARPAT 141:47362
AB The invention provides novel pyridines, pharmaceutical compns. comprising such pyridines, and the use of such compns. in treating injured mammalian nerve tissue, including but not limited to an injured spinal cord in one embodiment, the compds., compns., and methods of the instant invention treat a mammalian nerve tissue injury by restoring action potential or nerve impulse conduction through a nerve tissue lesion. Significantly, in vivo application of compds. of the instant invention established, on the basis of SSEP testing, that the compds. provide longer lasting effects at lower concns. than comparable treatment with the known agent 4-aminopyridine (4 AP).
IT **504-24-5**, 4-Aminopyridine
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(pyridines for treating **injured** mammalian **nerve** tissue)
IT **504-24-5**, 4-Aminopyridine
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(pyridines for treating **injured** mammalian **nerve** tissue)
RN 504-24-5 CAPLUS
CN 4-Pyridinamine (9CI) (CA INDEX NAME)



L6 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:888576 CAPLUS
DN 137:363093
TI Method and compositions using biomembrane fusion agents for treating mammalian nerve tissue injuries
IN Shi, Riyi; Borgens, Richard B.
PA Purdue Research Foundation, USA
SO PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002092107	A1	20021121	WO 2002-US13375	20020424
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2445612	AA	20021121	CA 2002-2445612	20020424
	US 2003118545	A1	20030626	US 2002-132542	20020424
	NZ 529526	A	20031219	NZ 2002-529526	20020424
	EP 1389121	A1	20040218	EP 2002-741682	20020424
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004527573	T2	20040909	JP 2002-589024	20020424
	US 2005069520	A1	20050331	US 2004-901481	20040728
PRAI	US 2001-286200P	P	20010424		
	US 2002-132542	A3	20020424		
	WO 2002-US13375	W	20020424		

AB To achieve, an in vivo repair of injured mammalian nerve tissue, an effective amount of a biomembrane fusion agent is administered to the injured nerve tissue. The application of the biomembrane fusion agent may be performed by directly contacting the agent with the nerve tissue at the site of the injury. Alternatively, the biomembrane fusion agent is delivered to the site of the injury through the blood supply after administration of the biomembrane fusion agent to the patient. The administration is preferably by parenteral administration including intravascular, i.m., s.c., or i.p. injection of an effective quantity of the biomembrane fusion agent so that an effective amount is delivered to the site of the nerve tissue injury. Biomembrane fusion agents include e.g. hydrophilic polymers (e.g. polyethylene glycol) and surfactants.

IT **504-24-5**, 4-Aminopyridine 25322-68-3, Polyethylene glycol
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biomembrane fusion agents for treating mammalian **nerve** tissue **injuries**)

IT **504-24-5**, 4-Aminopyridine
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(biomembrane fusion agents for treating mammalian **nerve tissue injuries**)
RN 504-24-5 CAPLUS
CN 4-Pyridinamine (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:693264 CAPLUS
DN 135:257269
TI Preparation of N-heterocyclyl amide compounds as 5-HT antagonists
IN Yamada, Akira; Tomishima, Masaki; Hayashida, Hisashi; Imanishi, Masashi; Spears, Glen W.; Ito, Kiyotaka; Takahashi, Fumie; Miyake, Hiroshi
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 239 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001068585	A1	20010920	WO 2001-JP1993	20010313
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001041128	A5	20010924	AU 2001-41128	20010313
	EP 1264820	A1	20021211	EP 2001-912338	20010313
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2004087798	A1	20040506	US 2002-221554	20021227
PRAI	JP 2000-70127	A	20000314		
	JP 2000-305947	A	20001005		
	WO 2001-JP1993	W	20010313		

OS CASREACT 135:257269; MARPAT 135:257269
AB Amides compds. represented by the general formula R1-A-X-NHCO-Y-R2 [wherein R1 is an optionally substituted heterocyclic group or optionally substituted phenyl; R2 is optionally substituted fused Ph, optionally substituted Ph, or optionally substituted thienyl; A is a group represented by the formula -(CH2)t-(O)m- or -(CR3R4)pNR5(CO)n- (wherein R3 and R4 each is hydrogen or R3 and R4 in combination form imino; R5 is hydrogen or lower alkyl; t is 0, 1, or 2; and p, m, and n each is 0 or 1); X is optionally substituted phenylene or an optionally substituted, divalent, nitrogenous heterocyclic group; and Y is a bond, lower alkylene, or lower alkenylene] and salts thereof are prepared Theses amides include phenylacetamide, cinnamides, 1H-indole-7-carboxamides, 3-(2-pyridyl)-2-propenamides, 5-phenyl-2-thiophenecarboxamides, 9H-carbazolecarboxamides, 3-phenyl-2-propenamides, 9H-fluorene-1-carboxamides, 2,3-dihydrobenz[b]oxepine-4-carboxamides, 1H-benzo[b]thiepin-4-carboxamides, and 3-(1H-indol-3-yl)-2-propenamides.

They are antagonists of 5-hydroxytryptamine (5-HT), in particular 5-HT2c, and are useful for the treatment of 5-HT-mediated diseases such as (1) central nervous system disorders in including anxiety, depression, obsessive-compulsive neurosis, migraine headache, anorexia, Alzheimer's disease, sleep disorder, over-eating, and panic, (2) withdrawal symptom caused by cocaine, ethanol, nicotine, and benzodiazepine, (3) schizophrenia, (4) spinal cord injury, and /or (5) head injury such as hydrocephalus. Thus, SOCl2 was added to a solution of (E)-4-phenyl-3-butenoic acid in benzene, heated under reflux for 1 h, and cooled, followed by adding 3-(imidazol-1-yl)aniline and Et3N, and the resulting mixture was stirred at room temperature for 1 h to give (3E)-N-[3-(imidazol-1-yl)phenyl]-4-phenyl-3-butenamide (I). I in vitro inhibited by 82% the binding of [3H]mesulergine to 5-HT2c receptor which was prepared from rat frontal lobe cortex.

IT 75-65-0, tert-Butyl alcohol, reactions 110-91-8, Morpholine, reactions 367-31-7, 4-Fluoro-1,2-benzenediamine 462-08-8, 3-Aminopyridine **504-24-5**, 4-Aminopyridine 591-54-8, 4-Aminopyrimidine 624-83-9, Methyl isocyanate 814-75-5, 2-Bromo-3-butanone 939-58-2, trans-2-Chlorocinnamic acid 940-62-5, (E)-3-(4-Chlorophenyl)acrylic acid 1068-57-1, Acetylhydrazine 1121-60-4, 2-Formylpyridine 1722-12-9, 2-Chloropyrimidine 1914-58-5, (E)-4-Phenyl-3-butenoic acid 2062-25-1, 3-[2-(Trifluoromethyl)phenyl]acrylic acid 2706-56-1, 2-(2-Pyridyl)ethylamine 2759-28-6, 1-Benzylpiperazine 3529-82-6, 3-Nitrophenyl isothiocyanate 3731-52-0, 3-Pyridinemethanamine 4110-35-4, 3,5-Dinitrobenzonitrile 4595-59-9, 5-Bromopyrimidine 5327-44-6, 3,5-Dinitroanisole 5720-06-9, 2-Methoxyphenylboronic acid 5873-89-2 6276-03-5, 9H-Fluorene-1-carboxylic acid 6952-67-6, 2-(3-Nitrophenyl)-1,3-dioxolane 13026-12-5, 3-(Naphthalen-1-yl)acrylic acid 13026-23-8, 3-(1,1'-Biphenyl-4-yl)acrylic acid 13331-27-6, 3-Nitrophenylboronic acid 14473-90-6, (E)-3-(3-Chlorophenyl)acrylic acid 16263-52-8, 3-Chloro-1,2-benzisoxazole 16642-92-5, (E)-3-(4-Trifluoromethylphenyl)acrylic acid 20010-99-5, 2-Aminomethylpyrazine 20595-44-2, (E)-3-(2,3-Dichlorophenyl)acrylic acid 20595-45-3, (E)-3-(2,4-Dichlorophenyl)acrylic acid 20826-04-4, 5-Bromonicotinic acid 21035-59-6 21630-48-8 22280-56-4, 2-Chloro-3-methyl-5-nitropyridine 26177-43-5, 3-Nitrobenzylamine hydrochloride 33786-89-9, 3,5-Diaminochlorobenzene 36052-25-2, 5-Aminonicotinic acid methyl ester 59002-79-8, 6-Fluoro-9H-carbazole-1-carboxylic acid 63413-91-2, 3-Phenylthioacrylic acid 69491-59-4, 3-(5-Pyrimidinyl)aniline 83823-06-7, 6-Chloro-2H-chromene-3-carboxylic acid 89260-48-0 89640-55-1, 3-Iodo-4-methoxypyridine 89878-14-8, Diethyl(3-pyridyl)borane 99368-67-9, 2-Chloro-5-nitro-3-(trifluoromethyl)pyridine 112677-67-5, 3-(Imidazol-1-yl)aniline 112898-33-6, (E)-3-(2,5-Difluorophenyl)acrylic acid 123947-73-9, 7-Methoxy-2,3-dihydrobenz[b]oxepin-4-carboxylic acid 123947-74-0, 8-Methoxy-2,3-dihydrobenz[b]oxepin-4-carboxylic acid 129768-95-2 135616-29-4, 8,9-Dihydro-7H-benzocycloheptene-6-carboxylic acid 138830-47-4, 4-Methyl-1-(3-nitrophenyl)-1H-imidazole 147700-58-1, (E)-3-(3,4-Difluorophenyl)acrylic acid 153936-26-6 174603-37-3, (E)-3-(2-Chloro-4-fluorophenyl)acrylic acid 176032-78-3 181633-42-1, 3-Amino-6-(2-methyl-3-pyridyloxy)pyridine 206353-51-7, 2,3-Dihydrobenz[b]oxepin-4-carboxylic acid 312619-48-0, (E)-3-[2,5-Bis(trifluoromethyl)phenyl]acrylic acid 326476-49-7 333792-46-4, 3-(1,2-Dimethylimidazol-5-yl)aniline 333792-92-0, 3-Methyl-2-(trifluoromethyl)-1H-indole-7-carboxylic acid 333793-36-5, 3-(4,5-Dimethylimidazol-1-yl)aniline 361549-63-5 361549-97-5 361550-35-8 361550-60-9 361551-42-0 361551-53-3 361551-64-6 361551-84-0 361551-95-3 361551-98-6 361552-00-3 361552-08-1 361552-10-5 361552-12-7 361552-15-0 361552-32-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of N-heterocyclyl amide compds. as 5-HT antagonists for treatment of 5-HT-mediated diseases such as central **nervous** system disorders, drug withdrawal symptom, schizophrenia, spinal code **injury**, and head **injury**)

IT 62-55-5, Thioacetamide 74-88-4, Methyl iodide, reactions 99-09-2, 3-Nitroaniline 99-29-6, 2-Bromo-6-chloro-4-nitroaniline 99-61-6, 3-Nitrobenzaldehyde 99-81-0, 2-Bromo-1-(4-nitrophenyl)ethanone 103-82-2, Phenylacetic acid, reactions 288-13-1, Pyrazole 345-16-4, 5-Fluoro-2-hydroxybenzoic acid 350-46-9, 4-Fluoro-1-nitrobenzene 364-76-1, 4-Fluoro-3-nitroaniline 621-82-9, Cinnamic acid, reactions 1194-02-1, 4-Fluorobenzonitrile 1739-84-0, 1,2-Dimethylimidazole 3731-51-9, 2-(Aminomethyl)pyridine 3752-25-8, 2-Chlorocinnamic acid 3819-88-3, 1-Fluoro-3-iodo-5-nitrobenzene 4548-45-2, 2-Chloro-5-nitropyridine 13889-98-0, 1-Acetylpiperazine **14432-12-3**, 4-Amino-2-chloropyridine 18197-26-7 18437-64-4, tert-Butyl 3-nitrophenylcarbamate 24424-99-5, Di-tert-butyl dicarbonate 68621-88-5, tert-Butyl 3-aminophenylcarbamate
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-heterocyclyl amide compds. as 5-HT antagonists for treatment of 5-HT-mediated diseases such as central **nervous** system disorders, drug withdrawal symptom, schizophrenia, spinal cord **injury**, and head **injury**)

IT **504-24-5**, 4-Aminopyridine
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-heterocyclyl amide compds. as 5-HT antagonists for treatment of 5-HT-mediated diseases such as central **nervous** system disorders, drug withdrawal symptom, schizophrenia, spinal code **injury**, and head **injury**)

RN 504-24-5 CAPLUS
CN 4-Pyridinamine (9CI) (CA INDEX NAME)



IT **14432-12-3**, 4-Amino-2-chloropyridine
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-heterocyclyl amide compds. as 5-HT antagonists for treatment of 5-HT-mediated diseases such as central **nervous** system disorders, drug withdrawal symptom, schizophrenia, spinal cord **injury**, and head **injury**)

RN 14432-12-3 CAPLUS
CN 4-Pyridinamine, 2-chloro- (9CI) (CA INDEX NAME)



RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:272926 CAPLUS
DN 135:14254
TI Treatment of the neuromuscular junction with 4-aminopyridine results in improved reinnervation following nerve injury in neonatal rats
AU Dekkers, J.; Waters, J.; Vrbova, G.; Greensmith, L.

CS Sobell Department of Neurophysiology, Institute of Neurology, London, WC1N 3BG, UK
SO Neuroscience (Oxford, United Kingdom) (2001), 103(1), 267-274
CODEN: NRSCDN; ISSN: 0306-4522
PB Elsevier Science Ltd.
DT Journal
LA English
AB During early postnatal development, nerve injury results in the death of a large proportion of motoneurones and poor recovery of muscle function. Our previous results have shown that premature enhancement of transmitter release from nerve terminals prevents the death of motoneurones following neonatal nerve injury. Whether this increase in motoneurone survival is reflected in an improvement in the reinnervation of muscle was studied here. The muscles in one hindlimb of newborn rats were treated with 4-aminopyridine. Three days later, the sciatic nerve was crushed in the treated leg. When the animals were seven, 14 and 21 days of age, the soleus and extensor digitorum longus muscles were removed and processed for GAP-43 (a 43-kDa growth-associated protein) and synaptophysin immunocytochem. Both GAP-43 and synaptophysin were expressed in normal soleus and extensor digitorum longus muscles at seven days. Synaptophysin was still expressed at 14 days, but GAP-43 expression had declined. Following nerve injury at three days of age, there was no GAP-43 or synaptophysin immunoreactivity in nerve terminals at seven days. By 21 days, there were 17.3 ± 2.1 GAP-43-pos. terminals per section in the soleus and 17.7 ± 1.4 in the extensor digitorum longus, with mean terminal areas of 47.5 ± 3.3 and 49.8 ± 2.6 μm2, resp. In animals in which nerve crush was preceded by 4-aminopyridine treatment, at 21 days there were 32.9 ± 2.6 GAP-43-immunoreactive terminals in the soleus and 44.9 ± 2.3 in the extensor digitorum longus, with a mean area of 122.7 ± 6.6 μm2 in the soleus and 136.2 ± 9.7 μm2 in the extensor digitorum longus. These results indicate that in muscles pretreated with 4-aminopyridine, prior to nerve crush at three days, there are significantly more terminals, which occupy a larger area than in untreated muscles. Thus, increasing transmitter release prior to nerve injury significantly improved the ability of axons to reinnervate muscle.
IT **504-24-5**, 4-Aminopyridine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(treatment of neuromuscular junction with aminopyridine improves reinnervation following neonatal **nerve injury**)
IT **504-24-5**, 4-Aminopyridine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(treatment of neuromuscular junction with aminopyridine improves reinnervation following neonatal **nerve injury**)
RN 504-24-5 CAPLUS
CN 4-Pyridinamine (9CI) (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1981:101776 CAPLUS
DN 94:101776
TI Effect of pyrithiamine on rat sciatic nerve. II. Morphological changes

during the last stages of thiamine deficiency
AU Oguchi, Emiko; Okazaki, Masako; Nomi, Minoru; Sakamoto, Koji
CS Sch. Med., Showa Univ., Tokyo, 142, Japan
SO Nippon Yakurigaku Zasshi (1980), 76(7), 567-80
CODEN: NYKZAU; ISSN: 0015-5691
DT Journal
LA Japanese
AB Rats were given pyrithiamin [534-64-5] (50 μg/100 g body weight) with a thiamin-depleted diet for 11 days, which caused severe tetanic convulsions. **Damage** of the myelinated axons was observed The dysfunction of the sciatic **nerve** induced by the thiamin-deficient diet together with pyrithiamin injection was believed to originate from the central **nervous** system.
AB Rats were given pyrithiamin [534-64-5] (50 μg/100 g body weight) with a thiamin-depleted diet for 11 days, which caused severe tetanic convulsions. **Damage** of the myelinated axons was observed The dysfunction of the sciatic **nerve** induced by the thiamin-deficient diet together with pyrithiamin injection was believed to originate from the central **nervous** system.
IT **534-64-5**
RL: BIOL (Biological study)
(**nerve damage** response to thiamin deficiency and injection of)
IT **534-64-5**
RL: BIOL (Biological study)
(**nerve damage** response to thiamin deficiency and injection of)
RN 534-64-5 CAPLUS
CN Pyridinium, 1-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-3-(2-hydroxyethyl)-2-methyl-, bromide, monohydrobromide (9CI) (CA INDEX NAME)



L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1944:42603 CAPLUS
DN 38:42603
OREF 38:6391d-f
TI Experimental nerve damage by derivatives of sulfanilamide
AU Boszormenyi, Zoltan; Meszaros, Antal
SO Wiener Medizinische Wochenschrift (1943), 93, 390-1
From: Chem. Zentr. II, 1823(1943).
CODEN: WMWOA4; ISSN: 0043-5341
DT Journal
LA Unavailable

AB Intraspinal injections of more or less dilute sulfapyridine and sulfathiazole derivs. caused in the rabbit immediate paralysis and liquefication of the spinal nerve substance, probably by alkaline effect. Intravenous injections did not cause toxic effects. After repeated oral administration obtaining a sulfonamide concentration in the blood of 31 to 48 mg.
% paralysis appeared after 14 days. The anatomical findings corresponded to a peripheral neuritis. Simultaneous administration of vitamin B1 prevented the paralysis completely or assuaged it considerably.

IT 72-14-0, Sulfathiazole **144-83-2**, Sulfapyridine
(derivs., **nerve damage** by)

IT **144-83-2**, Sulfapyridine
(derivs., **nerve damage** by)

RN 144-83-2 CAPLUS

CN Benzenesulfonamide, 4-amino-N-2-pyridinyl- (9CI) (CA INDEX NAME)



AN 2001:922595 CAPLUS
DN 137:122781
TI Mechanisms of axonal dysfunction after spinal cord injury: with an emphasis on the role of voltage-gated potassium channels
AU Nashmi, Raad; Fehlings, Michael G.
CS Playfair Neuroscience Unit, Division of Neurosurgery, University Health Network, Institute of Medical Science, The Toronto Western Hospital Research Institute, University of Toronto, Toronto, M5T 2S8, Can.
SO Brain Research Reviews (2001), 38(1-2), 165-191
CODEN: BRERD2; ISSN: 0165-0173
PB Elsevier Science B.V.
DT Journal; General Review
LA English
AB A review. Dysfunction of surviving axons which traverse the site of spinal cord **injury** (SCI) appears to contribute to posttraumatic neurol. deficits, though the underlying mechanisms remain unclear. Although demyelination of **injured** but surviving axons following trauma appear to be a major contributor of axonal conduction deficits, altered activity of ion channels may also play an important role. It was theorized that exposure of K+ channels as a result of demyelination would result in a reduced safety factor of action potential propagation across the demyelinated region of the axon. This theory and electrophysiol. studies using K+ channel blockers on animal **nerve** prepns. prompted the investigation of 4-aminopyridine (4-AP), a blocker of rapidly activating voltage-gated K+ channels, as a therapeutic agent in both multiple sclerosis and spinal cord **injured** patients. Several preliminary clin. trials have already demonstrated therapeutic benefit of 4-AP in both multiple sclerosis and spinal cord **injured** patients. In this review, the authors shall give a comprehensive summary of the mechanisms of axonal dysfunction following SCI and how axonal dysfunction may have resulted due to specific pathol. changes following trauma including the ultrastructural and mol. changes that occur to myelinated axons. The pathol. of spinal cord **injury** is very complex and many different mechanisms may contribute to axonal conduction deficits and the associated sensory and motor loss.
IT **504-24-5**, 4-Aminopyridine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(voltage-gated K channel blocker demyelinating axonal dysfunction after spinal cord injury)
RN 504-24-5 CAPLUS
CN 4-Pyridinamine (9CI) (CA INDEX NAME)



RE.CNT 216 THERE ARE 216 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

AN 2001:272926 CAPLUS
DN 135:14254
TI Treatment of the neuromuscular junction with 4-aminopyridine results in improved reinnervation following **nerve injury** in neonatal rats
AU Dekkers, J.; Waters, J.; Vrbova, G.; Greensmith, L.
CS Sobell Department of Neurophysiology, Institute of Neurology, London, WC1N 3BG, UK
SO Neuroscience (Oxford, United Kingdom) (2001), 103(1), 267-274
CODEN: NRSCDN; ISSN: 0306-4522
PB Elsevier Science Ltd.
DT Journal
LA English
AB During early postnatal development, **nerve injury** results in the death of a large proportion of motoneurones and poor recovery of muscle function. Our previous results have shown that premature enhancement of transmitter release from **nerve** terminals prevents the death of motoneurones following neonatal **nerve injury**. Whether this increase in motoneurone survival is reflected in an improvement in the reinnervation of muscle was studied here. The muscles in one hindlimb of newborn rats were treated with 4-aminopyridine. Three days later, the sciatic **nerve** was crushed in the treated leg. When the animals were seven, 14 and 21 days of age, the soleus and extensor digitorum longus muscles were removed and processed for GAP-43 (a 43-kDa growth-associated protein) and synaptophysin immunocytochem. Both GAP-43 and synaptophysin were expressed in normal soleus and extensor digitorum longus muscles at seven days. Synaptophysin was still expressed at 14 days, but GAP-43 expression had declined. Following **nerve injury** at three days of age, there was no GAP-43 or synaptophysin immunoreactivity in **nerve** terminals at seven days. By 21 days, there were 17.3 ± 2.1 GAP-43-pos. terminals per section in the soleus and 17.7 ± 1.4 in the extensor digitorum longus, with mean terminal areas of 47.5 ± 3.3 and 49.8 ± 2.6 μm2, resp. In animals in which **nerve** crush was preceded by 4-aminopyridine treatment, at 21 days there were 32.9 ± 2.6 GAP-43-immunoreactive terminals in the soleus and 44.9 ± 2.3 in the extensor digitorum longus, with a mean area of 122.7 ± 6.6 μm2 in the soleus and 136.2 ± 9.7 μm2 in the extensor digitorum longus. These results indicate that in muscles pretreated with 4-aminopyridine, prior to **nerve** crush at three days, there are significantly more terminals, which occupy a larger area than in untreated muscles. Thus, increasing transmitter release prior to **nerve injury** significantly improved the ability of axons to reinnervate muscle.
IT **504-24-5**, 4-Aminopyridine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(treatment of neuromuscular junction with aminopyridine improves reinnervation following neonatal **nerve injury**)
RN 504-24-5 CAPLUS
CN 4-Pyridinamine (9CI) (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN **97999-83-2** REGISTRY
ED Entered STN: 16 Sep 1985
CN Phosphinic amide, P,P-diphenyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Phosphinic amide, P,P-diphenyl-N-4-pyridyl- (7CI)
FS 3D CONCORD
MF C17 H15 N2 O P
SR CAOLD
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

```
=> s l2
L4            1 L2

=> d all

L4   ANSWER 1 OF 1  CAOLD  COPYRIGHT 2006 ACS on STN
AN   CA59:1677a  CAOLD
TI   diallyl phenylphosphinate
AU   Gefter, E. L.
TI   phosphoric acid amides
AU   Gutmann, Viktor; Moertl, G.; Utvary, K.
IT   1445-76-7   1499-21-4   2948-89-2   3426-89-9   6190-28-9   6230-69-9
     6941-20-4   7473-27-0  24625-67-0  27127-08-8  36163-87-8  41049-57-4
     56372-47-5  67071-69-6  68036-31-7  71847-21-7  97999-83-2
     98029-51-7 105976-12-3 105976-13-4
```

```
=> s l2
L3            3 L2

=> d bib abs hitstr 1-3

L3   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2004:513486  CAPLUS
DN   141:47362
TI   Pyridines for treating injured mammalian nerve tissue
IN   Borgens, Richard B.; Shi, Riyi; Byrn, Stephen R.; Smith, Daniel T.
PA   Purdue Research Foundation, USA
SO   PCT Int. Appl., 51 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
PI   WO 2004052291         A2    20040624    WO 2003-US38834         20031205
     WO 2004052291         A3    20041014
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
             NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
             TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2508165            AA    20040624    CA 2003-2508165         20031205
     US 2004171587         A1    20040902    US 2003-730495          20031205
     EP 1567497            A2    20050831    EP 2003-796756          20031205
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
PRAI US 2002-431637P       P     20021206
     WO 2003-US38834       W     20031205
OS   MARPAT 141:47362
AB   The invention provides novel pyridines, pharmaceutical compns. comprising
     such pyridines, and the use of such compns. in treating injured mammalian
     nerve tissue, including but not limited to an injured spinal cord in one
     embodiment, the compds., compns., and methods of the instant invention
     treat a mammalian nerve tissue injury by restoring action potential or
     nerve impulse conduction through a nerve tissue lesion.  Significantly, in
     vivo application of compds. of the instant invention established, on the
     basis of SSEP testing, that the compds. provide longer lasting effects at
     lower concns. than comparable treatment with the known agent
     4-aminopyridine (4 AP).
IT   97999-83-2P
     RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic
     preparation); THU (Therapeutic use); BIOL (Biological study); PREP
     (Preparation); USES (Uses)
        (pyridines for treating injured mammalian nerve tissue)
RN   97999-83-2  CAPLUS
CN   Phosphinic amide, P,P-diphenyl-N-4-pyridinyl- (9CI)  (CA INDEX NAME)
```



L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:505547 CAPLUS
DN 123:198508
TI Phosphorylated adenine derivatives as potential synthons for antiviral agents
AU El Masri, Marwan; Berlin, K. Darrell
CS Dep. Chem., Oklahoma State Univ., Stillwater, OK, 74078, USA
SO Organic Preparations and Procedures International (1995), 27(2), 161-9
CODEN: OPPIAK; ISSN: 0030-4948
PB Organic Preparations and Procedures, Inc.
DT Journal
LA English
OS CASREACT 123:198508
GI



I

AB Phosphorylated adenines I [R = Cl; R1 = H, Me] were prepared from 9-(2-hydroxyethyl)adenine (II) by reaction with ClP(O)(OC6H4R1-4)2. I [R = Cl] were converted to I [R = N3, pyridylamino]. II was also converted to phosphate esters and phosphonates and phosphates of aniline and 4-aminopyridine were also prepared
IT **97999-83-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of phosphorylated aniline and aminopyridine)
RN 97999-83-2 CAPLUS
CN Phosphinic amide, P,P-diphenyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1963:409108 CAPLUS
DN 59:9108
OREF 59:1677a-d
TI Phosphoric acid amides
AU Gutmann, V.; Moertl, G.; Utvary, K.
CS Tech. Hochschule, Vienna
SO Monatshefte fuer Chemie (1962), 93, 1114-16
CODEN: MOCMB7; ISSN: 0026-9247
DT Journal
LA Unavailable
OS CASREACT 59:9108
AB Primary and secondary amines with diphenylphosphorus2POCl (I), with a

tertiary amine, C5H5N, or the applied amine itself in excess as acid acceptor gave new amides which were insol. in H2O and could therefore be easily separated from by-products. I was prepared by the method of Gefter (CA 52, 19999d). The amine was carefully dried and reaction carried out in CCl4 over P2O5 by dropping I into excess of the dissolved amine with exclusion of atmospheric moisture. For the n-alkylamide, n-alkylamine was dissolved in CCl4, I added dropwise, the alkylammonium chloride filtered off, CCl4 distilled, the remaining oily product shaken with dilute K2CO3 solution, and the amide crystallized from Et2O. For the diethylamide, after removal of CCl4, the residue was dissolved in EtOH and crystallized at -10°. The isopropylamide was crystallized at lower temperature tert-Butylamide was crystallized from Et2O. Anilide, benzylamide, cyclohexylamide, N-methylanilide, o-, m-, and p-toluidides, m-, and p-chloroanilides, and α, and β-naphthylamides were crystallized from hot EtOH by cooling to -6°. For the diphenylamide the residue was shaken with dilute NaOH, washed with H2O, and crystallized from EtOH. For 2-, 3-, 4-aminopyridides pyridine was added as acceptor, and after distillation of solvent the oily product obtained was treated with H2O and crystallized from EtOH. The following diphenylphosphinamides, PH2P(O)R were prepared (R, m.p., % yield given): NEt2, 141-2°, 25; PrNH, 90-3°, 46; iso-PrNH, 146-8°, 53; BuNH, 93-5°, 56; tert-BuNH, 133-6°, 25; PhNH, 242-4°, 85; PH2N, 105-6°, 15; PhMeN, 116-18°, 82; 2-MeC6H4NH, 127-9°, 65; 3-MeC6H4NH, 250-50.5°, 87; 4-MeC6H4NH, 205-6° (sublimes 195°), 70; 3-ClC6H4NH, 252-3°, 65; 4-ClC6H4NH, 215-16°, 74; PhCH2NH, 111-12°, 87; α-C10H7-NH, 188-90°, 72; α-C10H7NH, 264-8°; 82; 2-NHC5H4N, 177-80°, 34; 3-NHC5H4N, 203-4°, 35; 4-NHC5H4N, 173-4°, 42; cyclo-C6H11NH, 197-7.5°, 82.

IT **97999-83-2**, Phosphinic amide, P,P-diphenyl-N-4-pyridyl- (preparation of)

RN 97999-83-2 CAPLUS

CN Phosphinic amide, P,P-diphenyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN **21915-82-2** REGISTRY
ED Entered STN: 16 Nov 1984
CN Phosphoramidic acid, 4-pyridinyl-, diphenyl ester (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Phosphoramidic acid, 4-pyridyl-, diphenyl ester (8CI)
FS 3D CONCORD
MF C17 H15 N2 O3 P
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.34	28.31

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.25

FILE 'CAPLUS' ENTERED AT 08:54:43 ON 13 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 13 Mar 2006 VOL 144 ISS 12
FILE LAST UPDATED: 12 Mar 2006 (20060312/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l5

L6 4 L5

=> d bib abs hitstr 1-4

L6 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:513486 CAPLUS
DN 141:47362
TI Pyridines for treating injured mammalian nerve tissue
IN Borgens, Richard B.; Shi, Riyi; Byrn, Stephen R.; Smith, Daniel T.
PA Purdue Research Foundation, USA
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004052291	A2	20040624	WO 2003-US38834	20031205
	WO 2004052291	A3	20041014		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2508165	AA	20040624	CA 2003-2508165	20031205
	US 2004171587	A1	20040902	US 2003-730495	20031205
	EP 1567497	A2	20050831	EP 2003-796756	20031205
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	US 2002-431637P	P	20021206		
	WO 2003-US38834	W	20031205		

OS MARPAT 141:47362
AB The invention provides novel pyridines, pharmaceutical compns. comprising such pyridines, and the use of such compns. in treating injured mammalian nerve tissue, including but not limited to an injured spinal cord in one embodiment, the compds., compns., and methods of the instant invention treat a mammalian nerve tissue injury by restoring action potential or nerve impulse conduction through a nerve tissue lesion. Significantly, in vivo application of compds. of the instant invention established, on the basis of SSEP testing, that the compds. provide longer lasting effects at lower concns. than comparable treatment with the known agent 4-aminopyridine (4 AP).
IT **21915-82-2P**
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pyridines for treating injured mammalian nerve tissue)
RN 21915-82-2 CAPLUS
CN Phosphoramidic acid, 4-pyridinyl-, diphenyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:505547 CAPLUS
DN 123:198508
TI Phosphorylated adenine derivatives as potential synthons for antiviral agents
AU El Masri, Marwan; Berlin, K. Darrell
CS Dep. Chem., Oklahoma State Univ., Stillwater, OK, 74078, USA
SO Organic Preparations and Procedures International (1995), 27(2), 161-9
CODEN: OPPIAK; ISSN: 0030-4948
PB Organic Preparations and Procedures, Inc.
DT Journal
LA English
OS CASREACT 123:198508
GI



I

AB Phosphorylated adenines I [R = Cl; R1 = H, Me] were prepared from 9-(2-hydroxyethyl)adenine (II) by reaction with ClP(O)(OC6H4R1-4)2. I [R = Cl] were converted to I [R = N3, pyridylamino]. II was also converted to phosphate esters and phosphonates and phosphates of aniline and 4-aminopyridine were also prepared
IT **21915-82-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of phosphorylated aniline and aminopyridine)
RN 21915-82-2 CAPLUS
CN Phosphoramidic acid, 4-pyridinyl-, diphenyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1984:423604 CAPLUS
DN 101:23604
TI Phosphoric acid ester amides with some 2-aminoheterocyclic compounds
AU Tadzhitdinov, Z. B.; Makhamatkhanov, M. M.; Maksudov, N. Kh.
CS Tashk. Inst. Inzh. Irrig. Mekh. Sel'sk. Khoz., Tashkent, USSR
SO Deposited Doc. (1982), SPSTL 761 Khp-D82, 6 pp. Avail.: SPSTL
DT Report
LA Russian
AB (RO)2P(O)NHR1 [I, R = Ph, p-MeC6H4; R1 = (un)substituted 2-benzothiazolyl, 4-pyridyl, 2-benzoxazolyl, 2-thiazolyl] were prepared in 40.4-82.3 % yields

by treating (RO)2P(O)Cl with R1NH2 in the presence of Et3N. I are potential pesticides (no data).

IT **21915-82-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 21915-82-2 CAPLUS
CN Phosphoramidic acid, 4-pyridinyl-, diphenyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1969:87504 CAPLUS
DN 70:87504
TI Amidophosphates of the pyridine series
AU Dregval, G. F.; Martynyuk, A. P.; Kovalenko, N. V.
CS Donets. Filial Vses. Nauch.-Issled Inst. Khim. Reaktiv. Osobo Chist. Khim. Veshch., Donetsk, USSR
SO Khim. Geterotsikl. Soedin., Sb. 1: Azotsoderzhashchie Geterotsikly (1967), 236-9. Editor(s): Hillers, S. Publisher: Izd. "Zinatne", Riga, USSR.
CODEN: 20NNA2
DT Conference
LA Russian
GI For diagram(s), see printed CA Issue.
AB 2-Aminopyridine (I) and 4-aminopyridine (II) underwent condensation with (ArO)2P(X)Cl (III) in the presence of Et3N to give amidophosphates IV and V, resp. Reaction of 2 moles I with 1 mole (RO)P(X)Cl2 (VI) gave amidophosphates VII. No attack on the ring N occurred. To an ice-cold, stirred solution of 0.1 mole I and 0.1 mole Et3N in 40 ml. C6H6 was added 0.1 mole III in 15 ml. C6H6. The mixture was heated on the steam bath 2.5 hrs. to give the following IV (Ar, X, % yield, and m.p. given): Ph, O, 62, 145-6°; Ph, S, 32, 103-4°; p-MeC6H4, O, 46, 169-71°; p-MeC6H4, S, 61, 128-9°. To a stirred suspension of 0.1 mole II and 0.1 mole Et3N in 30 ml. PhMe was added 0.1 mole III in 20 ml. PhMe. The mixture was refluxed 3 hrs. to give the following V (Ar, X, % yield, and m.p. given): Ph, O, 76, 190-1°; Ph, S, 70, 151-2°; p-MeC6H4, O, 37, 215-16°. To a stirred, cooled solution of 0.2 mole I and 0.2 mole Et3N in 30 ml. PhMe was added 0.1 mole VI in 15-20 ml. PhMe, and the mixture was heated on the steam bath 2 hrs. to give the following VII (R, X, % yield, and m.p. given): PhO, O, 66, 192-3°; PhO, S, 60, 171-2°; p-MeC6H4, O, 89, 168-9° (VIII); p-MeC6H4O, S, 33, 170-2°; Ph, O, 38, 212-14°. To a solution of 0.1 mole I and 0.2 mole Et3N in 20 ml. PhMe was added a solution of 0.1 mole (p-MeC6H4O)P(O)Cl2 in 15 ml. PhMe, and the mixture was heated on the steam bath for 2 hrs. to give 32% VIII.

IT **21915-82-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 21915-82-2 CAPLUS
CN Phosphoramidic acid, 4-pyridinyl-, diphenyl ester (9CI) (CA INDEX NAME)


N
O
NH
P
OPh
OPh

L15 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2006 ACS on STN



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

Ring System Data

Elemental Analysis EA	Elemental Sequence ES	Size of the Rings SZ	Ring System Formula RF	Ring Identifier RID	RID Occurrence Count
C3N2-C5N	NCNC2-NC5	5-6	C6N3	333.402.18	1

=> s 33.402.18/rid
L16 0 33.402.18/RID

=> s 33.402/rid
L17 0 33.402/RID

=> s 333.402.18/rid
L18 1618 333.402.18/RID

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	26.82	231.54

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-7.50

FILE 'CAPLUS' ENTERED AT 15:59:17 ON 08 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 8 Mar 2006 VOL 144 ISS 11
FILE LAST UPDATED: 7 Mar 2006 (20060307/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> s l18 and ((nerv? (l)(injur? or damag?)) or spin?)
           739 L18
        393107 NERV?
        150728 INJUR?
        378616 DAMAG?
         24012 NERV? (L)(INJUR? OR DAMAG?)
        616877 SPIN?
L19         20 L18 AND ((NERV? (L)(INJUR? OR DAMAG?)) OR SPIN?)

=> d bib hit hitstr 1-20

L19  ANSWER 1 OF 20  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2005:1046626  CAPLUS
DN   143:415589
TI   Development of novel 4-aminopyridine derivatives as potential treatments
     for neurological injury and disease
AU   Smith, Daniel T.; Shi, Riyi; Borgens, Richard B.; McBride, Jennifer M.;
     Jackson, Kevin; Byrn, Stephen R.
CS   Department of Industrial and Physical Pharmacy, Purdue University, West
     Lafayette, IN, 47907, USA
SO   European Journal of Medicinal Chemistry (2005), 40(9), 908-917
     CODEN: EJMCA5; ISSN: 0223-5234
PB   Elsevier Ltd.
DT   Journal
LA   English
AB   The amine position of the K+ channel blocker 4-aminopyridine was
     functionalized to form amide, carbamate and urea derivs. in an attempt to
     identify novel compds. which restore conduction in injured spinal
     cord. Eight derivs. were tested in vitro, using a double sucrose gap
     chamber, for the ability to restore conduction in isolated, injured guinea
     pig spinal cord. The Me, Et and t-Bu carbamates of
     4-aminopyridine induced an increase in the post injury compound action
     potential. The Me and Et carbamates were further tested in an in vivo
     model of spinal cord injury. These results represent the first
     time that 4-aminopyridine has been derivatized without losing its ability
     to restore function in injured spinal cord tissue.
ST   aminopyridine deriv prepn spinal cord injury treatment
IT   Nerve, disease
     Structure-activity relationship
        (aminopyridine derivs. as potential treatments for neurol.
        injury and disease)
IT   Nerve, disease
       Spinal cord, disease
        (injury; aminopyridine derivs. as potential treatments for
        neurol. injury and disease)
IT   Injury
        (spinal cord; aminopyridine derivs. as potential treatments
        for neurol. injury and disease)
IT   1122-58-3   5221-42-1 7397-68-4   22236-93-7   39642-87-0
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (aminopyridine derivs. as potential treatments for neurol. injury and
        disease)
IT   7397-68-4
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (aminopyridine derivs. as potential treatments for neurol. injury and
```

disease)
RN 7397-68-4 CAPLUS
CN 2H-Imidazo[4,5-c]pyridin-2-one, 1,3-dihydro- (9CI) (CA INDEX NAME)



RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1004734 CAPLUS
DN 143:306326
TI Production of 4-benzimidazol-2-yl-pyridazin-3-one derivatives and use thereof in medicaments
IN Schoenafinger, Karl; Hoelder, Swen; Will, David William; Matter, Hans; Mueller, Guenther; Bossart, Martin
PA Aventis Pharma Deutschland G.m.b.H., Germany
SO PCT Int. Appl., 126 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005085230	A1	20050915	WO 2005-EP2179	20050302
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 102004010194	A1	20051013	DE 2004-102004010194	20040302
PRAI DE 2004-102004010194	A	20040302		

OS MARPAT 143:306326
IT Head and Neck, disease
Spinal cord, disease
(injury, medicaments; preparation of 4-benzimidazol-2-yl-pyridazin-3-one derivs. with GSK-3β inhibitory activity)
IT Injury
(**spinal** cord, medicaments; preparation of 4-benzimidazol-2-yl-pyridazin-3-one derivs. with GSK-3β inhibitory activity)
IT 864463-60-5P 864463-61-6P 864463-63-8P 864463-64-9P 864463-65-0P
864463-66-1P 864463-67-2P 864463-68-3P 864463-69-4P 864463-70-7P,
4-(5-Chloro-1H-benzimidazol-2-yl)-6-methyl-2H-pyridazin-3-one
864463-71-8P 864463-72-9P 864463-73-0P 864463-74-1P 864463-75-2P
864463-76-3P 864463-77-4P 864463-78-5P 864463-79-6P 864463-80-9P
864463-81-0P **864463-82-1P**, 6-Chloro-4-(3H-imidazo[4,5-c]pyridin-2-yl)-2H-pyridazin-3-one 864463-83-2P 864463-85-4P 864463-86-5P
864463-87-6P, 4-(1H-Benzimidazol-2-yl)-6-(pyridin-4-yl)-2H-pyridazin-3-one
864463-89-8P 864463-90-1P 864463-91-2P 864463-92-3P 864463-93-4P
864463-95-6P 864463-96-7P **864463-97-8P**, 4-(3H-Imidazo[4,5-c]pyridin-2-yl)-6-(pyridin-4-yl)-2H-pyridazin-3-one 864463-98-9P

864779-80-6P 864779-81-7P 864779-82-8P 864779-83-9P 864779-84-0P
864779-85-1P 864779-86-2P 864779-87-3P 864779-89-5P,
4-(1H-Benzimidazol-2-yl)-6-(3-thienyl)-2H-pyridazin-3-one 864779-90-8P,
4-(1H-Benzimidazol-2-yl)-6-(3-thiazol-2-yl)-2H-pyridazin-3-one
864779-91-9P, 4-(1H-Benzimidazol-2-yl)-6-cyclopropyl-2H-pyridazin-3-one
864779-92-0P 864779-93-1P 864779-94-2P, 4-(1H-Benzimidazol-2-yl)-6-(3-
fluoropyridin-4-yl)-2H-pyridazin-3-one 864779-95-3P 864779-96-4P
864779-97-5P 864779-98-6P 864779-99-7P 864780-00-7P 864780-01-8P
864780-02-9P 864780-03-0P, 4-(1H-Benzimidazol-2-yl)-6-[2-
(dimethylamino)pyrimidin-4-yl]-2H-pyridazin-3-one 864780-04-1P
864780-05-2P 864780-06-3P 864780-07-4P, 4-(1H-Benzimidazol-2-yl)-6-
(morpholin-4-yl)-2H-pyridazin-3-one 864780-08-5P 864780-09-6P
864780-10-9P 864780-11-0P 864780-12-1P 864780-13-2P,
6-Chloro-4-(5-hydroxy-1H-benzimidazol-2-yl)-2H-pyridazin-3-one
864780-14-3P, 4-(1H-Benzimidazol-2-yl)-6-(pyrazol-1-yl)-2H-pyridazin-3-one
864780-15-4P, 4-(1H-Benzimidazol-2-yl)-6-(thiazol-4-yl)-2H-pyridazin-3-one
864780-17-6P 864780-18-7P, 4-(1H-Benzimidazol-2-yl)-6-(1-methyl-1H-
imidazol-4-yl)-2H-pyridazin-3-one **864780-20-1P** 864780-21-2P
864780-22-3P 864780-23-4P 864780-24-5P 864780-25-6P 864780-26-7P,
4-(1H-Benzimidazol-2-yl)-6-(2-methoxypyrimidin-4-yl)-2H-pyridazin-3-one
864780-27-8P 864780-28-9P 864780-29-0P 864780-30-3P 864780-31-4P,
4-(1H-Benzimidazol-2-yl)-6-(2-cyclopropylpyrimidin-4-yl)-2H-pyridazin-3-
one 864780-32-5P, 4-(1H-Benzimidazol-2-yl)-6-(pyrimidin-2-yl)-2H-
pyridazin-3-one 864780-33-6P, 4-(1H-Benzimidazol-2-yl)-6-(4-
methoxypyrimidin-2-yl)-2H-pyridazin-3-one 864780-34-7P,
4-(1H-Benzimidazol-2-yl)-6-[4-(dimethylamino)pyrimidin-2-yl]-2H-pyridazin-
3-one 864780-36-9P 864780-38-1P 864780-40-5P 864780-42-7P
864780-44-9P 864780-46-1P, 4-(1H-Benzimidazol-2-yl)-6-(pyrimidin-5-yl)-
2H-pyridazin-3-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of 4-benzimidazol-2-yl-pyridazin-3-one derivs. with GSK-3β
inhibitory activity)

IT **864463-82-1P**, 6-Chloro-4-(3H-imidazo[4,5-c]pyridin-2-yl)-2H-
pyridazin-3-one **864463-97-8P**, 4-(3H-Imidazo[4,5-c]pyridin-2-yl)-
6-(pyridin-4-yl)-2H-pyridazin-3-one **864780-20-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of 4-benzimidazol-2-yl-pyridazin-3-one derivs. with GSK-3β
inhibitory activity)

RN 864463-82-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-chloro-4-(1H-imidazo[4,5-c]pyridin-2-yl)- (9CI) (CA
INDEX NAME)



RN 864463-97-8 CAPLUS
CN 3(2H)-Pyridazinone, 4-(1H-imidazo[4,5-c]pyridin-2-yl)-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 864780-20-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-(4-hydroxy-3,5-dimethylphenyl)-4-(1H-imidazo[4,5-c]pyridin-2-yl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 864780-19-8
CMF C18 H15 N5 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:369222 CAPLUS
DN 142:430279
TI Preparation of aminofurazanyl imidazopyridines as Rho kinase inhibitors
IN Lee, Dennis; Stavenger, Robert A.; Goodman, Krista B.; Hilfiker, Mark A.; Cui, Haifeng; Viet, Andrew Q.
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 143 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005037197	A2	20050428	WO 2004-US32824	20041006
	WO 2005037197	A3	20050602		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-508894P P 20031006
US 2003-531949P P 20031223

OS MARPAT 142:430279

IT **Nerve**, disease
(**injury**, acute, treatment of; preparation of aminofurazanyl imidazopyridines as Rho kinase inhibitors)

IT **Spinal** cord, disease
(injury, treatment of; preparation of aminofurazanyl imidazopyridines as Rho kinase inhibitors)

IT Injury
(**spinal** cord, treatment of; preparation of aminofurazanyl imidazopyridines as Rho kinase inhibitors)

IT 850663-53-5P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide 850663-59-1P, N-[3-[[1-[4-[(2-Aminoethyl)oxy]phenyl]-2-(4-aminofurazan-3-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide 850663-69-3P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(methyloxy)benzamide 850663-70-6P 850663-71-7P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-3-pyridinecarboxamide 850663-72-8P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-(1,2,3,4-tetrahydroisoquinolin-7-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide 850663-77-3P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]benzamide 850663-85-3P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenol 850663-87-5P, 2-(4-Aminofurazan-3-yl)-1-ethyl-N-(phenylmethyl)-1H-imidazo[4,5-c]pyridin-6-amine 850663-88-6P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]phenol 850663-89-7P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]phenyl]ethanethioamide 850663-91-1P, 1-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]ethanone 850663-92-2P, 4-[2-(4-Aminofurazan-3-yl)-6-[(3-aminophenyl)oxy]-1H-imidazo[4,5-c]pyridin-1-yl]phenyl 2-methylpropanoate **850663-97-7P**, Methyl 3-[[2-(4-aminofurazan-3-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzoate 850664-03-8P, 1-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(4-morpholinyl)-1-butanol 850664-07-2P, 4-[1-Ethyl-6-[[3-[(1E)-3-(4-methyl-1-piperazinyl)-3-oxo-1-propen-1-yl]phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-11-8P, 1-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-2-methyl-4-(4-morpholinyl)-1-butanone 850664-14-1P, 1-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(4-methyl-1-piperazinyl)-4-oxo-1-butanone 850664-17-4P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]methyl]-N-[2-(4-morpholinyl)ethyl]benzamide 850664-21-0P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[[2-(4-morpholinyl)ethyl]oxy]benzamide 850664-22-1P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]benzenesulfonamide 850664-28-7P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-6-[[2-(4-morpholinyl)ethyl]oxy]-3-pyridinecarboxamide 850664-30-1P, 4-[6-[[3,4-Bis(methyloxy)phenyl]thio]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-31-2P, Methyl

3-[[2-(4-aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]benzoate 850664-32-3P, 4-[1-Ethyl-6-[[3-(methyloxy)phenyl]thio]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-33-4P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]benzoic acid 850664-35-6P, 4-[1-Ethyl-6-[[2-(methyloxy)phenyl]thio]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-38-9P, 4-[1-Ethyl-6-(1H-imidazol-2-ylthio)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-39-0P, 4-[6-(Cyclopentylthio)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-40-3P, 4-[1-Ethyl-6-(1,3-thiazol-2-ylthio)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-41-4P, 4-[1-Ethyl-6-[(phenylmethyl)thio]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-42-5P, 4-[1-Ethyl-6-(phenylthio)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-43-6P, Methyl 2-[[2-(4-aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]benzoate 850664-44-7P, N-[4-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]phenyl]acetamide 850664-45-8P, 4-[6-[(3-Chloro-4-fluorophenyl)thio]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-47-0P, 4-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]benzoic acid 850664-48-1P, N-[2-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]ethyl]acetamide 850664-49-2P, 4-[6-[(2,5-Dimethyl-3-furanyl)thio]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-50-5P, 4-[1-Ethyl-6-(phenylsulfinyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-51-6P, 4-[6-[(3,4-Dichlorophenyl)thio]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-52-7P, 4-[1-Ethyl-6-(2-pyridinylthio)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-53-8P, 4-[1-Ethyl-6-[(4-fluorophenyl)thio]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-54-9P, 7-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]-3-methyl-2H-chromen-2-one 850664-55-0P, 4-[1-Ethyl-6-[[4-(trifluoromethyl)phenyl]thio]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-56-1P 850664-57-2P, 4-[1-Ethyl-6-[[4-(methylthio)phenyl]thio]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-58-3P, 4-[1-Ethyl-6-(4-pyridinylthio)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-59-4P, 4-[1-Ethyl-6-[([1,3]thiazolo[4,5-b]pyridin-2-yl)thio]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-60-7P, 4-[1-Ethyl-6-[[5-(methyloxy)-1,3-benzothiazol-2-yl]thio]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-61-8P, Methyl (2E)-3-[4-[[2-(4-aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]phenyl]-2-propenoate 850664-62-9P, 4-[1-Ethyl-6-[[4-(methylsulfonyl)phenyl]sulfinyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-63-0P, 4-[1-Ethyl-6-[[4-(methylsulfinyl)phenyl]sulfinyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-64-1P, 4-[6-[(4-Fluorophenyl)oxy]-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-65-2P, 4-[1-Ethyl-6-[[3-(methyloxy)phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-66-3P, 4-[6-[(3,4-Dimethylphenyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-67-4P, 4-[6-[(3-Aminophenyl)oxy]-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-68-5P, 4-[6-[(4-Aminophenyl)oxy]-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-69-6P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzonitrile 850664-70-9P, N-[4-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide 850664-71-0P, 4-[1-Ethyl-6-[[3-(1-methylethyl)phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-72-1P, 4-[6-[[3-(Dimethylamino)phenyl]oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-73-2P, 4-[1-Ethyl-6-[[3-(4-morpholinyl)phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-74-3P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-methylbenzenesulfonamide 850664-75-4P, 4-[1-Ethyl-7-[[3-(methyloxy)phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-76-5P, 1,1-Dimethylethyl [3-[[2-(4-aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-

yl]oxy]phenyl]carbamate 850664-77-6P, 4-[2-(4-Aminofurazan-3-yl)-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-1-yl]phenol 850664-78-7P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]methanesulfonamide 850664-79-8P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-N'-methylurea 850664-80-1P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-[4-[[2-(dimethylamino)ethyl]oxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide 850664-81-2P, N-[4-[[2-(4-Aminofurazan-3-yl)-1-[4-[[2-(dimethylamino)ethyl]oxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide 850664-82-3P, Methyl 4-[[2-(4-aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzoate 850664-83-4P, Methyl 3-[[2-(4-aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzoate 850664-84-5P, 4-[6-[(4-Fluorophenyl)oxy]-1-(2-methyl-1,2,3,4-tetrahydro-7-isoquinolinyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-85-6P, 1-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]ethanol 850664-86-7P, 2-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-2-butanol 850664-87-8P, 6-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-3,4-dihydro-1(2H)-naphthalenone 850664-88-9P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-N'-(phenylmethyl)urea 850664-89-0P, Methyl 2-[3-[[2-(4-aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetate 850664-90-3P, [3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetic acid 850664-91-4P, 4-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzonitrile 850664-92-5P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzoic acid 850664-93-6P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-[4-[[2-(methylamino)ethyl]oxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide 850664-94-7P 850664-95-8P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-fluorobenzamide 850664-96-9P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-2-furancarboxamide 850664-97-0P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-2-methylpropanamide 850664-98-1P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]butanamide 850664-99-2P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-2-(methyloxy)acetamide 850665-00-8P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-morpholinecarboxamide 850665-01-9P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]benzamide 850665-02-0P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-fluorobenzenesulfonamide 850665-03-1P, N-[4-[[2-(4-Aminofurazan-3-yl)-1-(4-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide 850665-04-2P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N,N-dimethylbenzamide 850665-05-3P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-methylbenzamide 850665-06-4P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzamide 850665-07-5P, 4-[1-Phenyl-6-[[3-(1-piperidinylcarbonyl)phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850665-08-6P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-ethylbenzamide 850665-09-7P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-N-methylacetamide 850665-10-0P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(methyloxy)ethyl]benzamide 850665-11-1P, 1-[3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]ethanone 850665-12-2P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-N'-phenylurea 850665-13-3P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(methyloxy)benzenesulfonamide 850665-14-4P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-

yl]oxy]phenyl]-1-butanesulfonamide 850665-15-5P, 4-[1-Ethyl-6-[(phenylmethyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850665-16-6P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-[4-[[2-(dimethylamino)ethyl]oxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]methanesulfonamide 850665-17-7P, 4-[6-[(3-Nitrophenyl)oxy]-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850665-18-8P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-cyanobenzamide 850665-19-9P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]cyclohexanecarboxamide 850665-20-2P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-3-(methyloxy)benzamide 850665-21-3P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(dimethylamino)benzamide 850665-22-4P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]urea 850665-23-5P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-(cyclopropylmethyl)benzamide 850665-24-6P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[(4-methyl-1,3-thiazol-2-yl)methyl]benzamide 850665-25-7P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[(1,5-dimethyl-1H-pyrazol-4-yl)methyl]benzamide 850665-26-8P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(4-morpholinyl)propyl]benzamide 850665-27-9P, 4-[6-[(4-Fluorophenyl)oxy]-1-(1,2,3,4-tetrahydro-7-isoquinolinyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850665-28-0P, 4-[2-(4-Aminofurazan-3-yl)-6-bromo-1H-imidazo[4,5-c]pyridin-1-yl]phenol 850665-29-1P, N-[5-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]-2-(methyloxy)phenyl]acetamide 850665-30-4P, 1-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-1-propanone 850665-31-5P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(ethyloxy)propyl]benzamide 850665-32-6P, N-[4-[2-(4-Aminofurazan-3-yl)-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-1-yl]phenyl]methanesulfonamide 850665-33-7P, 4-[1-[2-(Aminoacetyl)-1,2,3,4-tetrahydro-7-isoquinolinyl]-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850665-34-8P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(ethyloxy)benzamide 850665-35-9P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-3-methylbutanamide 850665-36-0P, 4-[[[[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]amino]carbonyl]amino]benzoic acid 850665-37-1P, 4-[6-Bromo-1-[4-[[2-(dimethylamino)ethyl]oxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850665-38-2P, 2-[7-[2-(4-Aminofurazan-3-yl)-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-1-yl]-3,4-dihydro-2(1H)-isoquinolinyl]acetamide 850665-39-3P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]amino]benzenethiol 850665-40-6P, 4-[6-[(4-Fluorophenyl)oxy]-1-[4-[[2-(methylamino)ethyl]oxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850665-41-7P, 4-[2-(4-Aminofurazan-3-yl)-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-1-yl]-2-chlorophenol 850665-42-8P, 4-[1-[3-Chloro-4-[[2-(dimethylamino)ethyl]oxy]phenyl]-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850665-43-9P, 3-[[2-(4-Aminofurazan-3-yl)-1-(4-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]benzamide 850665-44-0P, N-[2-(Acetylamino)ethyl]-3-[[2-(4-aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzamide 850665-45-1P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[(tetrahydro-2-furanyl)methyl]benzamide 850665-46-2P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(dimethylamino)ethyl]benzamide 850665-47-3P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]benzamide 850665-48-4P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(2-pyridinyl)ethyl]benzamide 850665-49-5P, 3-[[2-(4-Aminofurazan-3-

yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(dimethylamino)propyl]benzamide 850665-50-8P, 4-[6-(1H-Benzimidazol-4-yloxy)-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850665-51-9P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-6-methyl-3-pyridinecarboxamide 850665-52-0P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-2-methyl-3-pyridinecarboxamide 850665-53-1P, 4-[1-[4-(Aminomethyl)phenyl]-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850665-54-2P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(1H-imidazol-1-yl)propyl]benzamide 850665-55-3P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]benzamide 850665-56-4P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-hydroxyphenyl)ethyl]benzamide 850665-57-5P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(3-pyridinyl)ethyl]benzamide 850665-58-6P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(phenyloxy)ethyl]benzamide 850665-59-7P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-[3,5-bis(methyloxy)phenyl]ethyl]benzamide 850665-60-0P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide 850665-61-1P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[(1,3-benzodioxol-5-yl)methyl]benzamide 850665-62-2P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[(1,4-dioxan-2-yl)methyl]benzamide 850665-63-3P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[(4-pyridinyl)methyl]benzamide 850665-64-4P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(1-pyrrolidinyl)propyl]benzamide 850665-65-5P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]benzamide 850665-66-6P
, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-pyridinyl)ethyl]benzamide 850665-67-7P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-(2-cyanoethyl)benzamide 850665-68-8P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-2-methylphenyl]acetamide 850665-69-9P, 7-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-4-methyl-2(1H)-quinolinone 850665-70-2P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-2-(dimethylamino)-5-pyrimidinecarboxamide 850665-71-3P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-2-(methyloxy)-3-pyridinecarboxamide 850665-72-4P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(1-piperidinyl)benzamide 850665-73-5P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(methyloxy)-3-(trifluoromethyl)benzamide 850665-74-6P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-3-fluoro-4-(methyloxy)benzamide 850665-75-7P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-3-chloro-4-(methyloxy)benzamide 850665-76-8P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(4-morpholinyl)benzamide 850665-77-9P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-2-methyl-1,3-thiazole-5-carboxamide 850665-78-0P 850665-79-1P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-methyl-3,4-dihydro-2H-1,4-benzoxazine-7-carboxamide 850665-80-4P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-(1,2,3,4-tetrahydro-7-isoquinolinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(methyloxy)benzamide 850665-81-5P 850665-82-6P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-(3-amino-3-oxopropyl)benzamide 850665-83-7P, N-[4-(Aminomethyl)phenyl]-3-[[2-(4-aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzamide 850665-84-8P, 4-[6-(1H-Benzimidazol-5-yloxy)-1-ethyl-1H-imidazo[4,5-

c]pyridin-2-yl]furazan-3-amine 850665-85-9P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]pyrazolo[1,5-a]pyridine-3-carboxamide 850665-86-0P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-1-methyl-1H-imidazole-2-carboxamide 850665-87-1P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-6-[(2,2,2-trifluoroethyl)oxy]-3-pyridinecarboxamide 850665-88-2P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(3,5-dimethyl-1H-pyrazol-1-yl)benzamide 850665-89-3P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(trifluoromethyl)-3-pyridinecarboxamide 850665-90-6P, 4-[2-(4-Aminofurazan-3-yl)-6-(methyloxy)-1H-imidazo[4,5-c]pyridin-1-yl]phenol 850665-91-7P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(1H-imidazol-1-yl)benzamide 850665-92-8P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-6-(1H-pyrazol-1-yl)-3-pyridinecarboxamide 850665-93-9P, 4-[1-[4-[[2-(Dimethylamino)ethyl]oxy]phenyl]-6-(methyloxy)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850665-94-0P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[[2-(dimethylamino)ethyl]oxy]benzamide 850665-95-1P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-1-methyl-4-piperidinecarboxamide 850665-96-2P, 4-[2-(4-Aminofurazan-3-yl)-6-[(3-aminophenyl)oxy]-1H-imidazo[4,5-c]pyridin-1-yl]phenyl 4-(methyloxy)benzoate 850665-97-3P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-(4-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(dimethylamino)butanamide 850665-98-4P 850665-99-5P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-[4-[[2-(dimethylamino)ethyl]oxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(methyloxy)benzamide 850666-00-1P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-(4-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]methanesulfonamide 850666-01-2P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-3,4-bis(methyloxy)benzamide 850666-02-3P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-2,3-dihydro-1-benzofuran-5-carboxamide 850666-03-4P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-chloro-2-pyridinecarboxamide 850666-04-5P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-[4-[[2-(dimethylamino)ethyl]oxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-6-methyl-3-pyridinecarboxamide 850666-05-6P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(dimethylamino)butanamide 850666-06-7P, 5-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-1,3-dimethyl-1,3-dihydro-2H-benzimidazol-2-one 850666-07-8P, 3-[[2-(4-Aminofurazan-3-yl)-1-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]benzamide 850666-08-9P, 3-[[2-(4-Aminofurazan-3-yl)-1-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]benzamide 850666-09-0P, 3-[[2-(4-Aminofurazan-3-yl)-1-[4-(trifluoromethyl)phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]benzamide 850666-10-3P, 3-[[2-(4-Aminofurazan-3-yl)-1-[4-(trifluoromethyl)phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]benzamide 850666-11-4P 850666-12-5P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-[4-[[2-(dimethylamino)ethyl]oxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-2-methylpropanamide 850666-13-6P, Methyl 3-[[2-(4-aminofurazan-3-yl)-1-(phenylmethyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzoate 850666-14-7P, 3-[[2-(4-Aminofurazan-3-yl)-1-(phenylmethyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzoic acid 850666-15-8P, 3-[[2-(4-Aminofurazan-3-yl)-1-(phenylmethyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]benzamide 850666-16-9P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-[4-[[2-(dimethylamino)ethyl]oxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-N'-methylurea 850666-17-0P, 3-[[2-(4-Aminofurazan-3-yl)-1-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide 850666-18-1P, 3-[[2-(4-Aminofurazan-3-yl)-

1-[4-(trifluoromethyl)phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide 850666-19-2P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[[4-(methyloxy)phenyl]methyl]benzamide 850666-20-5P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-(methyloxy)phenyl]benzamide 850666-21-6P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-(dimethylamino)phenyl]benzamide 850666-22-7P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(dimethylamino)phenyl]benzamide 850666-23-8P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(dimethylamino)benzamide 850666-24-9P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(methyloxy)benzamide 850666-25-0P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide 850666-26-1P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]benzamide 850666-27-2P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]benzamide 850666-29-4P, 4-(Aminomethyl)-N-[3-[[2-(4-aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]benzamide 850666-31-8P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-3-(3-pyridinyl)propanamide 850666-33-0P, 4-(Aminomethyl)-N-[3-[[2-(4-aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]benzamide 850666-35-2P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-(dimethylamino)phenyl]benzamide 850666-37-4P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-(4-morpholinyl)phenyl]benzamide 850666-39-6P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-(methyloxy)phenyl]benzamide 850666-41-0P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-3-(4-morpholinyl)propanamide 850666-43-2P, 3-[[2-(4-Aminofurazan-3-yl)-1-[2-(4-morpholinyl)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzoic acid 850666-45-4P, 3-[[2-(4-Aminofurazan-3-yl)-1-[2-(4-morpholinyl)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide 850666-47-6P, 3-[[2-(4-Aminofurazan-3-yl)-1-[2-(4-morpholinyl)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]benzamide 850666-49-8P, 4-[1-Ethyl-6-[[3-[[3-(4-morpholinyl)propyl]oxy]phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850666-51-2P, 1-[3-[[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]oxy]propyl]-2-pyrrolidinone 850666-53-4P, 4-[6-[[3-[[3-(4-Acetyl-1-piperazinyl)propyl]oxy]phenyl]oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(inhibitor; preparation of aminofurazanyl imidazopyridines as Rho kinase inhibitors)

IT **850666-54-5P**, 3-[[2-(4-Aminofurazan-3-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]benzamide 850666-55-6P, 3-[[2-(4-Aminofurazan-3-yl)-1-[2-(methyloxy)phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide 850666-56-7P, 3-[[2-(4-Aminofurazan-3-yl)-1-[2-(methyloxy)phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]benzamide 850666-57-8P, 3-[[2-(4-Aminofurazan-3-yl)-1-[2-(methyloxy)phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]benzamide 850666-58-9P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[[2-(4-morpholinyl)ethyl]oxy]phenyl]benzamide 850666-59-0P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-3-(3-hydroxyphenyl)propanamide 850666-60-3P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-

yl]oxy]phenyl]-3-(4-hydroxyphenyl)propanamide 850666-61-4P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(2-oxo-1-pyrrolidinyl)butanamide 850666-62-5P, 3-[[2-(4-Aminofurazan-3-yl)-1-[2-(methyloxy)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide 850666-63-6P, 3-[[2-(4-Aminofurazan-3-yl)-1-[2-(methyloxy)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]benzamide 850666-64-7P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-[4-hydroxy-3-(methyloxy)phenyl]ethyl]benzamide 850666-65-8P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-3-(2-oxo-1-pyrrolidinyl)propanamide 850666-66-9P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(2-oxo-1-pyrrolidinyl)butanamide 850666-67-0P, 3-[[2-(4-Aminofurazan-3-yl)-1-(cyclopropylmethyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]benzamide 850666-68-1P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[(4-piperidinyl)methyl]benzamide 850666-69-2P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-piperidinyl)ethyl]benzamide 850666-70-5P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[[2-(4-morpholinyl)ethyl]oxy]benzamide 850666-71-6P, N-[2-(4-Acetyl-1-piperazinyl)ethyl]-3-[[2-(4-aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzamide 850666-72-7P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]benzamide 850666-73-8P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[[2-(dimethylamino)ethyl]oxy]phenyl]benzamide 850666-74-9P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-(cyclopropylmethyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[[2-(4-morpholinyl)ethyl]oxy]benzamide 850666-75-0P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[[3-(dimethylamino)propyl]oxy]phenyl]benzamide 850666-76-1P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[[3-(1-piperidinyl)propyl]oxy]benzamide 850666-77-2P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[[2-(diethylamino)ethyl]oxy]benzamide 850666-78-3P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[[2-(1-pyrrolidinyl)ethyl]oxy]benzamide 850666-79-4P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[[2-[bis(1-methylethyl)amino]ethyl]oxy]benzamide 850666-80-7P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[[2-(1-piperidinyl)ethyl]oxy]benzamide 850666-81-8P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-hydroxybenzamide 850666-82-9P, N-[4-(Acetylamino)phenyl]-3-[[2-(4-aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzamide 850666-83-0P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-(2-oxo-2-phenylethyl)benzamide 850666-84-1P, N-[4-(Aminocarbonyl)phenyl]-3-[[2-(4-aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzamide 850666-86-3P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]benzamide 850666-88-5P, 3-[[2-(4-Aminofurazan-3-yl)-1-(6-methyl-2-pyridinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide 850666-90-9P, 3-[[2-(4-Aminofurazan-3-yl)-1-(6-methyl-2-pyridinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]benzamide 850666-92-1P, 4-[1-Ethyl-6-[[3-[[2-(4-morpholinyl)ethyl]oxy]phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850666-94-3P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-thiomorpholinyl)ethyl]benzamide 850666-96-5P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(tetrahydro-2H-pyran-4-yl)ethyl]benzamide 850666-98-7P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[[3-(1-piperazinyl)propyl]oxy]benzamide 850667-00-4P,

3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(1,1-dioxido-4-thiomorpholinyl)ethyl]benzamide 850667-02-6P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(1-oxido-4-thiomorpholinyl)ethyl]benzamide 850667-04-8P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(1-piperidinyl)propyl]benzamide 850667-06-0P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[(1-methyl-4-piperidinyl)oxy]benzamide 850667-08-2P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-3-(4-piperidinyl)propanamide 850667-10-6P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[[2-(1-piperazinyl)ethyl]oxy]benzamide 850667-12-8P, 3-[[2-(4-Aminofurazan-3-yl)-1-[2-(methyloxy)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]benzamide 850667-14-0P, 3-[[2-(4-Aminofurazan-3-yl)-1-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]benzamide 850667-16-2P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[(1,1-dioxido-4-thiomorpholinyl)methyl]phenyl]benzamide 850667-17-3P, 4-[1-(1,2,3,4-Tetrahydro-7-isoquinolinyl)-6-[[4-(trifluoromethyl)phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850667-18-4P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-[4-[[2-(4-morpholinyl)ethyl]oxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide 850667-19-5P, 3-[[2-(4-Aminofurazan-3-yl)-1-[3-(methyloxy)propyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide 850667-20-8P, 3-[[2-(4-Aminofurazan-3-yl)-1-[3-(methyloxy)propyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]benzamide 850667-21-9P, 3-[[2-(4-Aminofurazan-3-yl)-1-(2-methyl-4-pyridinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]benzamide 850667-22-0P, Methyl 3-[[2-(4-aminofurazan-3-yl)-1-(1,3-benzodioxol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzoate 850667-23-1P, 3-[[2-(4-Aminofurazan-3-yl)-1-(1,3-benzodioxol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide 850667-24-2P, Methyl 3-[[2-(4-aminofurazan-3-yl)-1-(1H-indazol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzoate 850667-25-3P, 3-[[2-(4-Aminofurazan-3-yl)-1-(1H-indazol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide 850667-26-4P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-[4-[[2-(1-pyrrolidinyl)ethyl]oxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide 850667-27-5P, 3-[[2-(4-Aminofurazan-3-yl)-1-[2-(dimethylamino)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide 850667-28-6P, Methyl 3-[[2-(4-aminofurazan-3-yl)-1-(4-piperidinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzoate 850667-29-7P, Methyl 3-[[2-(4-aminofurazan-3-yl)-1-(4-bromophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzoate 850667-30-0P, Methyl 3-[[2-(4-aminofurazan-3-yl)-1-(1H-benzimidazol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzoate 850667-31-1P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[(4-morpholinyl)methyl]benzamide 850667-32-2P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-5-(trifluoromethyl)phenyl]acetamide 850667-33-3P, 4-[6-[[3-Amino-5-(trifluoromethyl)phenyl]oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850667-34-4P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(dimethylamino)propyl]-N-methylbenzamide 850667-35-5P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-[4-[[2-(diethylamino)ethyl]oxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide 850667-36-6P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[(dimethylamino)methyl]phenyl]benzamide 850667-37-7P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[2-(dimethylamino)ethyl]phenyl]benzamide 850667-38-8P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[2-(1-pyrrolidinyl)ethyl]phenyl]benzamide 850667-39-9P,

3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(1-methyl-4-piperidinyl)propyl]benzamide 850667-40-2P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-methyl-N-[3-(1-methyl-4-piperidinyl)propyl]benzamide 850667-41-3P, 3-[[2-(4-Aminofurazan-3-yl)-1-(4-piperidinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide 850667-42-4P, 3-[[2-(4-Aminofurazan-3-yl)-1-(4-bromophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide 850667-43-5P, 3-[[2-(4-Aminofurazan-3-yl)-1-(1H-benzimidazol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide 850667-44-6P, 3-[[2-(4-Aminofurazan-3-yl)-1-(4-bromophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]benzamide 850667-45-7P, 3-[[2-(4-Aminofurazan-3-yl)-1-(4-piperidinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]benzamide 850667-46-8P, 4-[1-[4-[[2-(Dimethylamino)ethyl]oxy]phenyl]-6-[[3-(methylsulfonyl)phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850667-47-9P, 3-[[2-(4-Aminofurazan-3-yl)-1-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(1-methyl-4-piperidinyl)propyl]benzamide 850667-48-0P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[(dimethylamino)methyl]benzamide 850667-49-1P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-[2-(methyloxy)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide 850667-50-4P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-methyl-1-piperazinyl)ethyl]benzamide 850667-51-5P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-[3-(methyloxy)propyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide 850667-52-6P, 4-[1-Ethyl-6-[[3-[[3-(1-methyl-4-piperidinyl)propyl]oxy]phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850667-53-7P, 3-[[2-(4-Aminofurazan-3-yl)-1-(1,2,3,4-tetrahydro-7-isoquinolinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide 850667-54-8P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-[4-[[2-(1-piperidinyl)ethyl]oxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide 850667-55-9P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-[4-[(cyanomethyl)oxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide 850667-56-0P, 4-[1-Ethyl-6-[[3-(1H-imidazol-1-yl)phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850667-57-1P, 4-[1-Ethyl-6-[[3-(1,3-thiazol-5-yl)phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850667-58-2P, 4-[1-Ethyl-6-[[3-(1,3-oxazol-5-yl)phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850667-59-3P, 4-[1-Ethyl-6-[[3-(methylsulfonyl)phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850667-60-6P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-3-(dimethylamino)propanamide 850667-61-7P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(4-morpholinyl)butanamide 850667-62-8P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(diethylamino)butanamide 850667-63-9P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(methylamino)butanamide 850667-64-0P, N-[5-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-2-methylphenyl]acetamide 850667-65-1P, N-[5-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-2-chlorophenyl]acetamide 850667-66-2P, 4-[1-Ethyl-6-[[3-[[2-(1-methyl-4-piperidinyl)ethyl]oxy]phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850667-67-3P, 4-[1-Ethyl-6-[[3-[[4-(1-methyl-4-piperidinyl)butyl]oxy]phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850667-68-4P, 4-[1-(2,3-Dihydro-1H-isoindol-5-yl)-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850667-69-5P, 4-[1-Ethyl-6-[[3-[[(1-methyl-4-piperidinyl)methyl]oxy]phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850667-70-8P, 4-[1-Ethyl-6-[[3-[[(1-methyl-3-piperidinyl)methyl]oxy]phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850667-71-9P,

4-[1-Ethyl-6-[[3-[[2-(1-methyl-3-piperidinyl)ethyl]oxy]phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850667-72-0P, Methyl 3-[[2-(4-aminofurazan-3-yl)-1-(2-methyl-1,3-benzoxazol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzoate 850667-73-1P, 4-[1-Ethyl-6-[[3-[4-(1-methyl-4-piperidinyl)butyl]phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850667-74-2P, 1-[3-[[2-(4-Aminofurazan-3-yl)-1-(1,2,3,4-tetrahydroisoquinolin-7-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]ethanone
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(inhibitor; preparation of aminofurazanyl imidazopyridines as Rho kinase inhibitors)

IT 4487-56-3P, 2,4-Dichloro-5-nitropyridine 4487-57-4P 13091-23-1P, 4-Chloro-3-nitropyridine 57659-03-7P, 6-Oxo-1,6-dihydro-3-pyridinecarbonyl chloride 64214-66-0P, 4-Chloro-N-methyl-N-(methyloxy)butanamide 84487-15-0P 161006-18-4P, 3-[[(tert-Butyl)dimethylsilyl]oxy]phenol 405213-13-0P, N-Methyl-N-(methyloxy)-4-(4-morpholinyl)butanamide 607373-82-0P 607373-89-7P 850663-54-6P 850663-55-7P, 2-Chloro-5-nitro-N-phenyl-4-pyridinamine 850663-56-8P, N-[3-[[5-Nitro-4-(phenylamino)-2-pyridinyl]oxy]phenyl]acetamide 850663-57-9P, N-[3-[[5-Amino-4-(phenylamino)-2-pyridinyl]oxy]phenyl]acetamide 850663-58-0P, N-[3-[[2-(Cyanomethyl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide 850663-60-4P, 2-Chloro-N-[4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]-5-nitro-4-pyridinamine 850663-61-5P, N-[3-[[4-[(4-Hydroxyphenyl)amino]-5-nitro-2-pyridinyl]oxy]phenyl]acetamide 850663-62-6P 850663-63-7P, N-[3-[[5-Amino-4-[(4-hydroxyphenyl)amino]-2-pyridinyl]oxy]phenyl]acetamide 850663-64-8P, N-[3-[[2-(Cyanomethyl)-1-(4-hydroxyphenyl)-2,3-dihydro-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide 850663-67-1P, 1,1-Dimethylethyl [3-[[4-(ethylamino)-5-nitro-2-pyridinyl]oxy]phenyl]carbamate 850663-68-2P, 1,1-Dimethylethyl [3-[[5-amino-4-(ethylamino)-2-pyridinyl]oxy]phenyl]carbamate 850663-73-9P, 7-(2-Chloro-5-nitropyridin-4-ylamino)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 850663-74-0P, 7-[2-(3-Acetylaminophenoxy)-5-nitropyridin-4-ylamino]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 850663-75-1P, 7-[2-(3-Acetylaminophenoxy)-5-aminopyridin-4-ylamino]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 850663-76-2P, 7-[6-(3-Acetylaminophenoxy)-2-cyanomethylimidazo[4,5-c]pyridin-1-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 850663-78-4P 850663-79-5P 850663-80-8P, (6-Bromo-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)acetonitrile 850663-81-9P, (6-Bromo-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)(hydroxyimino)acetonitrile 850663-82-0P, 4-(6-Bromo-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-amine 850663-86-4P, 4-(6-Bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-amine 850663-93-3P, 2-Chloro-5-nitro-N-[4-[(phenylmethyl)oxy]phenyl]-4-pyridinamine 850663-94-4P, 1,1-Dimethylethyl [3-[[5-nitro-4-[[4-[(phenylmethyl)oxy]phenyl]amino]-2-pyridinyl]oxy]phenyl]carbamate 850663-95-5P, 1,1-Dimethylethyl [3-[[5-amino-4-[(4-hydroxyphenyl)amino]-2-pyridinyl]oxy]phenyl]carbamate 850663-96-6P, 4-[2-(4-Aminofurazan-3-yl)-6-[(3-aminophenyl)oxy]-1H-imidazo[4,5-c]pyridin-1-yl]phenol 850663-98-8P, Methyl 3-[(4-amino-5-nitro-2-pyridinyl)oxy]benzoate 850664-00-5P, Methyl 3-[(4,5-diamino-2-pyridinyl)oxy]benzoate **850664-02-7P** 850664-04-9P, 4-(4-Morpholinyl)-1-[3-[(phenylmethyl)oxy]phenyl]-1-butanone 850664-05-0P, 1-(3-Hydroxyphenyl)-4-(4-morpholinyl)-1-butanone 850664-08-3P, 3-[(1E)-3-(4-Methyl-1-piperazinyl)-3-oxo-1-propen-1-yl]phenol 850664-10-7P, 3-[3-(4-Methyl-1-piperazinyl)-3-oxopropyl]phenol 850664-12-9P, 2-Methyl-4-(4-morpholinyl)-1-[3-[(phenylmethyl)oxy]phenyl]-1-butanone 850664-13-0P, 1-(3-Hydroxyphenyl)-2-methyl-4-(4-morpholinyl)-1-butanone 850664-15-2P, 4-[3-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]phenyl]-4-

oxobutanoic acid 850664-16-3P, 1-(3-Hydroxyphenyl)-4-(4-methyl-1-piperazinyl)-4-oxo-1-butanone 850664-19-6P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]methyl]benzoic acid 850664-20-9P 850664-23-2P, 3-(Methyloxy)-N-[2-(4-morpholinyl)ethyl]benzenesulfonamide 850664-24-3P, 3-Hydroxy-N-[2-(4-morpholinyl)ethyl]benzenesulfonamide 850664-25-4P, N-[2-(4-Morpholinyl)ethyl]-3-[[5-nitro-4-(phenylamino)-2-pyridinyl]oxy]benzenesulfonamide 850664-26-5P, 3-[[5-Amino-4-(phenylamino)-2-pyridinyl]oxy]-N-[2-(4-morpholinyl)ethyl]benzenesulfonamide 850664-27-6P, 3-[[2-(Cyanomethyl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]benzenesulfonamide 850664-29-8P, N-[3-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-6-oxo-1,6-dihydro-3-pyridinecarboxamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aminofurazanyl imidazopyridines as Rho kinase inhibitors)

IT **850663-97-7P**, Methyl 3-[[2-(4-aminofurazan-3-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzoate **850666-54-5P**, 3-[[2-(4-Aminofurazan-3-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(inhibitor; preparation of aminofurazanyl imidazopyridines as Rho kinase inhibitors)

RN 850663-97-7 CAPLUS
CN Benzoic acid, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 850666-54-5 CAPLUS
CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



IT **850664-02-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aminofurazanyl imidazopyridines as Rho kinase inhibitors)

RN 850664-02-7 CAPLUS
CN Benzoic acid, 3-[[2-(cyanomethyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)



L19 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:513486 CAPLUS
DN 141:47362
TI Pyridines for treating **injured** mammalian **nerve** tissue
IN Borgens, Richard B.; Shi, Riyi; Byrn, Stephen R.; Smith, Daniel T.
PA Purdue Research Foundation, USA
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004052291	A2	20040624	WO 2003-US38834	20031205
	WO 2004052291	A3	20041014		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2508165	AA	20040624	CA 2003-2508165	20031205
	US 2004171587	A1	20040902	US 2003-730495	20031205
	EP 1567497	A2	20050831	EP 2003-796756	20031205
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	US 2002-431637P	P	20021206		
	WO 2003-US38834	W	20031205		

OS MARPAT 141:47362
TI Pyridines for treating **injured** mammalian **nerve** tissue
AB The invention provides novel pyridines, pharmaceutical compns. comprising such pyridines, and the use of such compns. in treating **injured** mammalian **nerve** tissue, including but not limited to an **injured spinal** cord in one embodiment, the compds., compns., and methods of the instant invention treat a mammalian **nerve** tissue **injury** by restoring action potential or **nerve** impulse conduction through a **nerve** tissue lesion. Significantly, in vivo application of compds. of the instant invention established, on the basis of SSEP testing, that the compds. provide longer lasting effects at lower concns. than comparable treatment with the known agent 4-aminopyridine (4 AP).
ST pyridine pharmaceutical CNS PNS **nerve injury** **nervous** system agent
IT Drug delivery systems
(carriers; pyridines for treating **injured** mammalian **nerve** tissue)
IT **Injury**
(central **nervous** system; pyridines for treating **injured** mammalian **nerve** tissue)

IT Central **nervous** system, disease
Nerve, disease
Peripheral **nervous** system, disease
(**injury**; pyridines for treating **injured** mammalian **nerve** tissue)

IT **Injury**
(neuronal; pyridines for treating **injured** mammalian **nerve** tissue)

IT Disease, animal
Hemorrhage
Human
Infection
Ischemia
Neoplasm
Nervous system agents
(pyridines for treating **injured** mammalian **nerve** tissue)

IT Neurotrophic factors
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pyridines for treating **injured** mammalian **nerve** tissue)

IT **Spinal** cord, disease
(stenosis; pyridines for treating **injured** mammalian **nerve** tissue)

IT **Nerve**
(tissue lesion; pyridines for treating **injured** mammalian **nerve** tissue)

IT **Injury**
(trauma, and traumatic **nerve** compression; pyridines for treating **injured** mammalian **nerve** tissue)

IT 504-24-5, 4-Aminopyridine
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(pyridines for treating **injured** mammalian **nerve** tissue)

IT 54287-92-2P 79546-31-9P 98400-69-2P
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pyridines for treating **injured** mammalian **nerve** tissue)

IT 5221-42-1P, N-(4-Pyridyl)Acetamide 5221-44-3P, N-(4-Pyridyl)Benzamide **7397-68-4P** 21915-82-2P 22236-93-7P 39642-87-0P 70298-89-4P 97999-83-2P 125329-97-7P 260262-86-0P 705925-39-9P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pyridines for treating **injured** mammalian **nerve** tissue)

IT 117652-47-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pyridines for treating **injured** mammalian **nerve** tissue)

IT 54-96-6, 3,4-Diaminopyridine 79-03-8, Propionyl chloride 79-22-1, Methyl chloroformate 98-88-4, Benzoyl chloride 108-23-6, Isopropyl chloroformate 108-24-7, Acetic acid anhydride 121-44-8, Triethylamine, reactions 501-53-1, Benzyl chloroformate 530-62-1 541-41-3, Ethyl

chloroformate 691-64-5 1499-21-4 2524-64-3 3282-30-2, Pivaloyl chloride 14794-31-1 24460-74-0, Dodecyl chloroformate
RL: RCT (Reactant); RACT (Reactant or reagent)
(pyridines for treating **injured** mammalian **nerve** tissue)

IT **7397-68-4P**
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pyridines for treating **injured** mammalian **nerve** tissue)

RN 7397-68-4 CAPLUS
CN 2H-Imidazo[4,5-c]pyridin-2-one, 1,3-dihydro- (9CI) (CA INDEX NAME)



L19 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:252624 CAPLUS
DN 140:303678
TI Preparation of imidazopyridines as modulators for the IgE immune response in the treatment of allergic and proliferative diseases
IN Sircar, Jagadish C.; Thomas, Richard J.; Richards, Mark L.; Sinha, Anjana
PA Avanir Pharmaceuticals, USA
SO PCT Int. Appl., 167 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004024897	A2	20040325	WO 2003-US30962	20030912
	WO 2004024897	A3	20040826		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2498495	AA	20040325	CA 2003-2498495	20030912
	US 2004116466	A1	20040617	US 2003-661296	20030912
	EP 1546157	A2	20050629	EP 2003-773067	20030912
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003014235	A	20050809	BR 2003-14235	20030912
	JP 2006503048	T2	20060126	JP 2004-536644	20030912
PRAI	US 2002-410761P	P	20020912		
	WO 2003-US30962	W	20030912		

OS MARPAT 140:303678
IT Organelle
(mitotic **spindle**, poison; compound for coadministration with imidazopyridines for modulation of the IgE-mediated immune response and for suppression of cytokines and leukocytes in the treatment of

proliferative diseases)

IT **675199-90-3P** 675199-92-5P **675199-94-7P**
675199-95-8P 675199-97-0P 675199-99-2P
675200-01-8P 675200-02-9P 675200-03-0P
675200-04-1P 675200-05-2P 675200-06-3P
675200-07-4P 675200-08-5P 675200-09-6P
675200-10-9P 675200-11-0P 675200-12-1P 675200-13-2P
675200-14-3P 675200-15-4P 675200-16-5P 675200-17-6P 675200-18-7P
675200-19-8P **675200-20-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(invention compound; preparation of imidazopyridines as modulators for the IgE-mediated immune response and for the suppression of cytokines and leukocytes in the treatment of asthma and proliferative diseases)

IT 2586-99-4P 2604-39-9P 3073-30-1P 3537-14-2P 4318-79-0P,
2,3,6-Pyridinetriamine 14432-13-4P 23244-87-3P, 2,4,5-Pyridinetriamine
75007-79-3P 89488-06-2P 104685-75-8P 104685-76-9P 675200-21-2P
675200-22-3P 675200-23-4P **675200-24-5P 675200-25-6P**
675200-26-7P 675200-27-8P 675200-28-9P
675200-29-0P 675200-30-3P 675200-31-4P
675200-32-5P 675200-33-6P 675200-34-7P 675200-35-8P
675200-36-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazopyridines as modulators for the IgE-mediated immune response and for the suppression of cytokines and leukocytes in the treatment of asthma and proliferative diseases)

IT **675199-90-3P 675199-94-7P 675199-95-8P**
675199-97-0P 675199-99-2P 675200-01-8P
675200-02-9P 675200-03-0P 675200-04-1P
675200-05-2P 675200-06-3P 675200-07-4P
675200-08-5P 675200-09-6P 675200-10-9P
675200-20-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(invention compound; preparation of imidazopyridines as modulators for the IgE-mediated immune response and for the suppression of cytokines and leukocytes in the treatment of asthma and proliferative diseases)

RN 675199-90-3 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, N-[4-[4-[(tricyclo[3.3.1.13,7]dec-1-ylcarbonyl)amino]-1H-imidazo[4,5-c]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 675199-94-7 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, N-[4-(4-chloro-1H-imidazo[4,5-c]pyridin-2-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 675199-95-8 CAPLUS
CN Cyclohexanecarboxamide, N-[4-[6-[(cyclohexylcarbonyl)amino]-1H-imidazo[4,5-c]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 675199-97-0 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, N-[4-[6-[(tricyclo[3.3.1.13,7]dec-1-ylcarbonyl)amino]-1H-imidazo[4,5-c]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 675199-99-2 CAPLUS
CN 2-Pyridinecarboxamide, N-[2-[4-[(cyclohexylcarbonyl)amino]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 675200-01-8 CAPLUS
CN Cycloheptanecarboxamide, N-[4-[6-[(cycloheptylcarbonyl)amino]-1H-imidazo[4,5-c]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 675200-02-9 CAPLUS
CN 2-Pyridinecarboxamide, N-[2-[4-[(tricyclo[3.3.1.13,7]dec-1-ylcarbonyl)amino]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 675200-03-0 CAPLUS
CN Cyclohexanecarboxamide, N-[4-(1H-imidazo[4,5-c]pyridin-2-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 675200-04-1 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, N-[4-(1H-imidazo[4,5-c]pyridin-2-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 675200-05-2 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, 4-oxo-N-[4-[6-[(tricyclo[3.3.1.13,7]dec-1-ylcarbonyl)amino]-1H-imidazo[4,5-c]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 675200-06-3 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, N-[4-(4,6-dichloro-1H-imidazo[4,5-c]pyridin-2-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 675200-07-4 CAPLUS
CN 2-Pyridinecarboxamide, N-[2-[4-[[(4-oxotricyclo[3.3.1.13,7]dec-1-yl)carbonyl]amino]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 675200-08-5 CAPLUS
CN Cyclohexanecarboxamide, N-[4-(4,6-dichloro-1H-imidazo[4,5-c]pyridin-2-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 675200-09-6 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, 4-hydroxy-N-[4-[6-[(tricyclo[3.3.1.13,7]dec-1-ylcarbonyl)amino]-1H-imidazo[4,5-c]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 675200-10-9 CAPLUS
CN 2-Pyridinecarboxamide, N-[2-[4-[[(4-hydroxytricyclo[3.3.1.13,7]dec-1-yl)carbonyl]amino]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 675200-20-1 CAPLUS
CN Cyclohexanecarboxamide, N-[4-[6-[(cyclohexylcarbonyl)amino]-1H-imidazo[4,5-c]pyridin-2-yl]phenyl]-, dimethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 675199-95-8
CMF C26 H31 N5 O2



CM 2

CRN 75-75-2
CMF C H4 O3 S



IT **675200-24-5P 675200-25-6P 675200-26-7P**
675200-27-8P 675200-28-9P 675200-29-0P
675200-30-3P 675200-31-4P 675200-32-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazopyridines as modulators for the IgE-mediated immune response and for the suppression of cytokines and leukocytes in the treatment of asthma and proliferative diseases)
RN 675200-24-5 CAPLUS
CN 1H-Imidazo[4,5-c]pyridin-6-amine, 2-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 675200-25-6 CAPLUS
CN Cyclohexanecarboxamide, N-[2-(4-nitrophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 675200-26-7 CAPLUS
CN Cyclohexanecarboxamide, N-[2-(4-aminophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 675200-27-8 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, N-[2-(4-nitrophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 675200-28-9 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, N-[2-(4-aminophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 675200-29-0 CAPLUS
CN Cycloheptanecarboxamide, N-[2-(4-nitrophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 675200-30-3 CAPLUS
CN Cycloheptanecarboxamide, N-[2-(4-aminophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 675200-31-4 CAPLUS
CN 2-Pyridinecarboxamide, N-[2-(4-nitrophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 675200-32-5 CAPLUS
CN 2-Pyridinecarboxamide, N-[2-(4-aminophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]- (9CI) (CA INDEX NAME)



L19 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:645401 CAPLUS
DN 140:287319
TI Synthesis of Ticlopidine Analogs Based on **Spinaceamine** and 2-Azaspinaceamine
AU Yutilov, Yu. M.; Smolyar, N. N.; Abramyants, M. G.; Izotova, N. P.
CS Litvinenko Institute of Physical and Organic Chemistry and Carbochemistry, National Academy of Sciences of Ukraine, Donetsk, Ukraine
SO Pharmaceutical Chemistry Journal (Translation of Khimiko-Farmatsevticheskii Zhurnal) (2003), 37(5), 243-245
CODEN: PCJOAU; ISSN: 0091-150X
PB Kluwer Academic/Consultants Bureau
DT Journal
LA English
OS CASREACT 140:287319
TI Synthesis of Ticlopidine Analogs Based on **Spinaceamine** and 2-Azaspinaceamine
IT **272-97-9**, 1H-Imidazo[4,5-c]pyridine 273-05-2, 1H-1,2,3-Triazolo[4,5-c]pyridine 611-19-8 45880-13-5 57680-52-1 108564-91-6 160752-04-5 675581-76-7 675581-77-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of ticlopidine analogs from imidazopyridines)
IT **675581-78-9P** 675581-79-0P 675581-80-3P 675581-81-4P 675581-82-5P 675581-83-6P 675581-84-7P 675581-85-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of ticlopidine analogs from imidazopyridines)

IT **272-97-9**, 1H-Imidazo[4,5-c]pyridine
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of ticlopidine analogs from imidazopyridines)

RN 272-97-9 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine (7CI, 8CI, 9CI) (CA INDEX NAME)



IT **675581-78-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of ticlopidine analogs from imidazopyridines)

RN 675581-78-9 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 5-[(2-chlorophenyl)methyl]-, chloride (9CI) (CA INDEX NAME)



RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:532661 CAPLUS

DN 139:101128

TI Preparation of chemokine receptor binding (benzimidazol-2-ylmethyl)(5,6,7,8-tetrahydroquinolin-8-yl)amines and related heterocyclic compounds with enhanced efficacy against AIDS and other disorders

IN Bridger, Gary J.; Skerlj, Renato T.; Kaller, Al; Harwig, Curtis; Bogucki, David; Wilson, Trevor; Crawford, Jason; McEachern, Ernest J.; Atsma, Bem; Nan, Siqiao; Zhou, Yuanxi; Schols, Dominique; Smith, Christopher Dennis; Di Fluri, Rosaria Maria

PA Anormed Inc., Can.; et al.

SO PCT Int. Appl., 360 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003055876	A1	20030710	WO 2002-US41407	20021223

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA	2467718	AA	20030710	CA 2002-2467718	20021223
AU	2002357379	A1	20030715	AU 2002-357379	20021223
BR	2002015050	A	20041013	BR 2002-15050	20021223
EP	1465889	A1	20041013	EP 2002-805977	20021223
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP	2005518397	T2	20050623	JP 2003-556406	20021223
NO	2004002578	A	20040907	NO 2004-2578	20040618
PRAI	US 2001-342716P	P	20011221		
	US 2002-350822P	P	20020117		
	WO 2002-US41407	W	20021223		

OS MARPAT 139:101128

IT **Spinal** column, disease
(spondyloarthropathy; preparation of chemokine receptor binding (benzimidazolylmethyl)(tetrahydroquinolinyl)amines and related heterocyclic compds. with enhanced efficacy against AIDS and other disorders)

IT 558441-51-3P 558441-52-4P 558441-53-5P 558441-54-6P 558441-55-7P, (1H-Benzimidazol-2-ylmethyl)((S)-pyrrolidin-2-ylmethyl)(5,6,7,8-tetrahydroquinolin-8-yl)amine trihydrobromide 558441-56-8P 558441-57-9P, (1H-Benzimidazol-2-ylmethyl)(piperidin-4-yl)(5,6,7,8-tetrahydroquinolin-8-yl)amine trihydrobromide 558441-59-1P 558441-62-6P 558441-64-8P 558441-66-0P, (1H-Benzimidazol-2-ylmethyl)[2-(imidazol-1-yl)ethyl](5,6,7,8-tetrahydroquinolin-8-yl)amine 558441-70-6P, (1H-Benzimidazol-2-ylmethyl)[3-(1H-imidazol-2-yl)propyl](5,6,7,8-tetrahydroquinolin-8-yl)amine 558441-74-0P 558441-75-1P, N1-(1H-Benzimidazol-2-ylmethyl)-N1-(5,6,7,8-tetrahydroquinolin-8-yl)propane-1,3-diamine trihydrobromide 558441-76-2P 558441-77-3P 558441-79-5P 558441-83-1P, N1-[[5-(4-Fluorophenyl)-1H-imidazol-2-yl]methyl]-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine 558441-86-4P 558441-88-6P, N1-(1H-Benzimidazol-2-ylmethyl)-N4-(pyridin-2-ylmethyl)-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine tetrahydrobromide 558441-89-7P, N1-(1H-Benzimidazol-2-ylmethyl)-N4-(1H-indol-3-ylmethyl)-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine 558441-91-1P, (1H-Benzimidazol-2-ylmethyl)[3-(piperidin-2-yl)propyl](5,6,7,8-tetrahydroquinolin-8-yl)amine trihydrobromide 558441-92-2P 558441-94-4P 558441-97-7P 558441-98-8P 558441-99-9P, N-(1H-Benzimidazol-2-ylmethyl)-N'-(pyrimidin-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine tetrahydrobromide 558442-00-5P, N-(1H-Benzimidazol-2-ylmethyl)-N'-(1H-imidazol-2-yl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine 558442-02-7P, N1-(1H-Benzimidazol-2-ylmethyl)-N4-(1H-indol-2-ylmethyl)-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine 558442-03-8P, (1H-Benzimidazol-2-ylmethyl)(5,6,7,8-tetrahydroquinolin-8-yl)(N,N-dimethyl-4-aminobutyl)amine trihydrobromide 558442-05-0P 558442-06-1P 558442-07-2P 558442-11-8P 558442-13-0P, N1-(1H-Benzimidazol-2-ylmethyl)-N1-[6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl]butane-1,4-diamine 558442-18-5P, (1H-Benzimidazol-2-ylmethyl)[3-(1H-imidazol-4-yl)propyl](5,6,7,8-tetrahydroquinolin-8-yl)amine 558442-20-9P 558442-21-0P, N-[4-[(1H-Benzimidazol-2-ylmethyl)(5,6,7,8-tetrahydroquinolin-8-yl)amino]butyl]benzenesulfonamide 558442-23-2P 558442-28-7P 558442-34-5P 558442-39-0P 558442-43-6P, N'-(1H-Benzimidazol-2-ylmethyl)-2-methyl-2-phenyl-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine 558442-47-0P, (1H-Benzimidazol-2-ylmethyl)(5,6,7,8-tetrahydroquinolin-8-yl)((4R)-4-

phenyl-4-aminobutyl)amine trihydrobromide 558442-55-0P, (1H-Benzimidazol-2-ylmethyl)(5,6,7,8-tetrahydroquinolin-8-yl)((1S)-1-phenyl-1-aminobut-4-yl)amine trihydrobromide 558442-57-2P, (1H-Benzimidazol-2-ylmethyl)(5,6,7,8-tetrahydroquinolin-8-yl)(4-amino-3-hydroxybutyl)amine 558442-65-2P, (1H-Benzimidazol-2-ylmethyl)(5,6,7,8-tetrahydroquinolin-8-yl)(4-amino-3-fluorobutyl)amine 558442-66-3P, [3-(1-Aminocyclopropyl)propyl][(1H-benzimidazol-2-yl)methyl](5,6,7,8-tetrahydroquinolin-8-yl)amine hydrobromide 558442-69-6P 558442-70-9P 558442-71-0P 558442-73-2P 558442-74-3P, N1-(1H-Benzimidazol-2-ylmethyl)-N1-(5,6,7,8-tetrahydroquinolin-8-yl)cyclohexane-trans-1,4-diamine trihydrobromide 558442-75-4P, N1-(1H-Benzimidazol-2-ylmethyl)-N1-((S)-5,6,7,8-tetrahydroquinolin-8-yl)-trans-cyclohexane-1,4-diamine trihydrochloride 558442-78-7P, N1-(1H-Benzimidazol-2-ylmethyl)-N1-(5,6,7,8-tetrahydroquinolin-8-yl)-N2-benzylcyclohexane-trans-1,4-diamine trihydrobromide 558442-79-8P, N1-(1H-Benzimidazol-2-ylmethyl)-N4-butyl-N1-(5,6,7,8-tetrahydroquinolin-8-yl)cyclohexane-trans-1,4-diamine trihydrobromide 558442-81-2P, N1-(1H-Benzimidazol-2-ylmethyl)-N1-(5,6,7,8-tetrahydroquinolin-8-yl)-N4,N4-dimethylcyclohexane-trans-1,4-diamine trihydrobromide 558442-82-3P 558442-83-4P, N-[trans-4-[(1H-Benzimidazol-2-ylmethyl)(5,6,7,8-tetrahydroquinolin-8-yl)amino]cyclohexyl]guanidine trihydrobromide 558442-85-6P, N1-(1H-Benzimidazol-2-ylmethyl)-N4-(1H-indol-3-ylmethyl)-N1-(5,6,7,8-tetrahydroquinolin-8-yl)cyclohexane-trans-1,4-diamine 558442-86-7P 558442-87-8P 558442-90-3P 558442-91-4P, N1-(1H-Benzimidazol-2-ylmethyl)-N4-(1H-indol-2-ylmethyl)-N1-(5,6,7,8-tetrahydroquinolin-8-yl)-cyclohexane-trans-1,4-diamine 558442-92-5P, (1H-Benzimidazol-2-ylmethyl)[cis-4-(morpholin-4-yl)cyclohexyl](5,6,7,8-tetrahydroquinolin-8-yl)amine trihydrobromide 558442-95-8P, (1H-Benzimidazol-2-ylmethyl)[trans-4-(morpholin-4-yl)cyclohexyl](5,6,7,8-tetrahydroquinolin-8-yl)amine trihydrobromide 558443-00-8P 558443-01-9P 558443-08-6P, N1-Allyl-N4-(1H-Benzimidazol-2-ylmethyl)-1-methyl-N4-(5,6,7,8-tetrahydroquinolin-8-yl)-trans-cyclohexane-1,4-diamine trihydrobromide 558443-09-7P 558443-15-5P 558443-16-6P 558443-24-6P, (Z)-N'-(1H-Benzimidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)but-2-ene-1,4-diamine 558443-25-7P, 2-[4-[(1H-Benzimidazol-2-ylmethyl)(5,6,7,8-tetrahydroquinolin-8-yl)amino]-(E)-but-2-enyl]isoindole-1,3-dione 558443-27-9P 558443-30-4P, N1-(1H-Benzimidazol-2-ylmethyl)-N1-(5,6,7,8-tetrahydroquinolin-8-yl)-(E)-but-2-ene-1,4-diamine 558443-31-5P, N1-(1H-Benzimidazol-2-ylmethyl)-N1-(5,6,7,8-tetrahydroquinolin-8-yl)but-2-yne-1,4-diamine 558443-33-7P 558443-37-1P, (E)-2-Aminomethyl-4-[(1H-benzimidazol-2-ylmethyl)(5,6,7,8-tetrahydroquinolin-8-yl)amino]but-2-en-1-ol 558443-42-8P, (Z)-2-Aminomethyl-4-[(1H-benzimidazol-2-ylmethyl)(5,6,7,8-tetrahydroquinolin-8-yl)amino]but-2-en-1-ol 558443-45-1P 558443-46-2P, N-(1H-Benzimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)cyclohexane-1,3-diamine trihydrobromide 558443-47-3P 558443-51-9P 558443-55-3P 558443-62-2P, N1-[(4,5,6,7-Tetrahydro-1H-benzimidazol-2-yl)methyl]-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine 558443-67-7P, N1-(1H-Benzimidazol-2-ylmethyl)-2-methylene-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine trihydrobromide 558443-74-6P, [[1-(2-Aminoethyl)cyclopropyl]methyl](1H-benzimidazol-2-ylmethyl)(5,6,7,8-tetrahydroquinolin-8-yl)amine trihydrobromide 558443-78-0P 558443-81-5P, N1-(1H-Benzimidazol-2-ylmethyl)-3,3-difluoro-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine 558443-89-3P, N1-(1H-Benzimidazol-2-ylmethyl)-2,2-difluoro-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine 558443-93-9P, (1H-Benzimidazol-2-ylmethyl)(5,6,7,8-tetrahydroquinolin-8-yl)[4-amino-3-(methoxyimino)butyl]amine 558444-12-5P 558444-20-5P 558444-29-4P, (1H-Benzimidazol-2-ylmethyl)(5,6,7,8-tetrahydroquinolin-8-yl)(1-amino-2-methylenebutan-4-yl)amine trihydrobromide 558444-42-1P, [(4-Methoxy-1H-benzimidazol-2-yl)methyl](5,6,7,8-tetrahydroquinolin-8-yl)(1-aminobutan-4-yl)amine trihydrobromide 558444-51-2P 558444-57-8P

558444-68-1P, N1-[(1-Methyl-1H-benzimidazol-2-yl)methyl]-N1-((S)-5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine trihydrochloride 558444-76-1P 558444-91-0P, N1-(1H-Benzimidazol-2-ylmethyl)-N1-(5,6,7,8-tetrahydroquinoxalin-5-yl)butane-1,4-diamine 558444-99-8P 558445-07-1P, N1-(1H-Benzimidazol-2-ylmethyl)-N1-((S)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)butane-1,4-diamine trihydrochloride 558445-09-3P 558445-18-4P 558445-27-5P, N1-[(5,6-Dimethyl-1H-benzimidazol-2-yl)methyl]-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine trihydrobromide 558445-34-4P 558445-36-6P, N1-[(4-Fluoro-1H-benzimidazol-2-yl)methyl]-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine trihydrobromide 558445-43-5P 558445-53-7P 558445-60-6P, N1-[(4,5-Dimethyl-1H-benzimidazol-2-yl)methyl]-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine trihydrobromide 558445-65-1P, N1-[(6-Fluoro-1H-benzimidazol-2-yl)methyl]-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine 558445-71-9P **558445-83-3P** 558445-86-6P, N1-[(5-Trifluoromethyl-1H-benzimidazol-2-yl)methyl]-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine trihydrobromide 558445-97-9P, N1-[(5,6-Dihydro-4H-imidazo[4,5,1-ij]quinolin-2-yl)methyl]-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine trihydrobromide 558446-08-5P, N1-[(1-Allyl-1H-benzimidazol-2-yl)methyl]-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine trihydrobromide 558446-18-7P 558446-29-0P 558446-39-2P 558446-47-2P, N1-[(4-Methyl-1H-imidazol-2-yl)methyl]-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine trihydrobromide 558446-53-0P, N1-[(1-Isopropyl-1H-imidazol-2-yl)methyl]-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine dihydrobromide 558446-60-9P 558446-70-1P, N1-[(4-Methyl-1-propyl-1H-imidazol-2-yl)methyl]-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine trihydrobromide 558446-79-0P 558446-86-9P, N1-[(1-Methyl-1H-imidazol-2-yl)methyl]-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine trihydrobromide 558446-92-7P, N1-[(1-Allyl-1H-imidazol-2-yl)methyl]-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine trihydrobromide 558446-97-2P 558447-02-2P 558447-14-6P, [2-[(1H-Benzimidazol-2-ylmethyl)(5,6,7,8-tetrahydroquinolin-8-yl)amino]ethyl]guanidine trihydrobromide 558447-20-4P, [[4-[(1H-Benzimidazol-2-ylmethyl)(5,6,7,8-tetrahydroquinolin-8-yl)amino]butyl]amino]acetic acid methyl ester trihydrobromide 558447-24-8P, Pyrazine-2-carboxylic acid N-[4-[(1H-benzimidazol-2-ylmethyl)((S)-5,6,7,8-tetrahydroquinolin-8-yl)amino]butyl]amide 558447-28-2P 558447-32-8P 558447-33-9P, N-[3-[(1H-Benzimidazol-2-ylmethyl)(5,6,7,8-tetrahydroquinolin-8-yl)amino]propyl]-6-hydroxynicotinamide trihydrobromide 558447-39-5P 558447-43-1P 558447-47-5P 558447-51-1P 558447-55-5P 558447-59-9P 558447-63-5P 558447-65-7P 558447-67-9P 558447-69-1P, N-[2-[(1H-Benzimidazol-2-ylmethyl)(5,6,7,8-tetrahydroquinolin-8-yl)amino]ethyl]-3,5-dichloroisonicotinamide 558447-75-9P, N-[3-[(1H-Benzimidazol-2-ylmethyl)(5,6,7,8-tetrahydroquinolin-8-yl)amino]propyl]-3,5-dichloroisonicotinamide 558447-78-2P 558447-82-8P, N-[4-[(1H-Benzimidazol-2-ylmethyl)((R)-5,6,7,8-tetrahydroquinolin-8-yl)amino]butyl]-3,5-dichloroisonicotinamide 558447-84-0P, N-[4-[[(1-Allyl-1H-imidazol-2-yl)methyl]((S)-5,6,7,8-tetrahydroquinolin-8-yl)amino]butyl]-3,5-dichloroisonicotinamide 558447-91-9P 558447-94-2P 558447-96-4P, N-[2-Aminomethyl-4-[(1H-benzimidazol-2-ylmethyl)((S)-5,6,7,8-tetrahydroquinolin-8-yl)amino]but-2-enyl]-3,5-dichloroisonicotinamide 558448-00-3P 558448-07-0P, (1H-Benzimidazol-2-ylmethyl)[cis-2-(piperidin-3-ylidene)ethyl](5,6,7,8-tetrahydroquinolin-8-yl)amine trihydrobromide 558448-17-2P, N-[4-[(1H-Benzimidazol-2-ylmethyl)((S)-5,6,7,8-tetrahydroquinolin-8-yl)amino]butyl]acetamide 558448-19-4P, [4-[(1H-Benzimidazol-2-ylmethyl)((S)-5,6,7,8-tetrahydroquinolin-8-yl)amino]butyl]urea 558448-21-8P, Pyrazine-2-carboxylic acid N-[3-[(1H-benzimidazol-2-ylmethyl)(5,6,7,8-tetrahydroquinolin-8-yl)amino]propyl]amide 558448-27-4P 558448-31-0P 558448-35-4P 558448-41-2P, [3-[[(1H-Benzimidazol-2-ylmethyl)(5,6,7,8-tetrahydroquinolin-8-

yl)amino]methyl]piperidin-1-yl](3,5-dichloropyridin-4-yl)methanone 558448-47-8P, [3-[[(1H-Benzimidazol-2-ylmethyl)(5,6,7,8-tetrahydroquinolin-8-yl)amino]methyl]pyrrolidin-1-yl](3,5-dichloropyridin-4-yl)methanone 558448-60-5P 558448-67-2P, 4-[(1H-Benzimidazol-2-ylmethyl)(5,6,7,8-tetrahydroquinolin-8-yl)amino]piperidine-1-carboxylic acid amide trihydrobromide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of chemokine receptor binding benzimidazolylmethyl tetrahydroquinolinyl amines and related heterocyclic compds. with enhanced efficacy against AIDS and other disorders)

IT **558445-83-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of chemokine receptor binding benzimidazolylmethyl tetrahydroquinolinyl amines and related heterocyclic compds. with enhanced efficacy against AIDS and other disorders)

RN 558445-83-3 CAPLUS
CN 1,4-Butanediamine, N-(1H-imidazo[4,5-c]pyridin-2-ylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)-, hydrobromide (10:33) (9CI) (CA INDEX NAME)



●33/10 HBr

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:454117 CAPLUS
DN 139:36439
TI Preparation of 2-pyridinone AMPA receptor antagonists for the treatment of demyelinating disorders and neurodegenerative diseases
IN Smith, Terence
PA Eisai Co., Ltd., Japan
SO PCT Int. Appl., 229 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003047577	A2	20030612	WO 2002-GB5542	20021206
WO 2003047577	A3	20030724		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA	2469076	AA	20030612	CA 2002-2469076	20021206
AU	2002347365	A1	20030617	AU 2002-347365	20021206
EP	1465626	A2	20041013	EP 2002-783299	20021206
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR	2002014705	A	20041123	BR 2002-14705	20021206
JP	2005515995	T2	20050602	JP 2003-548832	20021206
CN	1738618	A	20060222	CN 2002-827926	20021206
NO	2004002298	A	20040906	NO 2004-2298	20040603
PRAI GB	2001-29260	A	20011206		
	WO 2002-GB5542	W	20021206		

OS MARPAT 139:36439

IT **Spinal** cord, disease
(HIV- or HTLV-associated; preparation of pyridinone AMPA receptor antagonists
for treatment of demyelinating disorders and neurodegenerative diseases)

IT 380917-91-9P, 3-(2-Cyanophenyl)-5-(2-nitrophenyl)-1-phenyl-1,2-dihydropyridin-2-one 380917-92-0P, 5-(2-Aminophenyl)-3-(2-cyanophenyl)-1-phenyl-1,2-dihydropyridin-2-one 380917-94-2P, 3-(2-Chloro-3-pyridyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380917-95-3P, 3-(2-Cyanophenyl)-5-(2-pyridyl)-2-methoxypyridine 380917-96-4P, 3-(2-Cyanophenyl)-5-(2-pyridyl)-2(1H)-pyridone 380917-97-5P, 3-(2-Cyanophenyl)-1-phenyl-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380917-98-6P, 3-(2-Cyanophenyl)-5-(2-pyridyl)-1-(3-nitrophenyl)-1,2-dihydropyridin-2-one 380917-99-7P, 1-(3-Aminophenyl)-3-(2-cyanophenyl)-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380918-04-7P, 3-(2-Cyanophenyl)-5-(2-pyridyl)-1-(3-methoxycarbonylphenyl)-1,2-dihydropyridin-2-one 380918-07-0P, 3-(2-Chlorophenyl)-5-(2-pyridyl)-1-(4-methoxyphenyl)-1,2-dihydropyridin-2-one 380918-08-1P, 3-(2-Chlorophenyl)-5-(2-pyridyl)-1-(4-hydroxyphenyl)-1,2-dihydropyridin-2-one 380918-10-5P, 3-(2-Cyanophenyl)-5-(2-pyridyl)-1-(3-formylphenyl)-1,2-dihydropyridin-2-one 380918-11-6P, 3-(2-Cyanophenyl)-5-(2-pyridyl)-1-(3-hydroxymethylphenyl)-1,2-dihydropyridin-2-one 380918-16-1P, 3-(2-Cyanophenyl)-5-(2-pyridyl)-1-(4-methylthiophenyl)-1,2-dihydropyridin-2-one 380918-18-3P, 3-(2-Cyanophenyl)-5-(2-formylthiophen-3-yl)-1-phenyl-1,2-dihydropyridin-2-one 380919-56-2P, 5-(5-Acetoxypyridin-2-yl)-3-(2-cyanophenyl)-1-phenyl-1,2-dihydropyridin-2-one 380919-82-4P, 3-(4-Chlorophenylthio)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380920-55-8P 380920-71-8P, 1-[3-(Benzyloxy)phenyl]-3-(2-cyanophenyl)-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380920-73-0P, 3-[4-(tert-Butylaminosulfonyl)phenyl]-1-phenyl-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380920-81-0P, 3-(2-Formylthiophen-3-yl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380920-82-1P, 3-(2-Chloropyridin-5-yl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-10-8P, 3-(2-Cyanophenyl)-5-(2-pyridyl)-1-(3-hydroxyphenyl)-1,2-dihydropyridin-2-one 380921-14-2P, 1-[[1-(Benzyloxycarbonyl)piperidin-4-yl]methyl]-3-(2-cyanophenyl)-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380921-24-4P, 3-(2-Cyanophenyl)-1-(piperidin-4-yl)methyl-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380921-79-9P, 3-(2-Chlorophenyl)-5-(4-chlorophenylthio)-1-(3-pyridyl)-1,2-dihydropyridin-2-one 380921-87-9P, 3-(2-Cyanophenyl)-5-(2-pyridinecarbonyl)-1-phenyl-1,2-dihydropyridin-2-one 381248-06-2P 381725-50-4P, 1-Phenyl-5-(pyridin-2-yl)-2(1H)-pyridone **543699-86-1P**, 3-(2-Cyanophenyl)-5-(1H-imidazo[4,5-c]pyridin-2-yl)-1-phenyl-1,2-dihydropyridin-2-one

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(AMPA receptor antagonist; preparation of pyridinone AMPA receptor antagonists for treatment of demyelinating disorders and neurodegenerative diseases)

IT 380920-57-0P, 3-(2-Fluoropyridin-3-yl)-1-phenyl-5-(2-pyrimidinyl)-1,2-dihydropyridin-2-one 380920-58-1P, 3-(2-Fluoropyridin-3-yl)-1-(3-pyridyl)-5-(2-pyrimidinyl)-1,2-dihydropyridin-2-one 380920-59-2P, 3-(2-Cyanopyridin-3-yl)-1-phenyl-5-(2-pyrimidyl)-1,2-dihydropyridin-2-one 380920-60-5P, 3-(2-Cyanopyridin-3-yl)-1-(3-pyridyl)-5-(2-pyrimidinyl)-1,2-dihydropyridin-2-one 380920-61-6P, 3-(2-Cyanophenyl)-1-(3-nitrophenyl)-5-(2-pyrimidinyl)-1,2-dihydropyridin-2-one 380920-62-7P, 1-Phenyl-5-(2-pyridyl)-3-(thiazol-4-yl)-1,2-dihydropyridin-2-one 380920-63-8P, 3-(3-Oxo-1-cyclohexen-1-yl)-1-phenyl-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380920-64-9P, 3-(5,6-Dihydro-1,4-dioxin-2-yl)-1-phenyl-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380920-65-0P, 3-(2-Nitrophenyl)-1-phenyl-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380920-66-1P, 3-(4-Biphenylyl)-1-phenyl-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380920-67-2P, 3-(2-Acetylphenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380920-68-3P, 3-(3-Nitrophenyl)-1-phenyl-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380920-69-4P, 1-Phenyl-3-(4-pyridyl)-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380920-70-7P, 3-(4-Nitrophenyl)-1-phenyl-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380920-72-9P, 1-(3-Acetylphenyl)-3-(2-cyanophenyl)-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380920-74-1P, 3-(1-Naphthyl)-5-(2-pyridyl)-1-(3-pyridyl)-1,2-dihydropyridin-2-one 380920-75-2P, 3-(1-Naphthyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380920-76-3P, 3-(8-Quinolinyl)-5-(2-pyridyl)-1-(3-pyridyl)-1,2-dihydropyridin-2-one 380920-77-4P, 3-(8-Quinolinyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380920-78-5P, 3-(2-Naphthyl)-5-(2-pyridyl)-1-(3-pyridyl)-1,2-dihydropyridin-2-one 380920-79-6P, 3-(2-Naphthyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380920-80-9P, 3-(2-Pyrrolidinopyridin-5-yl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380920-83-2P, 3-(2-Fluoropyridin-5-yl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380920-84-3P, 3-(2-Ethylthiopyridin-5-yl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380920-85-4P, 3-(2-Cyanophenyl)-5-(2-pyridyl)-1-(2-naphthyl)-1,2-dihydropyridin-2-one 380920-86-5P, 3-(2-Cyanophenyl)-5-(2-pyridyl)-1-(1-naphthyl)-1,2-dihydropyridin-2-one 380920-87-6P, 3-(2-Cyanophenyl)-5-(2-pyridyl)-1-(8-quinolinyl)-1,2-dihydropyridin-2-one 380920-88-7P, 3-[1-(Benzenesulfonyl)indol-2-yl]-1-phenyl-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380920-89-8P, 3-(2-Cyanopyridin-3-yl)-5-(2-pyridyl)-1-(3-pyridyl)-1,2-dihydropyridin-2-one 380920-91-2P, 3-(2-Cyanophenyl)-5-(3-nitropyridin-2-yl)-1-phenyl-1,2-dihydropyridin-2-one 380920-92-3P, 3-(2-Cyanophenyl)-5-[2-(2,5-dimethylpyrrol-1-yl)pyridin-6-yl]-1-phenyl-1,2-dihydropyridin-2-one 380920-93-4P, 5-(2-Aminopyridin-6-yl)-3-(2-cyanophenyl)-1-phenyl-1,2-dihydropyridin-2-one 380920-94-5P, 3-(2-Cyanophenyl)-5-(5-nitropyridin-2-yl)-1-phenyl-1,2-dihydropyridin-2-one 380920-95-6P, 5-(6-Bromopyridin-2-yl)-3-(2-cyanophenyl)-1-phenyl-1,2-dihydropyridin-2-one 380920-96-7P, 3-(2-Cyanophenyl)-1-phenyl-5-(5-trifluoromethylpyridin-2-yl)-1,2-dihydropyridin-2-one 380920-97-8P, 3-(2-Cyanophenyl)-5-(2-morpholinopyridin-6-yl)-1-phenyl-1,2-dihydropyridin-2-one 380920-98-9P, 3-(2-Cyanophenyl)-5-(2-methoxycarbonylpyridin-6-yl)-1-phenyl-1,2-dihydropyridin-2-one 380920-99-0P, 5-[4-(tert-Butylaminosulfonyl)phenyl]-3-(2-cyanophenyl)-1-(3-pyridyl)-1,2-dihydropyridin-2-one 380921-00-6P, 3-(2-Cyanophenyl)-4-methyl-1-phenyl-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380921-01-7P, 1-Phenyl-3-(N'-phenylthioureido)-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380921-02-8P, 3-(2-Cyanophenyl)-1-phenyl-5-(N'-phenylureido)-1,2-dihydropyridin-2-one 380921-03-9P, 3-[4-(N'-Butylureido)phenyl]-1-phenyl-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380921-04-0P, 3-(2-Cyanophenyl)-1-phenyl-5-[(pyridin-2-

ylcarbonyl)amino]-1,2-dihydropyridin-2-one 380921-05-1P, 1-Phenyl-3-[[2-(1-pyrrolidino)acetyl]amino]-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380921-07-3P, 3-(3-Pyrrolidinopropionyl)amino-1-phenyl-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380921-08-4P, 5-Benzylamino-3-(2-cyanophenyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-09-5P, 3-Dibenzylamino-1-phenyl-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380921-11-9P, 1-Benzyloxymethyl-3-(2-cyanophenyl)-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380921-12-0P, 3-(2-Cyanophenyl)-1-cyclopentylmethyl-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380921-13-1P, 1-[[1-(tert-Butoxycarbonyl)piperidin-4-yl]methyl]-3-(2-cyanophenyl)-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380921-15-3P, 3-(Pyrrol-1-yl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-16-4P, 3-(2-Cyanophenylamino)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-17-5P, 3-(2-Pyridylamino)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-18-6P, 3-(1-Isoquinolylamino)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-19-7P, 3-(1-Indazolyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-20-0P, 3-(9-Carbazolyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-21-1P, 3-(Indol-1-yl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-22-2P, 3-(2-Methyl-5-phenylpyrrol-1-yl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-23-3P, 3-(2,5-Dimethylpyrrol-1-yl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-25-5P, 3-(2-Cyanophenyl)-1-[3-(4-piperidyloxy)phenyl]-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380921-26-6P, 1-(1-Benzoylpiperidin-4-yl)methyl-3-(2-cyanophenyl)-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380921-27-7P, 1-(1-Acetylpiperidin-4-yl)methyl-3-(2-cyanophenyl)-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380921-28-8P, 1-[3-[(N-Acetylpiperidin-4-yl)oxy]phenyl]-3-(2-cyanophenyl)-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380921-29-9P, 1-[3-[(N-Benzoylpiperidin-4-yl)oxy]phenyl]-3-(2-cyanophenyl)-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380921-30-2P, 1-[[1-(Benzenesulfonyl)piperidin-4-yl]methyl]-3-(2-cyanophenyl)-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380921-31-3P, 3-(2-Cyanophenyl)-1-[(1-methylsulfonylpiperidin-4-yl)methyl]-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380921-32-4P, 1-[3-[[1-(Benzenesulfonyl)piperidin-4-yl]oxy]phenyl]-3-(2-cyanophenyl)-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380921-33-5P, 3-(2-Cyanophenyl)-1-[3-[(1-methylsulfonylpiperidin-4-yl)oxy]phenyl]-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380921-34-6P, 3-(2-Cyanophenyl)-1-[(1-benzylpiperidin-4-yl)methyl]-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380921-35-7P, 3-(2-Cyanophenyl)-1-(1-methylpiperidin-4-yl)methyl-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380921-36-8P, 1-[3-[(N-Methylpiperidin-4-yl)oxy]phenyl]-3-(2-cyanophenyl)-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380921-37-9P, 1-[3-[(N-Benzylpiperidin-4-yl)oxy]phenyl]-3-(2-cyanophenyl)-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380921-38-0P, 3-(4-Sulfamoylphenyl)-1-phenyl-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380921-39-1P, 3-Cyclohexylaminocarbonyl-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-40-4P, 3-(2-Cyanophenyl)-5-(1-adamantylaminocarbonyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-41-5P, 3-(1-Adamantylaminocarbonyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-43-7P, 3-[(2-Phenylhydrazino)carbonyl]-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-44-8P, 3-Phenylaminocarbonyl-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-45-9P, 3-(2-Chlorophenyl)-5-(4-chlorobenzenesulfinyl)-1-(3-pyridyl)-1,2-dihydropyridin-2-one 380921-46-0P, 3-(2-Cyanophenyl)-5-(5-methyl-1H-benzimidazol-2-yl)-1-phenyl-1,2-dihydropyridin-2-one 380921-47-1P, 3-(2-Cyanophenyl)-5-(4-methyl-1H-benzimidazol-2-yl)-1-phenyl-1,2-dihydropyridin-2-one 380921-48-2P, 3-(2-Cyanophenyl)-5-(5,6-dichloro-1H-benzimidazol-2-yl)-1-phenyl-1,2-dihydropyridin-2-one 380921-49-3P, 3-(5,6-Dichloro-1H-benzimidazol-2-yl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-50-6P, 3-(6-Chloro-1H-benzimidazol-2-yl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-51-7P, 3-[1-(Pyridin-4-yl)benzimidazol-2-yl]-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-52-8P, 3-[1-(1-Benzylpiperidin-4-

yl)benzimidazol-2-yl]-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-53-9P, 3-(2-Cyanophenyl)-5-(5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2-yl)-1-phenyl-1,2-dihydropyridin-2-one 380921-54-0P, 3-(5,6-Dihydro-4H-imidazo[4,5,1-ij]quinolin-2-yl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-55-1P, 3-(1-Phenylbenzimidazol-2-yl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-56-2P, 3-(2-Chlorophenyl)-5-(6-chloro-1H-benzimidazol-2-yl)-1-phenyl-1,2-dihydropyridin-2-one 380921-58-4P, 3-(5-Methyl-1H-benzimidazol-2-yl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-59-5P, 3-(2-Cyanophenyl)-5-[1-(1-benzylpiperidin-4-yl)benzimidazol-2-yl]-1-phenyl-1,2-dihydropyridin-2-one 380921-60-8P, 3-(2-Cyanophenyl)-5-(5-methoxy-1H-benzimidazol-2-yl)-1-phenyl-1,2-dihydropyridin-2-one 380921-62-0P, 3-(2-Cyanophenyl)-5-[1-(pyridin-4-yl)benzimidazol-2-yl]-1-phenyl-1,2-dihydropyridin-2-one 380921-63-1P, 3-(2-Chlorophenyl)-5-(5-trifluoromethylbenzothiazol-2-yl)-1-phenyl-1,2-dihydropyridin-2-one 380921-64-2P, 3-(5-Trifluoromethylbenzothiazol-2-yl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-65-3P, 3-(2-Benzothiazolyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-66-4P, 5-(2-Benzothiazolyl)-3-[2-(2-benzothiazolyl)phenyl]-1-phenyl-1,2-dihydropyridin-2-one 380921-67-5P, 5-(2-Benzoxazolyl)-3-[2-(2-benzoxazolyl)phenyl]-1-phenyl-1,2-dihydropyridin-2-one 380921-68-6P, 3-(2-Benzoxazolyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-69-7P, 3-(2-Chlorophenyl)-5-(5-chlorobenzoxazol-2-yl)-1-phenyl-1,2-dihydropyridin-2-one 380921-70-0P, 3-(5-Chlorobenzoxazol-2-yl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-71-1P, 3-[1-(Piperidin-4-yl)benzimidazol-2-yl]-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-72-2P, 3-(2-Cyanophenyl)-5-[1-(piperidin-4-yl)benzimidazol-2-yl]-1-phenyl-1,2-dihydropyridin-2-one 380921-73-3P, 3-(2-Cyanophenyl)-5-(2-pyridyl)-1-(piperidin-3-yl)-1,2-dihydropyridin-2-one 380921-74-4P, 3-(2-Cyanophenyl)-5-(N-methylpiperidin-2-yl)-1-phenyl-1,2-dihydropyridin-2-one 380921-75-5P, 3-(2-Cyanophenyl)-5-(2-pyridyl)-1-(3-nitro-4-methylphenyl)-1,2-dihydropyridin-2-one 380921-76-6P, 3-(4-Chlorobenzenesulfinyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-77-7P, 3-(2-Ethylsulfinylpyridin-5-yl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-78-8P, 3-(2-Ethylpyridin-5-yl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-80-2P, 3-(2-Cyanophenyl)-5-(1H-benzimidazol-2-yl)-1-phenyl-1,2-dihydropyridin-2-one 380921-81-3P, 3-(2-Cyanophenyl)-5-(4-methylimidazo[4,5-b]pyridin-2-yl)-1-phenyl-1,2-dihydropyridin-2-one 380921-84-6P, 3-(2-Cyanothiophen-3-yl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-85-7P, 3-[2-(5-Oxazolyl)phenyl]-1-phenyl-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380921-86-8P, 3-[2-(5-Oxazolyl)thiophen-3-yl]-1-phenyl-5-(2-pyridyl)-1,2-dihydropyridin-2-one 380921-88-0P, 5-(2-Pyridinecarbonyl)-1-phenyl-3-phenyl-1,2-dihydropyridin-2-one 380921-89-1P, 3-(2-Cyanophenyl)-5-(α-hydroxy-2-picolyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-90-4P, 3-(2-Cyanophenyl)-5-[2-(pyridin-2-yl)vinyl]-1-phenyl-1,2-dihydropyridin-2-one 380921-91-5P, 3-[2-[2-(Ethoxycarbonyl)vinyl]thiophe n-3-yl]-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-92-6P, 3-(2-Cyanophenyl)-5-[1-(1-methylpiperidin-4-yl)benzimidazol-2-yl]-1-phenyl-1,2-dihydropyridin-2-one 380921-93-7P, 3-(2-Cyanophenyl)-5-(2-pyridyl)-1-(N-benzylpiperidin-3-yl)-1,2-dihydropyridin-2-one 380921-94-8P, 3-(4-Chlorobenzenesulfonyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-95-9P, 3-(2-Chlorophenyl)-5-(4-chlorobenzenesulfonyl)-1-(3-pyridyl)-1,2-dihydropyridin-2-one 380921-96-0P, 3-(2-Ethylsulfonylpyridin-5-yl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380922-38-3P, 3-(2-Adamantyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 381728-77-4P, 3-(2-Dimethylaminomethylphenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one dihydrochloride 543699-59-8P, 3-(2-Cyanophenyl)-5-(2-hydroxymethylthiophen-3-yl)-1-phenyl-1,2-dihydropyridin-2-one 543699-60-1P, 3-(2-Methoxycarbonylphenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 543699-61-2P, 3-(2-Methylaminocarbonylphenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-

2-one 543699-63-4P, 3-(2-Cyanophenyl)-5-(2-pyridyl)-1-(2-methoxyphenyl)-1,2-dihydropyridin-2-one 543699-64-5P, 3-(2-Methoxyphenyl)-5-(2-pyridyl)-1-(3-pyridyl)-1,2-dihydropyridin-2-one 543699-68-9P, 3-[4-(2-Cyanophenyl)piperidin-1-yl]-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 543699-70-3P, 3-(2-Cyanophenyl)-5-(1-methyl-1,2,3,6-tetrahydropyridin-2-yl)-1-phenyl-1,2-dihydropyridin-2-one 543699-75-8P, 3-(2-Cyanophenyl)-5-(2-pyridyl)-1-(pyrrol-3-yl)-1,2-dihydropyridin-2-one 543699-76-9P, 1-Phenyl-3-[[3-(4-phenylpiperidino)propionyl]amino]-5-(2-pyridyl)-1,2-dihydropyridin-2-one 543699-80-5P, 3-[1-[4-(2-Cyanophenyl)piperidino]carbonyl]-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one **543699-87-2P**, 3-(1H-Imidazo[4,5-c]pyridin-2-yl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 543699-88-3P, 3-(2-Cyanophenyl)-1-phenyl-5-(3-phenyl-1,2,4-oxadiazol-5-yl)-1,2-dihydropyridin-2-one 543699-89-4P, 3-(3-Phenyl-1,2,4-oxadiazol-5-yl)-1-phenyl-5-(2-pyridyl)-1,2-dihydropyridin-2-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(AMPA receptor antagonist; preparation of pyridinone AMPA receptor antagonists for treatment of demyelinating disorders and neurodegenerative diseases)

IT **543699-86-1P**, 3-(2-Cyanophenyl)-5-(1H-imidazo[4,5-c]pyridin-2-yl)-1-phenyl-1,2-dihydropyridin-2-one
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(AMPA receptor antagonist; preparation of pyridinone AMPA receptor antagonists for treatment of demyelinating disorders and neurodegenerative diseases)

RN 543699-86-1 CAPLUS

CN Benzonitrile, 2-[1,2-dihydro-5-(1H-imidazo[4,5-c]pyridin-2-yl)-2-oxo-1-phenyl-3-pyridinyl]- (9CI) (CA INDEX NAME)



IT **543699-87-2P**, 3-(1H-Imidazo[4,5-c]pyridin-2-yl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(AMPA receptor antagonist; preparation of pyridinone AMPA receptor antagonists for treatment of demyelinating disorders and neurodegenerative diseases)

RN 543699-87-2 CAPLUS

CN [2,3'-Bipyridin]-6'(1'H)-one, 5'-(1H-imidazo[4,5-c]pyridin-2-yl)-1'-phenyl- (9CI) (CA INDEX NAME)



L19 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:356448 CAPLUS
DN 138:368781
TI Preparation of N-(azabicyclyl)arylamides for therapeutic use as nicotinic acetylcholine receptor agonists
IN Walker, Daniel P.; Jacobsen, Eric Jon; Piotrowski, David W.; Wishka, Donn G.; Corbett, Jeffrey W.; Groppi, Vincent E., Jr.; Acker, Brad A.; Rauckhorst, Mark R.
PA Pharmacia & Upjohn Company, USA
SO PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003037896	A1	20030508	WO 2002-US31579	20021017
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2464194	AA	20030508	CA 2002-2464194	20021017
	EP 1438308	A1	20040721	EP 2002-784010	20021017
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002013760	A	20041019	BR 2002-13760	20021017
	JP 2005511574	T2	20050428	JP 2003-540177	20021017
PRAI	US 2001-344436P	P	20011026		
	US 2001-342674P	P	20011221		
	WO 2002-US31579	W	20021017		

OS MARPAT 138:368781
AB N-(azabicyclyl)arylamides, such as RNR1C(:X)W [R = azabicyclyl; R1 = H, alkyl, cycloalkyl, haloalkyl, aryl; W = heteroaryl; X = O, S], were prepared for therapeutic use as nicotinic acetylcholine receptor agonists. These amides are useful for the treatment of central **nervous** system disorders, such as cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain **injury**, behavioral and cognitive problems associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated

with Lewy Bodies, Huntington's disease, depression, general anxiety disorder, age-related macular degeneration, Parkinson's disease, tardive dyskinesia, Pick's disease, post traumatic stress disorder, dysregulation of food intake including bulimia and anorexia **nervosa**, withdrawal symptoms associated with smoking cessation and dependent drug cessation, Gilles de la Tourette's Syndrome, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain. Thus, the fumarate salt of amide I was prepared via a multistep synthetic sequence which included intramol. cyclization of trans-3-(tert-butoxycarbonylamino)-4-(2-hydroxyethyl)-1-(phenylmethyl)pyrrolidine to form exo-3-(tert-butoxycarbonylamino)-1-azabicyclo[2.2.1]heptane, which contains the target azabicyclic ring, and subsequent amidation of the corresponding azabicyclic amine with 1,3-benzoxazole-5-carboxylic acid. The prepared amides were assayed for human α7-5HT3 receptor binding activity.

IT 521277-58-7P 521277-59-8P 521277-61-2P 521277-62-3P 521277-65-6P
521277-68-9P 521277-69-0P 521277-72-5P 521277-79-2P 521277-80-5P
521277-85-0P 521277-96-3P 521277-98-5P 521277-99-6P,
N-[exo-(4S)-1-Azabicyclo[2.2.1]hept-3-yl]-1H-indazole-5-carboxamide fumarate 521278-05-7P 521278-06-8P 521278-10-4P 521278-11-5P
521278-18-2P 521278-19-3P, N-[(3R,5R)-1-Azabicyclo[3.2.1]oct-3-yl]-1,3-benzothiazole-6-carboxamide fumarate 521278-21-7P 521278-23-9P
521278-26-2P 521278-30-8P 521278-32-0P 521278-34-2P 521278-36-4P
521278-38-6P 521278-39-7P 521278-41-1P 521278-43-3P 521278-46-6P
521278-48-8P 521278-50-2P 521278-54-6P 521278-56-8P 521278-58-0P
521278-60-4P 521278-62-6P 521278-64-8P 521278-66-0P 521278-68-2P
521278-70-6P 521278-72-8P 521278-74-0P 521278-76-2P 521278-78-4P
521278-80-8P 521278-82-0P 521278-84-2P 521278-85-3P 521278-87-5P
521278-89-7P 521278-91-1P 521278-93-3P 521278-95-5P 521278-97-7P
521278-99-9P 521279-01-6P 521279-03-8P 521279-05-0P 521279-07-2P
521279-09-4P 521279-11-8P 521279-13-0P 521279-15-2P 521279-17-4P
521279-19-6P 521279-21-0P 521279-23-2P 521279-25-4P 521279-27-6P
521279-29-8P 521279-31-2P 521279-33-4P 521279-35-6P 521279-37-8P
521279-39-0P 521279-41-4P 521279-43-6P 521279-45-8P 521279-47-0P
521279-49-2P 521279-51-6P 521279-53-8P 521279-55-0P 521279-57-2P
521279-59-4P 521279-61-8P 521279-63-0P 521279-66-3P 521279-68-5P
521279-70-9P 521279-72-1P 521279-74-3P 521279-76-5P 521279-78-7P
521279-80-1P 521279-82-3P 521279-84-5P 521279-86-7P 521279-88-9P
521279-90-3P 521279-92-5P 521279-93-6P 521279-95-8P 521279-97-0P
521279-99-2P 521280-01-3P 521280-03-5P 521280-05-7P 521280-06-8P
521280-08-0P 521280-10-4P 521280-12-6P 521280-14-8P 521280-16-0P
521280-18-2P 521280-20-6P 521280-22-8P 521280-24-0P 521280-26-2P
521280-28-4P 521280-30-8P 521280-32-0P **521280-34-2P**
521280-36-4P 521280-38-6P 521280-40-0P 521284-86-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(azabicyclyl)arylamides for therapeutic use as nicotinic acetylcholine receptor agonists)

IT **521280-34-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(azabicyclyl)arylamides for therapeutic use as nicotinic acetylcholine receptor agonists)

RN 521280-34-2 CAPLUS
CN 3H-Imidazo[4,5-c]pyridine-6-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:334903 CAPLUS
DN 138:353988
TI Preparation of benzimidazoles and analogs and their use as protein kinase inhibitors
IN Edwards, Michael Louis; Cox, Paul Joseph; Amendola, Shelley; Deprets, Stephanie Daniele; Gillespy, Timothy Alan; Edlin, Christopher David; Morley, Andrew David; Gardner, Charles J.; Pedgrift, Brian; Bouchard, Herve; Babin, Didier; Gauzy, Laurence; Le Brun, Alain; Majid, Tahir Nedeem; Reader, John C.; Payne, Lloyd J.; Khan, Nawaz M.; Cherry, Michael
PA Aventis Pharmaceuticals Inc., USA
SO PCT Int. Appl., 711 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003035065	A1	20030501	WO 2002-GB4763	20021024
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	FR 2831537	A1	20030502	FR 2001-13868	20011026
	CA 2465247	AA	20030501	CA 2002-2465247	20021024
	US 2004048868	A1	20040311	US 2002-279834	20021024
	US 6897208	B2	20050524		
	EP 1441725	A1	20040804	EP 2002-801954	20021024
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002013562	A	20040831	BR 2002-13562	20021024
	JP 2005509633	T2	20050414	JP 2003-537632	20021024
	US 2006014756	A1	20060119	US 2005-29064	20050104
PRAI	FR 2001-13868	A	20011026		
	GB 2002-6893	A	20020322		
	GB 2002-6895	A	20020322		
	US 2002-395060P	P	20020711		
	US 2002-395151P	P	20020711		
	US 2002-279834	A1	20021024		
	WO 2002-GB4763	W	20021024		

OS MARPAT 138:353988
IT Reperfusion
Spinal cord, disease

(injury; preparation of benzimidazoles and analogs and their use as protein kinase inhibitors)

IT Injury
(**spinal** cord; preparation of benzimidazoles and analogs and their use as protein kinase inhibitors)

IT Inflammation
Spinal column, disease
(spondylitis, rheumatoid; preparation of benzimidazoles and analogs and their use as protein kinase inhibitors)

IT 88710-42-3P, 2-Phenyl-1H-imidazo[4,5-b]pyrazine 109073-55-4P, 2-(5-Methyl-1H-pyrazol-3-yl)-1H-benzimidazole 109073-56-5P, 5,6-Dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-1H-benzimidazole 142535-86-2P, 1H-Benzimidazole-5-carboxylic acid benzylamide 380653-63-4P, 2-(1H-Pyrazol-3-yl)-1H-benzimidazole 485833-00-9P, 3-(1H-Benzimidazol-2-yl)-1H-indazole 485833-01-0P, 5-Methoxy-2-(1H-indazol-3-yl)-1H-benzimidazole 485833-80-5P, 2-(1H-Indazole-3-yl)-3H-imidazo[4,5-b]pyridine **485834-70-6P**, 2-(1H-Indazol-3-yl)-3H-imidazo[4,5-c]pyridine 518355-10-7P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid benzylamide 518355-11-8P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-methylamide 518355-12-9P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-ethylamide 518355-13-0P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-isopropylamide 518355-14-1P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenylamide 518355-15-2P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenethylamide 518355-16-3P, [2-(1H-Indazol-3-yl)-1H-benzimidazol-5-yl]morpholinomethanone 518355-17-4P, [2-(1H-Indazol-3-yl)-1H-benzimidazol-5-yl](4-methylpiperazin-1-yl)methanone 518355-18-5P 518355-19-6P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(isobutyl)amide 518355-20-9P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(cyclohexylmethyl)amide 518355-22-1P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(2-furfuryl)amide 518355-23-2P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzyl-N-methylamide 518355-25-4P, 5,6-Dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole 518355-26-5P, 2-(1H-Indazol-3-yl)-3H-benzimidazole-4-carboxylic acid 518355-28-7P 518355-30-1P, 2-(4-Bromo-2H-pyrazol-3-yl)-5,6-dimethyl-1H-benzimidazole 518355-31-2P, 2-(5-Ethyl-2H-pyrazol-3-yl)-5,6-dimethyl-1H-benzimidazole 518355-32-3P, 2-(5-Ethyl-2H-pyrazol-3-yl)-4,5-ethylenedioxy-1H-benzimidazole 518355-33-4P, 2-(5-Ethyl-2H-pyrazol-3-yl)-5-methoxy-1H-benzimidazole 518355-34-5P, 2-(5-Ethyl-2H-pyrazol-3-yl)-4-hydroxy-1H-benzimidazole 518355-35-6P, 2-(5-Ethyl-2H-pyrazol-3-yl)-5-bromo-1H-benzimidazole 518355-36-7P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid 4-sulfamoylbenzylamide 518355-37-8P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid (3-ethoxypropyl)amide 518355-38-9P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid 4-bromobenzylamide 518355-39-0P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid 4-methanesulfonylbenzylamide 518355-40-3P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid (naphthalen-1-ylmethyl)amide 518355-41-4P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid 4-trifluoromethylbenzylamide 518355-42-5P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid (thiophen-2-ylmethyl)amide 518355-43-6P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid 4-dimethylaminobenzylamide 518355-44-7P, 4-[[[2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carbonyl]amino]methyl]piperidine-1-carboxylic acid tert-butyl ester 518355-45-8P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid 4-nitrobenzylamide 518355-46-9P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid (pyridin-3-ylmethyl)amide 518355-47-0P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid 3-bromobenzylamide 518355-48-1P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid 3-methoxybenzylamide 518355-49-2P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)amide 518355-50-5P,

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid (benzo[b]thiophen-3-ylmethyl)amide 518355-51-6P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid (1,3-dimethyl-1H-pyrazol-4-ylmethyl)amide 518355-52-7P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid 2-trifluoromethoxybenzylamide 518355-53-8P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid 2-methylbenzylamide 518355-54-9P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid (3-methylthiophen-2-ylmethyl)amide 518355-56-1P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid 2-trifluoromethylbenzylamide 518355-57-2P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid 4-phenoxybenzylamide 518355-58-3P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid 3-trifluoromethoxybenzylamide 518355-59-4P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid (3-isopropoxypropyl)amide 518355-60-7P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid (1-methyl-1H-pyrazol-4-ylmethyl)amide 518355-61-8P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid 4-isopropylbenzylamide 518355-62-9P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid (2,5-dimethylfuran-3-ylmethyl)amide 518355-63-0P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid (benzo[b]thiophen-2-ylmethyl)amide 518355-64-1P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid [3-(3-acetylaminophenoxy)propyl]amide 518355-65-2P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid (6-chloropyridin-3-ylmethyl)amide 518355-66-3P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid ([2,2']bithiophenyl-5-ylmethyl)amide 518355-67-4P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid (2,3-dihydrobenzofuran-5-ylmethyl)amide 518355-68-5P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid 4-cyanobenzylamide 518355-69-6P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid (5-chlorobenzo[b]thiophen-3-ylmethyl)amide 518355-70-9P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid 3-trifluoromethylbenzylamide 518355-71-0P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid 2-methylsulfanylbenzylamide 518355-72-1P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid (tetrahydropyran-4-ylmethyl)amide 518355-73-2P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid (2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)amide 518355-74-3P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid (furan-3-ylmethyl)amide 518355-75-4P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid 2-nitrobenzylamide 518355-76-5P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid (thiophen-3-ylmethyl)amide 518355-77-6P 518355-78-7P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid (1-methyl-1H-benzimidazol-2-ylmethyl)amide 518355-79-8P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid 3-methylbenzylamide 518355-80-1P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid 3-chlorobenzylamide 518355-81-2P, 2-(1H-Indazol-3-yl)-3H-benzimidazole-4-carboxylic acid 4-sulfamoylbenzylamide 518355-82-3P, 2-(1H-Indazol-3-yl)-3H-benzimidazole-4-carboxylic acid (3-ethoxypropyl)amide 518355-83-4P, 2-(1H-Indazol-3-yl)-3H-benzimidazole-4-carboxylic acid 4-bromobenzylamide 518355-84-5P, 2-(1H-Indazol-3-yl)-3H-benzimidazole-4-carboxylic acid (naphthalen-1-ylmethyl)amide 518355-85-6P, 2-(1H-Indazol-3-yl)-3H-benzimidazole-4-carboxylic acid (thiophen-2-ylmethyl)amide 518355-86-7P, 2-(1H-Indazol-3-yl)-3H-benzimidazole-4-carboxylic acid 4-dimethylaminobenzylamide 518355-87-8P, 2-(1H-Indazol-3-yl)-3H-benzimidazole-4-carboxylic acid 4-nitrobenzylamide 518355-88-9P, 2-(1H-Indazol-3-yl)-3H-benzimidazole-4-carboxylic acid (pyridin-3-ylmethyl)amide 518355-89-0P, 2-(1H-Indazol-3-yl)-3H-benzimidazole-4-carboxylic acid 3-bromobenzylamide 518355-90-3P, 2-(1H-Indazol-3-yl)-3H-benzimidazole-4-carboxylic acid 3-methoxybenzylamide 518355-91-4P, 2-(1H-Indazol-3-yl)-3H-benzimidazole-4-carboxylic acid (benzo[b]thiophen-3-ylmethyl)amide 518355-92-5P, 2-(1H-Indazol-3-yl)-3H-benzimidazole-4-carboxylic acid 4-phenoxybenzylamide 518355-93-6P, 2-(1H-Indazol-3-yl)-3H-benzimidazole-

4-carboxylic acid 3-trifluoromethoxybenzylamide 518355-94-7P, 2-(1H-Indazol-3-yl)-3H-benzimidazole-4-carboxylic acid (6-chloropyridin-3-ylmethyl)amide 518355-95-8P, 2-(1H-Indazol-3-yl)-3H-benzimidazole-4-carboxylic acid (2,3-dihydrobenzofuran-5-ylmethyl)amide 518355-96-9P, 2-(1H-Indazol-3-yl)-3H-benzimidazole-4-carboxylic acid 3-trifluoromethylbenzylamide 518355-97-0P, 2-(1H-Indazol-3-yl)-3H-benzimidazole-4-carboxylic acid 2-methylsulfanylbenzylamide 518355-98-1P, 2-(1H-Indazol-3-yl)-3H-benzimidazole-4-carboxylic acid (furan-3-ylmethyl)amide 518355-99-2P, 2-(1H-Indazol-3-yl)-3H-benzimidazole-4-carboxylic acid 2-nitrobenzylamide 518356-00-8P 518356-01-9P, 2-(1H-Indazol-3-yl)-3H-benzimidazole-4-carboxylic acid 3-chlorobenzylamide 518356-02-0P, 2-(1H-Indazol-3-yl)-3H-benzimidazole-4-carboxylic acid phenylamide 518356-03-1P, 2-(1H-Indazol-3-yl)-3H-benzimidazole-4-carboxylic acid benzylamide 518356-04-2P, 2-(1H-Indazol-3-yl)-3H-benzimidazole-4-carboxylic acid phenethylamide 518356-05-3P, 3-(6-Phenyl-1H-benzimidazol-2-yl)-2H-indazole 518356-06-4P, 3-[6-(2,4-Dichlorophenyl)-1H-benzimidazol-2-yl]-2H-indazole 518356-07-5P, 3-(6-Naphthalen-1-yl-1H-benzimidazol-2-yl)-2H-indazole 518356-08-6P, 3-[6-(4-Fluorophenyl)-1H-benzimidazol-2-yl]-2H-indazole 518356-09-7P, 3-[6-(4-Chlorophenyl)-1H-benzimidazol-2-yl]-2H-indazole 518356-10-0P, 3-[6-(4-Methoxyphenyl)-1H-benzimidazol-2-yl]-2H-indazole 518356-11-1P, 3-[6-(3-Chloro-4-fluorophenyl)-1H-benzimidazol-2-yl]-2H-indazole 518356-12-2P, 3-[6-(3,5-Dichlorophenyl)-1H-benzimidazol-2-yl]-2H-indazole 518356-13-3P, 3-(6-Thianthren-1-yl-1H-benzimidazol-2-yl)-2H-indazole 518356-14-4P, 3-(6-Biphenyl-4-yl-1H-benzimidazol-2-yl)-2H-indazole 518356-15-5P, 3-(6-p-Tolyl-1H-benzimidazol-2-yl)-2H-indazole 518356-16-6P, 3-(6-m-Tolyl-1H-benzimidazol-2-yl)-2H-indazole 518356-17-7P, 3-(6-o-Tolyl-1H-benzimidazol-2-yl)-2H-indazole 518356-18-8P, 3-(6-Thiophen-3-yl-1H-benzimidazol-2-yl)-2H-indazole 518356-19-9P, 3-[6-(3-Trifluoromethylphenyl)-1H-benzimidazol-2-yl]-2H-indazole 518356-20-2P, 3-[6-(4-Trifluoromethylphenyl)-1H-benzimidazol-2-yl]-2H-indazole 518356-21-3P, 3-[6-(3-Chlorophenyl)-1H-benzimidazol-2-yl]-2H-indazole 518356-22-4P, 3-[6-(3-Methoxyphenyl)-1H-benzimidazol-2-yl]-2H-indazole 518356-23-5P, 3-[6-(3,5-Dimethylphenyl)-1H-benzimidazol-2-yl]-2H-indazole 518356-24-6P, 3-[6-(3,4-Dimethylphenyl)-1H-benzimidazol-2-yl]-2H-indazole 518356-25-7P, 3-(6-Benzo[1,3]dioxol-5-yl-1H-benzimidazol-2-yl)-2H-indazole 518356-26-8P, 3-[6-(4-tert-Butylphenyl)-1H-benzimidazol-2-yl]-2H-indazole 518356-27-9P, 3-(6-Hex-1-enyl-1H-benzimidazol-2-yl)-2H-indazole 518356-28-0P, 3-[6-(3,4-Dimethoxyphenyl)-1H-benzimidazol-2-yl]-2H-indazole 518356-29-1P, 3-[2-(2H-Indazol-3-yl)-3H-benzimidazol-5-yl]phenol 518356-30-4P, 4-[2-(2H-Indazol-3-yl)-3H-benzimidazol-5-yl]phenol 518356-31-5P, 3-[6-(3,4-Dichlorophenyl)-1H-benzimidazol-2-yl]-2H-indazole 518356-32-6P, 3-[6-(4-Trifluoromethoxyphenyl)-1H-benzimidazol-2-yl]-2H-indazole 518356-33-7P, 1-[4-[2-(2H-Indazol-3-yl)-3H-benzimidazol-5-yl]phenyl]ethanone 518356-34-8P, 3-(6-Benzo[b]thiophen-2-yl-1H-benzimidazol-2-yl)-2H-indazole 518356-35-9P, 3-[6-(3,4,5-Trimethoxyphenyl)-1H-benzimidazol-2-yl]-2H-indazole 518356-36-0P, 1-[5-[2-(2H-Indazol-3-yl)-3H-benzimidazol-5-yl]thiophen-2-yl]ethanone 518356-38-2P, 3-[6-(4-Benzyloxyphenyl)-1H-benzimidazol-2-yl]-2H-indazole 518356-40-6P 518356-41-7P 518356-42-8P, 3-[6-(4-Ethylsulfanylphenyl)-1H-benzimidazol-2-yl]-2H-indazole 518356-43-9P, 3-[6-(2,4-Difluorophenyl)-1H-benzimidazol-2-yl]-2H-indazole 518356-44-0P, 3-[6-(3-Trifluoromethoxyphenyl)-1H-benzimidazol-2-yl]-2H-indazole 518356-45-1P, 3-[6-(4-Fluoro-2-methylphenyl)-1H-benzimidazol-2-yl]-2H-indazole 518356-46-2P, 3-[6-[2-(4-Fluorophenyl)vinyl]-1H-benzimidazol-2-yl]-2H-indazole 518356-47-3P, 3-[6-[2-(4-Chlorophenyl)vinyl]-1H-benzimidazol-2-yl]-2H-indazole 518356-48-4P, 3-[4-[2-(2H-Indazol-3-yl)-3H-benzimidazol-5-yl]phenyl]propionic acid 518356-49-5P, [4-[2-(2H-Indazol-3-yl)-3H-benzimidazol-5-yl]phenyl]methanol 518356-50-8P, 3-(6-Furan-2-yl-1H-benzimidazol-2-yl)-2H-indazole 518356-51-9P, 3-[6-(4-Isopropylphenyl)-1H-benzimidazol-2-yl]-2H-indazole

518356-52-0P, 3-[6-(4-Methanesulfonylphenyl)-1H-benzimidazol-2-yl]-2H-indazole 518356-53-1P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid [(5-methoxy-4-oxo-4H-pyran-2-yl)methyl]amide 518356-54-2P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid 4-acetylaminobenzylamide 518356-55-3P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid 3-nitrobenzylamide 518356-56-4P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid 2-fluorobenzylamide 518356-57-5P 518356-58-6P 518356-59-7P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid 4-bromo-2-fluorobenzylamide 518356-60-0P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid 4-chloro-2-fluorobenzylamide 518356-61-1P 518356-62-2P 518356-63-3P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid (4'-chlorobiphenyl-4-ylmethyl)amide 518356-64-4P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid [(3',5'-dichlorobiphenyl-4-yl)methyl]amide 518356-65-5P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid [(4'-fluorobiphenyl-4-yl)methyl]amide 518356-66-6P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid 2,6-difluoro-3-methylbenzylamide 518356-67-7P 518356-68-8P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid 4-chlorobenzylamide 518356-69-9P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid 4-chloro-2-methylbenzylamide 518356-70-2P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid 4-fluorobenzylamide 518356-71-3P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid [(2'-chlorobiphenyl-4-yl)methyl]amide 518356-72-4P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid (6-trifluoromethylpyridin-3-ylmethyl)amide 518356-73-5P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid (5-(pyridin-2-yl)thiophen-2-ylmethyl)amide 518356-74-6P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid (3-imidazol-1-ylpropyl)amide 518356-75-7P, 4-[2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carbonyl]piperazine-1-carboxylic acid tert-butyl ester 518356-76-8P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid (2,6-difluoro-4-chlorobenzyl)amide 518356-77-9P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid (2,4-dichloro-6-fluorobenzyl)amide 518356-78-0P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid (3-fluoro-4-chlorobenzyl)amide 518356-79-1P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid (2-fluoro-4-chloro-6-methylbenzyl)amide 518356-80-4P, 2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid (6-methoxypyridin-3-ylmethyl)amide 518356-81-5P, 2-[5-(Benzyloxy)-1H-pyrazol-3-yl]-1H-benzimidazole 518356-82-6P, 2-[5-(3-Phenylallyloxy)-1H-pyrazol-3-yl]-1H-benzimidazole 518356-83-7P, 2-[5-(2-Methylallyloxy)-1H-pyrazol-3-yl]-1H-benzimidazole 518356-85-9P, 2-[5-(3-Bromobenzyloxy)-1H-pyrazol-3-yl]-1H-benzimidazole 518356-86-0P, 3-[[5-(1H-Benzimidazol-2-yl)-1H-pyrazol-3-yloxy]methyl]benzonitrile 518356-87-1P, 2-[5-(4-Trifluoromethylbenzyloxy)-1H-pyrazol-3-yl]-1H-benzimidazole 518356-88-2P, 2-[5-(3,4-Dichlorobenzyloxy)-1H-pyrazol-3-yl]-1H-benzimidazole 518356-89-3P, 2-[5-(Pentafluorophenylmethoxy)-2H-pyrazol-3-yl]-1H-benzimidazole 518356-90-6P, 2-[5-(4-tert-Butylbenzyloxy)-2H-pyrazol-3-yl]-1H-benzimidazole 518356-91-7P, 2-[5-[2-(Benzenesulfonylmethyl)benzyloxy]-2H-pyrazol-3-yl]-1H-benzimidazole 518356-92-8P, 4-[[5-(1H-Benzimidazol-2-yl)-1H-pyrazol-3-yloxy]methyl]benzonitrile 518356-93-9P, 2-[5-(Biphenyl-4-ylmethoxy)-2H-pyrazol-3-yl]-1H-benzimidazole 518356-94-0P, 2,3-Dichlorobenzenesulfonic acid 5-(1H-benzimidazol-2-yl)-1H-pyrazol-3-yl ester 518356-97-3P, 2-[5-(3-Methoxybenzyloxy)-2H-pyrazol-3-yl]-1H-benzimidazole 518356-98-4P, 2-[5-(1H-Benzimidazol-2-yl)-1H-pyrazol-3-yloxy]-1-p-tolylethanone 518356-99-5P, 1-[5-(1H-Benzimidazol-2-yl)-1H-pyrazol-3-yloxy]-3,3,4,4,4-pentafluorobutan-2-one 518357-00-1P, 2-[5-(1H-Benzimidazol-2-yl)-1H-pyrazol-3-yloxy]-1-biphenyl-4-ylethanone 518357-01-2P, 1-[5-(1H-Benzimidazol-2-yl)-1H-pyrazol-3-yloxy]butan-2-one 518357-02-3P, 2-[5-(1H-Benzimidazol-2-yl)-1H-pyrazol-3-yloxy]-1-(4-dimethylaminophenyl)ethanone 518357-03-4P, 2-[5-(1H-Benzimidazol-2-yl)-1H-pyrazol-3-yloxy]-1-(3-phenylisoxazol-5-yl)ethanone 518357-04-5P,

2-[5-(1H-Benzimidazol-2-yl)-1H-pyrazol-3-yloxy]-N-phenylacetamide 518357-05-6P, 1-[5-(1H-Benzimidazol-2-yl)-1H-pyrazol-3-yloxy]-3,3-dimethylbutan-2-one 518357-06-7P, 1-Adamantan-1-yl-2-[5-(1H-benzimidazol-2-yl)-1H-pyrazol-3-yloxy]ethanone 518357-07-8P, 2-[5-(1H-Benzimidazol-2-yl)-1H-pyrazol-3-yloxy]-1-naphthalen-2-ylethanone 518357-08-9P, 4-[2-[5-(1H-Benzimidazol-2-yl)-1H-pyrazol-3-yloxy]acetyl]benzonitrile 518357-09-0P, 6-[2-[5-(1H-Benzimidazol-2-yl)-1H-pyrazol-3-yloxy]acetyl]-3,4-dihydro-1H-quinolin-2-one 518357-10-3P, 2-[5-(1H-Benzimidazol-2-yl)-1H-pyrazol-3-yloxy]-1-(4-trifluoromethoxyphenyl)ethanone 518357-11-4P, 5-[2-[5-(1H-Benzimidazol-2-yl)-1H-pyrazol-3-yloxy]acetyl]-2-chlorobenzenesulfonamide 518357-12-5P, 2-[5-(1H-Benzimidazol-2-yl)-1H-pyrazol-3-yloxy]-1-(4-methoxyphenyl)ethanone 518357-13-6P, 2-[5-(1H-Benzimidazol-2-yl)-1H-pyrazol-3-yloxy]-1-cyclopropylethanone 518357-15-8P, 2,2-Dimethylpropionic acid 5-(1H-benzimidazol-2-yl)-1H-pyrazol-3-yl ester 518357-16-9P, Benzyloxyacetic acid 5-(1H-benzimidazol-2-yl)-1H-pyrazol-3-yl ester 518357-17-0P, Benzoic acid 5-(1H-benzimidazol-2-yl)-1H-pyrazol-3-yl ester 518357-18-1P, 4-Methoxybenzoic acid 5-(1H-benzimidazol-2-yl)-1H-pyrazol-3-yl ester 518357-19-2P, Phenylacetic acid 5-(1H-benzimidazol-2-yl)-1H-pyrazol-3-yl ester 518357-20-5P, 2,3,4,5,6-Pentafluorobenzoic acid 5-(1H-benzimidazol-2-yl)-1H-pyrazol-3-yl ester 518357-21-6P, Cyclopropanecarboxylic acid 5-(1H-benzimidazol-2-yl)-1H-pyrazol-3-yl ester 518357-22-7P, 2,2,3,3,4,4,4-Heptafluorobutyric acid 5-(1H-benzimidazol-2-yl)-1H-pyrazol-3-yl ester 518357-23-8P, Cyclopentanecarboxylic acid 5-(1H-benzimidazol-2-yl)-1H-pyrazol-3-yl ester 518357-24-9P, 3-Phenylpropionic acid 5-(1H-benzimidazol-2-yl)-1H-pyrazol-3-yl ester 518357-25-0P, Biphenyl-4-carboxylic acid 5-(1H-benzimidazol-2-yl)-1H-pyrazol-3-yl ester 518357-26-1P, 3,5-Bis(trifluoromethyl)benzoic acid 5-(1H-benzimidazol-2-yl)-1H-pyrazol-3-yl ester 518357-27-2P, 4-Trifluoromethylbenzoic acid 5-(1H-benzimidazol-2-yl)-1H-pyrazol-3-yl ester 518357-28-3P, Thiophene-2-carboxylic acid 5-(1H-benzimidazol-2-yl)-1H-pyrazol-3-yl ester 518357-96-5P, 3-[6-(3-Benzyloxyphenyl)-1H-benzimidazol-2-yl]-2H-indazole 518986-46-4P, 5,6-Dimethyl-2-(5-thiophen-2-yl-2H-pyrazol-3-yl)-1H-benzimidazole 518986-47-5P, 3-(6-Phenyl-1H-benzimidazol-2-yl)-1H-indazole 518986-51-1P, 2-[5-(3,7-Dimethylocta-2,6-dienyloxy)-1H-pyrazol-3-yl]-1H-benzimidazole 518986-53-3P, 2-[5-(2-Morpholinoethoxy)-2H-pyrazol-3-yl]-1H-benzimidazole 518986-54-4P, 2-[5-(2-Piperidin-1-ylethoxy)-2H-pyrazol-3-yl]-1H-benzimidazole 518986-55-5P, Isonicotinic acid 5-(1H-benzimidazol-2-yl)-1H-pyrazol-3-yl ester 518986-60-2P, 5,6-Dimethyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-1H-benzimidazole 518986-63-5P, 6-Chloro-5-methyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-1H-benzimidazole 518986-66-8P, 6-Chloro-2-(5-ethylsulfanyl-1H-pyrazol-3-yl)-5-methyl-1H-benzimidazole 518986-68-0P, 2-(5-Methylsulfanyl-1H-pyrazol-3-yl)-5-trifluoromethyl-1H-benzimidazole 518986-70-4P, 2-(5-Cyclopropylmethylsulfanyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzimidazole 518986-72-6P, 2-(5-Ethylsulfanyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzimidazole 518986-74-8P, 5,6-Dimethyl-2-[5-(pyridin-3-ylmethylsulfanyl)-1H-pyrazol-3-yl]-1H-benzimidazole 518986-76-0P, 5-Fluoro-2-[5-(methylsulfanyl)-1H-pyrazol-3-yl]-1H-benzimidazole 518986-78-2P, 5,6-Dimethyl-2-(5-phenethylsulfanyl-1H-pyrazol-3-yl)-1H-benzimidazole 518986-80-6P, 4-Methyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-1H-benzimidazole
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of benzimidazoles and analogs and their use as protein kinase inhibitors)

IT **485834-70-6P**, 2-(1H-Indazol-3-yl)-3H-imidazo[4,5-c]pyridine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of benzimidazoles and analogs and their use as

protein kinase inhibitors)
RN 485834-70-6 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 2-(1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:319714 CAPLUS
DN 138:338157
TI Preparation of 1,4-disubstituted benzo-fused ureas as cytokine inhibitors
IN Cirillo, Pier F.; Hammach, Abdelhakim; Regan, John R.
PA Boehringer Ingelheim Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 100 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003032989	A1	20030424	WO 2002-US32809	20021011
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2462441	AA	20030424	CA 2002-2462441	20021011
	US 2003162968	A1	20030828	US 2002-269173	20021011
	US 6825184	B2	20041130		
	EP 1438048	A1	20040721	EP 2002-801703	20021011
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005506350	T2	20050303	JP 2003-535792	20021011
PRAI	US 2001-330254P	P	20011018		
	WO 2002-US32809	W	20021011		

OS MARPAT 138:338157
IT Inflammation
Spinal column, disease
(ankylosing spondylitis; preparation of 1,4-disubstituted benzo-fused ureas for treating cytokine-mediated diseases)
IT 96-35-5, Methyl glycolate **272-97-9**, 5-Azabenzimidazole
623-51-8, Ethyl thioglycolate 776-34-1, 4-Nitro-1-naphthylamine
1074-98-2, 3-Methyl-4-nitropyridine-N-oxide 1188-33-6,
N,N-Dimethylformamide diethyl acetal 3535-88-4 15862-34-7,
2-Hydroxy-3-nitro-5-bromopyridine 27532-96-3, Glycine tert-butyl ester hydrochloride 93434-59-4, Benzyl 2-hydroxy-3-phenylpropionate
285984-47-6 294852-07-6 404010-35-1 515843-46-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 1,4-disubstituted benzo-fused ureas as cytokine inhibitors)

IT **272-97-9**, 5-Azabenzimidazole
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 1,4-disubstituted benzo-fused ureas as cytokine inhibitors)
RN 272-97-9 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine (7CI, 8CI, 9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:221697 CAPLUS
DN 138:238006
TI Preparation of N-[7-aza[2.2.1]bicycloheptanyl]arylamides for therapeutic use as nicotinic acetylcholine receptor agonists
IN Wishka, Donn G.; Walker, Daniel Patrick; Corbett, Jeffrey W.; Reitz, Steven Charles; Rauckhorst, Mark R.; Groppi, Vincent E., Jr.
PA Pharmacia & Upjohn Company, USA
SO PCT Int. Appl., 224 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003022856	A1	20030320	WO 2002-US25959	20020904
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2460075	AA	20030320	CA 2002-2460075	20020904
	US 2003105089	A1	20030605	US 2002-234575	20020904
	EP 1425286	A1	20040609	EP 2002-757132	20020904
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002012477	A	20040824	BR 2002-12477	20020904
	JP 2005527472	T2	20050915	JP 2003-526930	20020904
PRAI	US 2001-322100P	P	20010912		
	US 2001-322333P	P	20010912		
	US 2001-322346P	P	20010912		
	US 2002-399530P	P	20020730		
	WO 2002-US25959	W	20020904		

OS MARPAT 138:238006
AB 7-Aza[2.2.1]bicycloheptane derivs., such as amides I [R1 = H, alkyl, cycloalkyl, haloalkyl, aryl; R2 = H, benzyl, alkyl, haloalkyl, cycloalkyl, aryl; W = heteroaryl; X = O, S], were prepared for therapeutic use as nicotinic acetylcholine receptor agonists. These amides are useful for the treatment of central **nervous** system disorders, such as cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration

associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain **injury**, behavioral and cognitive problems associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, depression, general anxiety disorder, age-related macular degeneration, Parkinson's disease, tardive dyskinesia, Pick's disease, post traumatic stress disorder, dysregulation of food intake including bulimia and anorexia **nervosa**, withdrawal symptoms associated with smoking cessation and dependent drug cessation, Gilles de la Tourette's Syndrome, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain. Thus, amide dihydrochloride II was prepared via a multistep synthetic sequence which included cycloaddn. of N-tert-butoxycarbonylpyrrole with BrC.tplbond.CCO2Me to form the azabicyclic ring, and subsequent amidation reaction of tert-Bu (1S,2R,4R)-2-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate with 3-methylfuro[2,3-c]pyridine-5-carboxylic acid. The prepared amides were assayed for human α7-5HT3 receptor binding activity.

IT 501899-60-1P 501899-61-2P 501899-62-3P 501899-63-4P 501899-64-5P
501899-65-6P 501899-66-7P 501899-67-8P 501899-68-9P 501899-69-0P
501899-70-3P 501899-71-4P 501899-72-5P 501899-73-6P 501899-74-7P
501899-75-8P 501899-76-9P 501899-77-0P 501899-78-1P 501899-79-2P
501899-80-5P 501899-81-6P 501899-82-7P 501899-83-8P 501899-84-9P
501899-85-0P 501899-86-1P 501899-87-2P 501899-88-3P 501899-89-4P
501899-90-7P 501899-91-8P 501899-92-9P 501899-93-0P 501899-94-1P
501899-95-2P 501899-96-3P 501899-97-4P 501899-98-5P 501899-99-6P
501900-00-1P 501900-01-2P 501900-02-3P 501900-03-4P 501900-04-5P
501900-05-6P 501900-06-7P 501900-07-8P 501900-08-9P 501900-09-0P
501900-10-3P 501900-11-4P 501900-12-5P 501900-13-6P 501900-14-7P
501900-15-8P 501900-16-9P 501900-17-0P 501900-18-1P 501900-19-2P
501900-20-5P 501900-21-6P 501900-22-7P 501900-23-8P 501900-24-9P
501900-25-0P 501900-26-1P 501900-27-2P 501900-28-3P 501900-29-4P
501900-30-7P 501900-31-8P 501900-32-9P 501900-33-0P 501900-34-1P
501900-35-2P 501900-36-3P 501900-37-4P 501900-38-5P 501900-39-6P
501900-40-9P 501900-41-0P 501900-42-1P 501900-43-2P 501900-44-3P
501900-45-4P 501900-46-5P 501900-47-6P 501900-48-7P 501900-49-8P
501900-50-1P 501900-51-2P 501900-52-3P 501900-53-4P 501900-54-5P
501900-55-6P 501900-56-7P 501900-57-8P 501900-58-9P 501900-59-0P
501900-60-3P 501900-61-4P 501900-62-5P 501900-63-6P 501900-64-7P
501900-65-8P 501900-66-9P 501900-67-0P 501900-68-1P 501900-69-2P
501900-70-5P 501900-71-6P 501900-72-7P 501900-73-8P 501900-74-9P
501900-75-0P 501900-76-1P 501900-77-2P 501900-78-3P 501900-79-4P
501900-80-7P 501900-81-8P 501900-82-9P 501900-83-0P 501900-84-1P
501900-85-2P 501900-86-3P 501900-87-4P 501900-88-5P 501900-89-6P
501900-90-9P 501900-91-0P 501900-92-1P 501900-93-2P 501900-94-3P
501900-95-4P 501900-96-5P 501900-97-6P 501900-98-7P 501900-99-8P
501901-00-4P 501901-01-5P 501901-02-6P 501901-03-7P
501901-04-8P 501901-05-9P 501901-06-0P 501901-07-1P
501901-08-2P 501901-09-3P 501901-10-6P 501901-11-7P 501901-12-8P
501901-13-9P 501901-14-0P 501901-15-1P 501901-16-2P 501901-17-3P
501901-18-4P 501901-19-5P 501901-20-8P 501901-21-9P 501901-22-0P
501901-23-1P 501901-24-2P 501901-25-3P 501901-26-4P 501901-27-5P
501901-28-6P 501901-29-7P 501901-30-0P 501901-31-1P 501901-32-2P
501901-33-3P 501901-34-4P 501901-35-5P 501901-36-6P 501901-37-7P
501901-38-8P 501901-39-9P 501901-40-2P 501901-41-3P 501901-42-4P
501901-43-5P 501901-44-6P 501901-45-7P 501901-46-8P 501901-47-9P
501901-48-0P 501901-49-1P 501901-50-4P 501901-51-5P 501901-52-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-[7-aza[2.2.1]bicycloheptanyl]arylamides for therapeutic use as nicotinic acetylcholine receptor agonists)

IT **501901-04-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-[7-aza[2.2.1]bicycloheptanyl]arylamides for therapeutic use as nicotinic acetylcholine receptor agonists)

RN 501901-04-8 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine-6-carboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:964354 CAPLUS
DN 138:24866
TI Preparation and formulation of N-quinuclidinyl-heteroaryls as nicotinic acetylcholinergic receptor modulators for the treatment of a variety of central nervous system disorders
IN Walker, Daniel P.; Wishka, Donn G.; Corbett, Jeffrey W.; Rauckhorst, Mark R.; Piotrowski, David W.; Groppi, Vincent E., Jr.
PA Pharmacia & Upjohn Company, USA
SO PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002100858	A2	20021219	WO 2002-US16570	20020606
WO 2002100858	A3	20030220		
WO 2002100858	C1	20031224		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2445471	AA	20021219	CA 2002-2445471	20020606
US 2003073707	A1	20030417	US 2002-163565	20020606
US 6828330	B2	20041207		
EP 1404674	A2	20040407	EP 2002-778934	20020606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

	JP 2004534065	T2	20041111	JP 2003-503625	20020606
	US 2004224977	A1	20041111	US 2004-865149	20040610
PRAI	US 2001-297629P	P	20010612		
	US 2001-297630P	P	20010612		
	US 2001-297631P	P	20010612		
	US 2001-297632P	P	20010612		
	US 2001-297633P	P	20010612		
	US 2001-328548P	P	20011011		
	US 2002-373496P	P	20020418		
	US 2002-163565	A3	20020606		
	WO 2002-US16570	W	20020606		

OS MARPAT 138:24866

AB N-quinuclidinyl-heteroaryls, such as amides I [R1 = H, alkyl, cycloalkyl, haloalkyl, aryl; R2 = H, benzyl, alkyl, haloalkyl, cycloalkyl, aryl; W = aryl, heteroaryl; X = O, S], were prepared for therapeutic use in the treatment of central **nervous** system disorders, such as cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain **injury**, behavioral and cognitive problems associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, depression, general anxiety disorder, age-related macular degeneration, Parkinson's disease, tardive dyskinesia, Pick's disease, post traumatic stress disorder, dysregulation of food intake including bulimia and anorexia **nervosa**, withdrawal symptoms associated with smoking cessation and dependent drug cessation, Gilles de la Tourette's Syndrome, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain. Thus, the fumarate salt of (3R)-N-quinuclidinyl amide II was prepared via the formation of 6-benzoxazolecarboxylic acid in 89% yield by cyclization of 4-amino-3-hydroxybenzoic acid and (MeO)3C at 100° for 2 h followed by amide formation of the acid with (R)-(+)-3-aminoquinuclidine dihydrochloride using DIEA in a 5:1 mixture of THF/DMF and subsequent fumarate salt formation. The prepared quinuclidine derivs. were assayed for nicotinic acetylcholinergic receptor binding activity using brain cell membrane prepared from male Sprague-Dawley rats.

IT 478169-36-7P 478169-37-8P, N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-1,3-benzoxazole-6-carboxamide fumarate 478169-39-0P 478169-40-3P
478169-41-4P 478169-42-5P 478169-43-6P 478169-44-7P 478169-45-8P
478169-46-9P 478169-47-0P 478169-48-1P 478169-49-2P 478169-50-5P
478169-51-6P 478169-57-2P 478169-60-7P 478169-61-8P 478169-66-3P
478169-67-4P 478169-73-2P 478169-75-4P 478169-76-5P 478169-78-7P
478169-79-8P 478169-80-1P 478169-81-2P 478169-82-3P 478169-83-4P
478169-84-5P 478169-85-6P 478169-86-7P 478169-87-8P 478169-88-9P
478169-89-0P 478169-90-3P 478169-91-4P 478169-92-5P 478169-93-6P
478169-94-7P 478169-95-8P 478169-96-9P 478169-97-0P 478169-98-1P
478169-99-2P 478170-00-2P 478170-01-3P 478170-02-4P 478170-03-5P
478170-04-6P 478170-05-7P 478170-06-8P 478170-07-9P 478170-08-0P
478170-09-1P 478170-10-4P 478170-11-5P 478170-12-6P 478170-13-7P
478170-14-8P 478170-15-9P 478170-16-0P 478170-17-1P 478170-18-2P
478170-19-3P 478170-20-6P 478170-21-7P 478170-22-8P 478170-23-9P
478170-24-0P 478170-25-1P 478170-26-2P 478170-27-3P 478170-28-4P
478170-29-5P **478170-30-8P** 478170-31-9P 478170-32-0P
478170-33-1P 478170-34-2P 478170-35-3P 478170-36-4P 478170-37-5P
478170-38-6P 478170-39-7P 478170-40-0P 478170-41-1P 478170-42-2P
478170-43-3P 478170-44-4P 478170-45-5P 478170-46-6P 478170-47-7P
478170-48-8P 478170-49-9P 478170-50-2P 478170-51-3P 478170-52-4P
478170-53-5P 478170-54-6P 478170-55-7P 478170-56-8P 478170-57-9P
478170-58-0P 478170-59-1P **478170-60-4P** 478170-61-5P

478170-62-6P 478170-63-7P 478170-64-8P 478170-65-9P 478170-66-0P
478170-67-1P 478170-68-2P 478170-69-3P 478170-70-6P 478170-71-7P
478170-72-8P 478170-73-9P 478170-74-0P 478170-75-1P 478170-76-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and formulation of N-quinuclidinyl-heteroaryls as nicotinic acetylcholinergic receptor modulators for treatment of a variety of central nervous system disorders)

IT **478170-30-8P 478170-60-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and formulation of N-quinuclidinyl-heteroaryls as nicotinic acetylcholinergic receptor modulators for treatment of a variety of central nervous system disorders)

RN 478170-30-8 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine-6-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478170-60-4 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine-6-carboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L19 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:543326 CAPLUS
DN 138:89731
TI Reduction of Imidazo[4,5-c]pyridine and [1,2,3]Triazolo[4,5-c]pyridine Derivatives to **Spinaceamines** and 2-Azaspinaceamines
AU Yutilov, Yu. M.; Smolyar, N. N.; Astashkina, N. V.
CS Litvinenko Institute of Physical Organic and Coal Chemistry, National Academy of Sciences of Ukraine, Donetsk, 83114, Ukraine
SO Russian Journal of Organic Chemistry (Translation of Zhurnal Organicheskoi Khimii) (2002), 38(3), 419-423
CODEN: RJOCEQ; ISSN: 1070-4280
PB MAIK Nauka/Interperiodica Publishing
DT Journal

LA English
OS CASREACT 138:89731
TI Reduction of Imidazo[4,5-c]pyridine and [1,2,3]Triazolo[4,5-c]pyridine Derivatives to **Spinaceamines** and 2-Azaspinaceamines
AB Reduction of 1-substituted [1,2,3]triazolo[4,5-c]pyridines with nickel-aluminum alloy in aqueous alkali gave 2-azaspinaceamines. Reduction of imidazo[4,5-c]pyridine and [1,2,3]triazolo[4,5-c]pyridine derivs. with formic acid in the presence of triethylamine resulted in formation of 5-formylspinaceamines and 2-azaspinaceamines. The 5-formyl group in the latter can be removed by acid hydrolysis. Unsubstituted 2-azaspinaceamine, an aza analog of natural **spinaceamine**, was synthesized for the first time.
ST **spinaceamine** prepn; redn imidazopyridine triazolopyridine prepn; azaspinaceamine prepn; formyl **spinaceamine** prepn deformylation decarbonylation; **spinaceaminecarboxaldehyde** triazolopyridinecarboxaldehyde formyl triazolopyridine prepn deformylation
IT Formylation
(deformylation; reduction of imidazo[4,5-c]pyridine and [1,2,3]triazolo[4,5-c]pyridine derivs. to **spinaceamines** and 2-azaspinaceamines)
IT Decarbonylation
Formylation
Reducing agents
Reduction
Reduction catalysts
(reduction of imidazo[4,5-c]pyridine and [1,2,3]triazolo[4,5-c]pyridine derivs. to **spinaceamines** and 2-azaspinaceamines)
IT 7440-02-0, Raney nickel, reactions
RL: RGT (Reagent); RACT (Reactant or reagent)
(catalyst; reduction of imidazo[4,5-c]pyridine and [1,2,3]triazolo[4,5-c]pyridine derivs. to **spinaceamines** and 2-azaspinaceamines)
IT 88-89-1 **272-97-9**, 1H-Imidazo[4,5-c]pyridine 273-05-2, 1H-1,2,3-Triazolo[4,5-c]pyridine 5028-32-0, 1-Methyl-1H-Imidazo[4,5-c]pyridine 45880-13-5, 1,2-Dimethyl-1H-Imidazo[4,5-c]pyridine 57680-52-1, 1-Methyl-1H-1,2,3-Triazolo[4,5-c]pyridine 61532-35-2, 1-Phenyl-1H-Imidazo[4,5-c]pyridine **63604-59-1**, 2-Methyl-1H-Imidazo[4,5-c]pyridine **75007-92-0**, 2-Phenyl-1H-Imidazo[4,5-c]pyridine 89734-93-0, 1-Methyl-2-phenyl-1H-Imidazo[4,5-c]pyridine 108564-91-6, 1-(Phenylmethyl)-1H-1,2,3-Triazolo[4,5-c]pyridine 129303-82-8, 1-Phenyl-1H-1,2,3-Triazolo[4,5-c]pyridine 160752-04-5, 1-Ethyl-1H-1,2,3-Triazolo[4,5-c]pyridine 187405-79-4, 1,4-Diethyl-1H-1,2,3-Triazolo[4,5-c]pyridine
RL: RCT (Reactant); RACT (Reactant or reagent)
(reduction of imidazo[4,5-c]pyridine and [1,2,3]triazolo[4,5-c]pyridine derivs. to **spinaceamines** and 2-azaspinaceamines)
IT 485402-41-3P 485402-43-5P 485402-44-6P 485402-46-8P 485402-48-0P 485402-50-4P 485402-52-6P 485402-53-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(reduction of imidazo[4,5-c]pyridine and [1,2,3]triazolo[4,5-c]pyridine derivs. to **spinaceamines** and 2-azaspinaceamines)
IT 11114-68-4
RL: RGT (Reagent); RACT (Reactant or reagent)
(reduction of imidazo[4,5-c]pyridine and [1,2,3]triazolo[4,5-c]pyridine derivs. to **spinaceamines** and 2-azaspinaceamines)
IT 62002-31-7P 87673-91-4P 98175-84-9P 160752-42-1P, 1-Ethyl-4,5,6,7-Tetrahydro-1H-1,2,3-Triazolo[4,5-c]pyridine dihydrochloride 160752-44-3P, 4,5,6,7-Tetrahydro-1-(phenylmethyl)-1H-1,2,3-Triazolo[4,5-c]pyridine 485402-33-3P, 4,5,6,7-Tetrahydro-1-methyl-1H-1,2,3-Triazolo[4,5-c]pyridine dihydrochloride 485402-34-4P 485402-35-5P 485402-36-6P 485402-37-7P 485402-38-8P, 4,5,6,7-Tetrahydro-1H-1,2,3-Triazolo[4,5-c]pyridine dihydrochloride

485402-39-9P 485402-40-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(reduction of imidazo[4,5-c]pyridine and [1,2,3]triazolo[4,5-c]pyridine derivs. to **spinaceamines** and 2-azaspinaceamines)

IT **272-97-9**, 1H-Imidazo[4,5-c]pyridine **63604-59-1**,
2-Methyl-1H-Imidazo[4,5-c]pyridine **75007-92-0**,
2-Phenyl-1H-Imidazo[4,5-c]pyridine
RL: RCT (Reactant); RACT (Reactant or reagent)
(reduction of imidazo[4,5-c]pyridine and [1,2,3]triazolo[4,5-c]pyridine derivs. to **spinaceamines** and 2-azaspinaceamines)

RN 272-97-9 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 63604-59-1 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 2-methyl- (9CI) (CA INDEX NAME)



RN 75007-92-0 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 2-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:709741 CAPLUS
DN 135:257257
TI Preparation of 2-(piperazinyl)pyrimidones as GSK3β inhibitors
IN Almario-Garcia, Antonio; Frost, Jonathan Reid; Li, Adrien-Tak; Ando, Ryoichi; Shoda, Aya
PA Sanofi-Synthelabo, Fr.; Mitsubishi-Tokyo Pharmaceuticals, Inc.
SO Eur. Pat. Appl., 18 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1136483	A1	20010926	EP 2000-400801	20000323
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	WO 2001070728	A1	20010927	WO 2001-EP3639	20010322
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2001062150 A5 20011003 AU 2001-62150 20010322
PRAI EP 2000-400801 A 20000323
EP 2000-400802 A 20000323
EP 2000-400803 A 20000323
WO 2001-EP3639 W 20010322
OS MARPAT 135:257257
AB The title compds. [I; R1 = aryl, heterocyclic ring having 1-4 heteroatoms selected from O, S, N, alkyl substituted by aryl; R2 = 2-, 3- or 4-pyridyl optionally substituted by alkyl, alkoxy or a halogen; n = 1-2] which are used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β such as Alzheimer's disease, Parkinson's disease, frontoparietal dementia, corticobasal degeneration, Pick's disease, cerebrovascular accidents, brain and **spinal** trauma, and peripheral neuropathies, were prepared and formulated. The compds. I [R2 = 4-pyridyl] were prepared by condensation of Et 3-(4-pyridyl)-3-oxopropionate (preparation given) with the amidine II or by reacting 2-(methylthio)-6-(pyridin-4-yl)pyrimidin-4(1H)-one (preparation given) with the piperazine III. All exemplified compds. I such as I [R1 = 2,5-Me2C6H3; R2 = 4-pyridyl; n = 1] showed IC50's of 0.1-10 μM against GSK3β.
ST piperazinylpyrimidone prepn formulation glycogen synthase kinase 3beta inhibitor; pyrimidone piperazinyl prepn formulation glycogen synthase kinase 3beta inhibitor; Alzheimer disease piperazinylpyrimidone prepn formulation; Parkinson disease piperazinylpyrimidone prepn formulation; dementia frontoparietal piperazinylpyrimidone prepn formulation; Pick disease piperazinylpyrimidone prepn formulation; cerebrovascular accident piperazinylpyrimidone prepn formulation; trauma brain **spinal** cord piperazinylpyrimidone prepn formulation; peripheral neuropathy piperazinylpyrimidone prepn formulation; corticobasal degeneration piperazinylpyrimidone prepn formulation
IT Brain, disease
Spinal cord
(trauma; preparation of 2-(piperazinyl)pyrimidones as GSK3β inhibitors)
IT 362468-12-0P 362468-13-1P 362468-14-2P 362468-15-3P 362468-16-4P
362468-17-5P 362468-18-6P 362468-19-7P 362468-20-0P 362468-21-1P
362468-22-2P 362468-23-3P 362468-24-4P 362468-25-5P 362468-26-6P
362468-27-7P 362468-28-8P 362468-29-9P 362468-30-2P 362468-31-3P
362468-32-4P 362468-33-5P 362468-34-6P 362468-35-7P
362468-36-8P 362468-37-9P 362468-38-0P 362468-39-1P 362468-40-4P
362468-41-5P 362468-42-6P 362468-43-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-(piperazinyl)pyrimidones as GSK3β inhibitors)
IT **362468-32-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-(piperazinyl)pyrimidones as GSK3β inhibitors)
RN 362468-32-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[4-(1H-imidazo[4,5-c]pyridin-4-yl)-1-piperazinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:688234 CAPLUS
DN 133:266589
TI Preparation of heterocyclic derivatives as chemokine receptor antagonists effective against HIV, tumor, and allergy
IN Bridger, Gary; Skerlj, Renato; Kaller, Al; Harwig, Curtis; Bogucki, David; Wilson, Trevor R.; Crawford, Jason; McEachern, Ernest J.; Atsma, Bem; Nan, Siqiao; Zhou, Yuanxi; Schols, Dominique
PA Anormed Inc., Can.
SO PCT Int. Appl., 274 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000056729	A1	20000928	WO 2000-CA321	20000324
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2368047	AA	20000928	CA 2000-2368047	20000324
	EP 1163238	A1	20011219	EP 2000-913979	20000324
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000010655	A	20020213	BR 2000-10655	20000324
	TR 200102799	T2	20020722	TR 2001-200102799	20000324
	NZ 514709	A	20030328	NZ 2000-514709	20000324
	JP 2003524620	T2	20030819	JP 2000-606590	20000324
	US 6750348	B1	20040615	US 2000-535314	20000324
	AU 775123	B2	20040715	AU 2000-35460	20000324
	NO 2001004593	A	20011029	NO 2001-4593	20010921
	US 2004235823	A1	20041125	US 2004-837467	20040430
PRAI	US 1999-125823P	P	19990324		
	US 2000-535314	A3	20000324		
	WO 2000-CA321	W	20000324		

OS MARPAT 133:266589

IT **Spinal** column
(ankylosing spondylitis; preparation of heterocyclic derivs. as chemokine receptor antagonists effective against HIV, tumor, and allergy)

IT **Spinal** column
(spondyloarthropathy; preparation of heterocyclic derivs. as chemokine receptor antagonists effective against HIV, tumor, and allergy)

IT 155791-73-4P 297769-01-8P 297769-02-9P 297769-03-0P 297769-04-1P
297769-05-2P 297769-06-3P 297769-07-4P 297769-08-5P 297769-09-6P
297769-10-9P 297769-11-0P 297769-12-1P 297769-13-2P 297769-14-3P
297769-15-4P 297769-16-5P 297769-17-6P 297769-18-7P 297769-19-8P
297769-20-1P 297769-21-2P 297769-22-3P 297769-23-4P 297769-24-5P
297769-25-6P 297769-26-7P 297769-27-8P 297769-28-9P 297769-29-0P
297769-30-3P 297769-31-4P 297769-33-6P 297769-34-7P 297769-35-8P
297769-36-9P 297769-37-0P 297769-38-1P 297769-39-2P 297769-40-5P
297769-41-6P 297769-42-7P 297769-43-8P 297769-44-9P 297769-45-0P
297769-46-1P 297769-47-2P 297769-48-3P 297769-49-4P 297769-50-7P
297769-51-8P 297769-52-9P 297769-53-0P 297769-54-1P 297769-55-2P
297769-56-3P 297769-57-4P 297769-58-5P 297769-59-6P 297769-60-9P
297769-61-0P 297769-62-1P **297769-63-2P** 297769-64-3P
297769-65-4P 297769-66-5P 297769-67-6P 297769-68-7P 297769-69-8P
297769-70-1P 297769-71-2P 297769-72-3P 297769-73-4P 297769-74-5P
297769-75-6P 297769-76-7P 297769-77-8P 297769-78-9P 297769-79-0P
297769-80-3P 297769-81-4P 297769-82-5P 297769-83-6P 297769-84-7P
297769-85-8P 297769-86-9P 297769-87-0P 297769-89-2P 297769-91-6P
297769-93-8P 297769-97-2P 297769-99-4P 297770-01-5P 297770-03-7P
297770-05-9P 297770-07-1P 297770-09-3P 297770-11-7P 297770-13-9P
297770-15-1P 297770-17-3P 297770-19-5P 297770-21-9P 297770-23-1P
297770-25-3P 297770-27-5P 297770-28-6P 297770-29-7P 297770-30-0P
297770-31-1P 297770-32-2P 297770-33-3P 297770-34-4P 297770-35-5P
297770-36-6P 297770-37-7P 297770-39-9P 297770-40-2P 297770-41-3P
297770-42-4P 297770-43-5P 297770-44-6P 297770-45-7P 297770-46-8P
297770-47-9P 297770-48-0P 297770-49-1P 297770-50-4P 297770-51-5P
297770-52-6P 297770-53-7P 297770-54-8P 297770-55-9P 297770-56-0P
297770-57-1P 297770-58-2P 297770-59-3P 297770-60-6P 297770-61-7P
297770-62-8P 297770-63-9P 297770-64-0P 297770-65-1P 297770-66-2P
297770-67-3P 297770-68-4P 297770-69-5P 297770-70-8P 297770-71-9P
297770-72-0P 297770-73-1P 297770-74-2P 297770-75-3P 297770-76-4P
297770-77-5P 297770-78-6P 297770-79-7P 297770-80-0P 297770-81-1P
297770-82-2P 297770-83-3P 297770-84-4P 297770-85-5P 297770-86-6P
297770-87-7P 297770-88-8P 297770-89-9P 297770-90-2P 297770-91-3P
297770-92-4P 297770-93-5P 297770-94-6P 297770-95-7P 297770-96-8P
297770-97-9P 297770-98-0P 297770-99-1P 297771-00-7P 297771-01-8P
297771-02-9P 297771-03-0P 297771-04-1P 297771-05-2P 297771-06-3P
297771-07-4P 297771-08-5P 297771-09-6P 297771-10-9P 297771-11-0P
297771-12-1P 297771-14-3P 297771-15-4P 297771-16-5P 297771-17-6P
297771-18-7P 297771-19-8P 297771-20-1P 297771-21-2P 297771-22-3P
297771-23-4P 297771-24-5P 297771-25-6P 297771-26-7P 297771-27-8P
297771-28-9P 297771-29-0P 297771-30-3P 297771-31-4P 297771-32-5P
297771-33-6P 297771-34-7P 297771-35-8P 297771-36-9P 297771-37-0P
297771-38-1P 297771-39-2P 297771-40-5P 297771-41-6P 297771-42-7P
297771-43-8P 297771-44-9P 297771-45-0P 297771-46-1P 297771-47-2P
297771-48-3P 297771-49-4P 297771-50-7P 297771-51-8P 297771-52-9P
297771-53-0P 297771-54-1P 297771-55-2P 297771-56-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic derivs. as chemokine receptor antagonists effective against HIV, tumor, and allergy)

IT 297771-57-4P 297771-58-5P 297771-59-6P 297771-60-9P 297771-61-0P
297771-62-1P 297771-63-2P 297771-64-3P 297771-65-4P 297771-66-5P
297771-67-6P 297771-68-7P 297771-69-8P 297771-70-1P 297771-71-2P
297771-72-3P 297771-73-4P 297771-74-5P 297771-75-6P 297771-76-7P

297771-77-8P 297771-78-9P 297771-79-0P 297771-80-3P
297771-81-4P 297771-82-5P 297771-83-6P 297771-84-7P 297771-85-8P
297771-86-9P 297771-87-0P 297771-88-1P 297771-89-2P 297771-90-5P
297771-91-6P 297771-92-7P 297771-93-8P 297771-94-9P 297771-95-0P
297771-96-1P 297771-97-2P 297771-98-3P 297771-99-4P 297772-00-0P
297772-01-1P 297772-03-3P 297772-04-4P 297772-05-5P 297772-06-6P
297772-07-7P 297772-08-8P 297772-09-9P 297772-10-2P 297772-11-3P
297772-12-4P 297772-13-5P 297772-14-6P 297772-51-1P 298182-52-2P
298681-21-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic derivs. as chemokine receptor antagonists effective against HIV, tumor, and allergy)

IT 66-99-9, 2-Naphthaldehyde 85-41-6, Phthalimide 93-09-4, 2-Naphthoic acid 94-52-0, 5-Nitro-benzimidazole 98-01-1, Furfural, reactions 98-03-3, Thiophene-2-carboxaldehyde 98-59-9, p-Toluenesulfonyl chloride 98-97-5, 2-Pyrazinecarboxylic acid 98-98-6, Picolinic acid 100-70-9, 2-Cyanopyridine 104-01-8, 4-Methoxyphenylacetic acid 109-73-9, n-Butylamine, reactions 109-96-6, 3-Pyrroline 122-97-4, 3-Phenylpropanol 134-32-7, 1-Naphthalenamine 135-02-4, o-Anisaldehyde 156-87-6, 3-Amino-1-propanol **272-97-9**, 1H-Imidazo[4,5-c]pyridine 532-24-1, Tropinone 578-66-5, 8-Aminoquinoline 607-34-1, 5-Nitroquinoline 607-35-2, 8-Nitroquinoline 612-96-4, 2-Phenylquinoline 613-51-4, 7-Nitroquinoline 615-18-9, 2-Chlorobenzoxazole 616-30-8, 3-Amino-1,2-propanediol 623-27-8, 1,4-Benzenedicarboxaldehyde 670-95-1, 4-Phenylimidazole 1003-29-8, Pyrrole-2-carboxaldehyde 1121-60-4, 2-Pyridinecarboxaldehyde 1122-58-3, 4-(Dimethylamino)-pyridine 1477-55-0, 1,3-Benzenedimethanamine 1694-92-4, 2-Nitrobenzenesulfonyl chloride 1913-12-8 2045-79-6, 2-(Methoxyphenyl)ethylamine 2217-40-5 2472-22-2, 6-Methoxy-2-tetralone 2483-46-7 2578-45-2, 2-Chloro-3,5-dinitropyridine 2706-56-1, 2-(2-Aminoethyl)-pyridine 3034-50-2, 4-Imidazolecarboxaldehyde 3171-45-7, 4,5-Dimethylphenylene-1,2-diamine 3182-95-4, L-Phenylalaninol 3731-51-9, 2-Aminomethylpyridine 3920-50-1, 3-Pyrazolecarboxaldehyde 4024-14-0, 1-Methyl-2-tetralone 4133-34-0, 7-Methoxy-2-tetralone 4294-57-9, p-Tolylmagnesium bromide 4530-20-5, N-(tert-Butoxycarbonyl)glycine 4857-04-9, 2-Chloromethylbenzimidazole 5292-43-3, tert-Butyl bromoacetate 5470-96-2, 2-Quinolinecarboxaldehyde 6232-88-8, α-Bromo-p-toluic acid 6982-39-4, trans-2-Aminocyclohexanol 10111-08-7, Imidazole-2-carboxaldehyde 10200-59-6, Thiazole-2-carboxaldehyde 10500-57-9, 5,6,7,8-Tetrahydroquinoline 13952-84-6, sec-Butylamine 14649-03-7 15761-38-3, N-(tert-Butoxycarbonyl)-L-alanine 15761-39-4, Boc-L-proline 24424-99-5, Di-tert-butyl dicarbonate 36164-42-8 42464-80-2 68832-13-3 69610-40-8 76513-69-4, 2-(Trimethylsilyl)ethoxymethyl chloride 79099-07-3, N-Boc-4-piperidone 89711-08-0 117507-66-1 136159-63-2 137618-48-5 141222-95-9 181657-57-8 255383-17-6 255383-18-7 298181-75-6, N-[1-Methylene-4-(carboxaldehyde)phenylene]-N-(2-nitrobenzenesulfonyl)-2-(aminomethyl)pyridine 298181-77-8 298181-78-9 298181-79-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heterocyclic derivs. as chemokine receptor antagonists effective against HIV, tumor, and allergy)

IT **297769-63-2P 297771-77-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic derivs. as chemokine receptor antagonists effective against HIV, tumor, and allergy)

RN 297769-63-2 CAPLUS

CN 1,4-Benzenedimethanamine, N-(1H-imidazo[4,5-c]pyridin-2-ylmethyl)-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)- (9CI) (CA INDEX NAME)



RN 297771-77-8 CAPLUS
CN 1,4-Benzenedimethanamine, N-(1H-imidazo[4,5-c]pyridin-2-ylmethyl)-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)-, hydrobromide (10:49) (9CI) (CA INDEX NAME)



●49/10 HBr

IT **272-97-9**, 1H-Imidazo[4,5-c]pyridine
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heterocyclic derivs. as chemokine receptor antagonists effective against HIV, tumor, and allergy)
RN 272-97-9 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine (7CI, 8CI, 9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:132329 CAPLUS
DN 131:302
TI Possible involvement of DNA methylation in 5-azacytidine-induced neuronal cell apoptosis
AU Nakayama, H.; Kajikawa, S.; Shinozuka, J.; Su, W-P.; Doi, K.
CS Department of Veterinary Pathology, Faculty of Agriculture, The University of Tokyo, Tokyo, 113-8657, Japan
SO Histology and Histopathology (1999), 14(1), 143-150
CODEN: HIHIES; ISSN: 0213-3911

PB Histology and Histopathology
DT Journal
LA English
AB Eight chems. that are cytidine analogs or nucleosides (5-azacytidine (5AzC), 5-azadeoxycytidine, 6-azacytidine, 5-azacytosin, cytidine, 3-deazaadenine, 3-deazauridine and 6-azauridine) were examined for the ability to induce neuronal apoptosis. 5AzC and 5-azadeoxycytidine induced apoptosis in the brain and **spinal** cord of the fetuses at 24 h after the injection to dams, while the other chems. tested failed to induce apoptosis. In the system of PC12 cells, only 5AzC induced apoptosis, and other chems. failed to provoke morphol. and biochem. changes characteristic of apoptosis. 5AzC, 5-azadeoxycytidine and 6-azacytidine failed to induce apoptosis in C6 cells. Gel electrophoresis after MspI or HapII digestions revealed no apparent evidence of DNA demethylation after 5AzC-treatment in either fetal brains or PC12 cells. These results indicate that DNA demethylation is possibly involved in 5AzC-induced neuronal apoptosis although no direct evidence of DNA demethylation was obtained.
IT Apoptosis
Brain
Neuroglia
Spinal cord
(DNA methylation involvement in 5-azacytidine-induced neuronal cell apoptosis)
IT 54-25-1, 6-Azauridine 65-46-3, Cytidine 320-67-2, 5-Azacytidine 931-86-2, 5-Azacytosine 2353-33-5, 5-Azadeoxycytidine 3131-60-0, 6-Azacytidine **6811-77-4**, 3-Deazaadenine 23205-42-7, 3-Deazauridine
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(DNA methylation involvement in 5-azacytidine-induced neuronal cell apoptosis)
IT **6811-77-4**, 3-Deazaadenine
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(DNA methylation involvement in 5-azacytidine-induced neuronal cell apoptosis)
RN 6811-77-4 CAPLUS
CN 1H-Imidazo[4,5-c]pyridin-4-amine (9CI) (CA INDEX NAME)



RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1994:483184 CAPLUS
DN 121:83184
TI Synthesis of imidazo[4,5-c]pyridines with a trifluoromethyl group at C-4 and/or C-6
AU Gautam, Rakesh K.; Fujii, Shozo; Nishida, Masakazu; Kimoto, Hiroshi; Cohen, Louis A.
CS Natl. Ind. Res. Inst. Nagoya, Nagoya, 462, Japan
SO Journal of Heterocyclic Chemistry (1994), 31(2), 453-5
CODEN: JHTCAD; ISSN: 0022-152X
DT Journal
LA English

AB Thermal condensation of histamine with trifluoroacetaldehyde gives 4-(trifluoromethyl)**spinacamine** and subsequent dehydrogenation with selenium dioxide leads to 4-(trifluoromethyl)-1H-imidazo[4,5-c]pyridine (42%). Fluorination with sulfur tetrafluoride of L-**spinacine**, obtained from the condensation of L-histidine with formaldehyde, affords 6-(trifluoromethyl)**spinacamine**, which can be converted to 6-(trifluoromethyl)-1H-imidazo[4,5-c]pyridine with selenium dioxide (49%). Application of the sequential reactions to 4-(trifluoromethyl)-L-**spinacine** gives 4,6-bis(trifluoromethyl)-1H-imidazo[4,5-c]pyridine. Dehydrogenation of the tetrahydropyridine ring also occurred during the fluorination with sulfur tetrafluoride.

ST **spinacamine** trifluoromethyl; imidazopyridine trifluoromethyl

IT 113306-69-7, 4-(Trifluoromethyl)**spinacamine**
RL: RCT (Reactant); RACT (Reactant or reagent)
(dehydrogenation of)

IT 59981-63-4, L-**Spinacine** 113306-67-5, 4-(Trifluoromethyl)-L-**spinacine** 113351-14-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(fluorination of)

IT **156335-71-6P** 156335-72-7P 156335-73-8P 156335-74-9P **156335-75-0P 156335-76-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

IT **156335-71-6P 156335-75-0P 156335-76-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 156335-71-6 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine, 6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 156335-75-0 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine, 4,6-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 156335-76-1 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine, 4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L19 ANSWER 19 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1989:496540 CAPLUS
DN 111:96540
TI Nitrogen NMR studies on some fused ring nitrogen heterocycles
AU Stefaniak, L.; Witanowski, M.; Mahmoud, U.; Roberts, J. D.; Webb, G. A.
CS Inst. Org. Chem., Pol. Acad. Sci., Warsaw, Pol.
SO Journal of Crystallographic and Spectroscopic Research (1989), 19(1), 159-66
CODEN: JCREDB; ISSN: 0277-8068
DT Journal
LA English
ST nitrogen 14 15 NMR heterocycle; shielding additivity nitrogen NMR heterocycle; **spin** nuclear coupling nitrogen heterocycle; nuclear coupling shielding nitrogen heterocycle; fused ring nitrogen heterocycle NMR
IT **Spin**, nuclear coupling
(nitrogen-proton, in nitrogen heterocycles)
IT 91-18-9, Pteridine **272-97-9**, 1H-Imidazo[4,5-c]pyridine 274-88-4, Tetrazolo[1,5-c]pyrimidine 274-98-6, 1,2,4-Triazolo[4,3-a]pyrimidine 275-02-5, [1,2,4]Triazolo[1,5-a]pyrimidine 35523-67-2 122099-14-3
RL: PRP (Properties)
(nitrogen-15 NMR of)
IT 12586-59-3
RL: PRP (Properties)
(**spin**, nitrogen-proton, in nitrogen heterocycles)
IT **272-97-9**, 1H-Imidazo[4,5-c]pyridine
RL: PRP (Properties)
(nitrogen-15 NMR of)
RN 272-97-9 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine (7CI, 8CI, 9CI) (CA INDEX NAME)



L19 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1953:20107 CAPLUS
DN 47:20107
OREF 47:3480b-d
TI Bacteriological and pharmacological studies on purine analogs. I
AU Dimmling, Theodor; Hein, Helmut
CS Univ. Wurzburg, Germany
SO Arzneimittel-Forschung (1952), 2, 515-20
CODEN: ARZNAD; ISSN: 0004-4172
DT Journal
LA Unavailable
AB The following 11 compds. were tested for their inhibitory effect upon the growth of 16 different bacteria: 5-azabenzimidazole (**Spinazole**) (I) as Co-complex; the dihydrochloride of the 4,5,6,7-tetrahydro derivative of I and its 6-carboxylate; 4- and 7-amino derivs. of I; biquinazole; bibenzothiazole; 2-aminobenzothiazole; 2-aminobenzoxazole; 2,4-diaminoquinazoline (II); the Co-complex of 4 methylimidazole. II is the most active compound On the isolated frog heart, II causes diminution of the contractions, and in high doses diastolic paralysis. II causes damage to leucocytes and macrophages and in consequence of its high toxicity it is not suitable for therapeutic application.
IT 136-95-8, Benzothiazole, 2-amino- 1899-48-5, Quinazoline, 2,4-diamino-

4271-09-4, Bibenzothiazole 4570-41-6, Benzoxazole, 2-amino-
6811-77-4, Imidazo[4,5-c]pyridine, 4-amino- 6882-74-2,
Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro- 32106-04-0,
Imidazo[4,5-c]pyridine, cobalt derivative 59981-63-4, **Spinacine**
792138-97-7, Imidazo[4,5-c]pyridine, 7-amino-
(bacteriological and pharmacological studies on)

IT **6811-77-4**, Imidazo[4,5-c]pyridine, 4-amino- **792138-97-7**,
Imidazo[4,5-c]pyridine, 7-amino-
(bacteriological and pharmacological studies on)

RN 6811-77-4 CAPLUS

CN 1H-Imidazo[4,5-c]pyridin-4-amine (9CI) (CA INDEX NAME)



RN 792138-97-7 CAPLUS

CN 1H-Imidazo[4,5-c]pyridin-7-amine (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 15:27:13 ON 08 MAR 2006)

FILE 'REGISTRY' ENTERED AT 15:28:34 ON 08 MAR 2006
L1 1 S PYRIDINE/CN
L2 1365174 S 46.156.30/RID

FILE 'CAPLUS' ENTERED AT 15:31:09 ON 08 MAR 2006

FILE 'REGISTRY' ENTERED AT 15:31:29 ON 08 MAR 2006
L3 19032 S L2 AND (4(W)AMINO)

FILE 'CAPLUS' ENTERED AT 15:32:08 ON 08 MAR 2006
L4 24236 S L3
L5 92 S L4(L)SPIN?
L6 6 S L3(L)(NERV?(L)(INJUR? OR DAMAG?))

FILE 'REGISTRY' ENTERED AT 15:36:05 ON 08 MAR 2006
L7 407740 S L2 AND AMINO
L8 297977 S L2 AND (AMINO(5A)(PYRID? OR PYRIDIN?))
L9 283724 S L8 NOT L3

FILE 'CAPLUS' ENTERED AT 15:37:43 ON 08 MAR 2006
L10 99286 S L9
L11 21 S L9(L)(NERV?(L)(INJUR? OR DAMAG?))

FILE 'STNGUIDE' ENTERED AT 15:51:50 ON 08 MAR 2006

```
     FILE 'STNGUIDE' ENTERED AT 15:54:50 ON 08 MAR 2006

     FILE 'REGISTRY' ENTERED AT 15:54:53 ON 08 MAR 2006

     FILE 'CAPLUS' ENTERED AT 15:55:30 ON 08 MAR 2006
L12             1 S  141:47362/DN
L13           ANALYZE L12 1 RN :      32 TERMS

     FILE 'REGISTRY' ENTERED AT 15:55:49 ON 08 MAR 2006
L14            32 S L13
L15             2 S L14 AND ?IMIDAZ?
L16             0 S 33.402.18/RID
L17             0 S 33.402/RID
L18          1618 S 333.402.18/RID

     FILE 'CAPLUS' ENTERED AT 15:59:17 ON 08 MAR 2006
L19            20 S L18 AND ((NERV? (L)(INJUR? OR DAMAG?)) OR SPIN?)

=> s l20 and spin?
L20 NOT FOUND
The L-number entered could not be found.  To see the definition
of L-numbers, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s l19 and spin?
         616877 SPIN?
L20           17 L19 AND SPIN?

=> s l19 not l20
L21            3 L19 NOT L20

=> d bib hit hitstr 1-3

L21  ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2003:356448  CAPLUS
DN   138:368781
TI   Preparation of N-(azabicyclyl)arylamides for therapeutic use as nicotinic
     acetylcholine receptor agonists
IN   Walker, Daniel P.; Jacobsen, Eric Jon; Piotrowski, David W.; Wishka, Donn
     G.; Corbett, Jeffrey W.; Groppi, Vincent E., Jr.; Acker, Brad A.;
     Rauckhorst, Mark R.
PA   Pharmacia & Upjohn Company, USA
SO   PCT Int. Appl., 116 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     ---------------     ----   --------    --------------------     --------
PI   WO 2003037896        A1    20030508    WO 2002-US31579          20021017
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
             CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2464194           AA    20030508    CA 2002-2464194          20021017
     EP 1438308           A1    20040721    EP 2002-784010           20021017
```

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

	BR 2002013760	A	20041019	BR 2002-13760	20021017
	JP 2005511574	T2	20050428	JP 2003-540177	20021017
PRAI	US 2001-344436P	P	20011026		
	US 2001-342674P	P	20011221		
	WO 2002-US31579	W	20021017		

OS MARPAT 138:368781

AB N-(azabicyclyl)arylamides, such as RNR1C(:X)W [R = azabicyclyl; R1 = H, alkyl, cycloalkyl, haloalkyl, aryl; W = heteroaryl; X = O, S], were prepared for therapeutic use as nicotinic acetylcholine receptor agonists. These amides are useful for the treatment of central **nervous** system disorders, such as cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain **injury**, behavioral and cognitive problems associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, depression, general anxiety disorder, age-related macular degeneration, Parkinson's disease, tardive dyskinesia, Pick's disease, post traumatic stress disorder, dysregulation of food intake including bulimia and anorexia **nervosa**, withdrawal symptoms associated with smoking cessation and dependent drug cessation, Gilles de la Tourette's Syndrome, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain. Thus, the fumarate salt of amide I was prepared via a multistep synthetic sequence which included intramol. cyclization of trans-3-(tert-butoxycarbonylamino)-4-(2-hydroxyethyl)-1-(phenylmethyl)pyrrolidine to form exo-3-(tert-butoxycarbonylamino)-1-azabicyclo[2.2.1]heptane, which contains the target azabicyclic ring, and subsequent amidation of the corresponding azabicyclic amine with 1,3-benzoxazole-5-carboxylic acid. The prepared amides were assayed for human α7-5HT3 receptor binding activity.

IT 521277-58-7P 521277-59-8P 521277-61-2P 521277-62-3P 521277-65-6P
521277-68-9P 521277-69-0P 521277-72-5P 521277-79-2P 521277-80-5P
521277-85-0P 521277-96-3P 521277-98-5P 521277-99-6P,
N-[exo-(4S)-1-Azabicyclo[2.2.1]hept-3-yl]-1H-indazole-5-carboxamide
fumarate 521278-05-7P 521278-06-8P 521278-10-4P 521278-11-5P
521278-18-2P 521278-19-3P, N-[(3R,5R)-1-Azabicyclo[3.2.1]oct-3-yl]-1,3-benzothiazole-6-carboxamide fumarate 521278-21-7P 521278-23-9P
521278-26-2P 521278-30-8P 521278-32-0P 521278-34-2P 521278-36-4P
521278-38-6P 521278-39-7P 521278-41-1P 521278-43-3P 521278-46-6P
521278-48-8P 521278-50-2P 521278-54-6P 521278-56-8P 521278-58-0P
521278-60-4P 521278-62-6P 521278-64-8P 521278-66-0P 521278-68-2P
521278-70-6P 521278-72-8P 521278-74-0P 521278-76-2P 521278-78-4P
521278-80-8P 521278-82-0P 521278-84-2P 521278-85-3P 521278-87-5P
521278-89-7P 521278-91-1P 521278-93-3P 521278-95-5P 521278-97-7P
521278-99-9P 521279-01-6P 521279-03-8P 521279-05-0P 521279-07-2P
521279-09-4P 521279-11-8P 521279-13-0P 521279-15-2P 521279-17-4P
521279-19-6P 521279-21-0P 521279-23-2P 521279-25-4P 521279-27-6P
521279-29-8P 521279-31-2P 521279-33-4P 521279-35-6P 521279-37-8P
521279-39-0P 521279-41-4P 521279-43-6P 521279-45-8P 521279-47-0P
521279-49-2P 521279-51-6P 521279-53-8P 521279-55-0P 521279-57-2P
521279-59-4P 521279-61-8P 521279-63-0P 521279-66-3P 521279-68-5P
521279-70-9P 521279-72-1P 521279-74-3P 521279-76-5P 521279-78-7P
521279-80-1P 521279-82-3P 521279-84-5P 521279-86-7P 521279-88-9P
521279-90-3P 521279-92-5P 521279-93-6P 521279-95-8P 521279-97-0P
521279-99-2P 521280-01-3P 521280-03-5P 521280-05-7P 521280-06-8P
521280-08-0P 521280-10-4P 521280-12-6P 521280-14-8P 521280-16-0P
521280-18-2P 521280-20-6P 521280-22-8P 521280-24-0P 521280-26-2P
521280-28-4P 521280-30-8P 521280-32-0P **521280-34-2P**

521280-36-4P 521280-38-6P 521280-40-0P 521284-86-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(azabicyclyl)arylamides for therapeutic use as nicotinic acetylcholine receptor agonists)

IT **521280-34-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(azabicyclyl)arylamides for therapeutic use as nicotinic acetylcholine receptor agonists)

RN 521280-34-2 CAPLUS
CN 3H-Imidazo[4,5-c]pyridine-6-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:221697 CAPLUS
DN 138:238006
TI Preparation of N-[7-aza[2.2.1]bicycloheptanyl]arylamides for therapeutic use as nicotinic acetylcholine receptor agonists
IN Wishka, Donn G.; Walker, Daniel Patrick; Corbett, Jeffrey W.; Reitz, Steven Charles; Rauckhorst, Mark R.; Groppi, Vincent E., Jr.
PA Pharmacia & Upjohn Company, USA
SO PCT Int. Appl., 224 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003022856	A1	20030320	WO 2002-US25959	20020904
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2460075	AA	20030320	CA 2002-2460075	20020904
	US 2003105089	A1	20030605	US 2002-234575	20020904
	EP 1425286	A1	20040609	EP 2002-757132	20020904
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

	BR 2002012477	A	20040824	BR 2002-12477	20020904
	JP 2005527472	T2	20050915	JP 2003-526930	20020904
PRAI	US 2001-322100P	P	20010912		
	US 2001-322333P	P	20010912		
	US 2001-322346P	P	20010912		
	US 2002-399530P	P	20020730		
	WO 2002-US25959	W	20020904		

OS MARPAT 138:238006

AB 7-Aza[2.2.1]bicycloheptane derivs., such as amides I [R1 = H, alkyl, cycloalkyl, haloalkyl, aryl; R2 = H, benzyl, alkyl, haloalkyl, cycloalkyl, aryl; W = heteroaryl; X = O, S], were prepared for therapeutic use as nicotinic acetylcholine receptor agonists. These amides are useful for the treatment of central **nervous** system disorders, such as cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain **injury**, behavioral and cognitive problems associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, depression, general anxiety disorder, age-related macular degeneration, Parkinson's disease, tardive dyskinesia, Pick's disease, post traumatic stress disorder, dysregulation of food intake including bulimia and anorexia **nervosa**, withdrawal symptoms associated with smoking cessation and dependent drug cessation, Gilles de la Tourette's Syndrome, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain. Thus, amide dihydrochloride II was prepared via a multistep synthetic sequence which included cycloaddn. of N-tert-butoxycarbonylpyrrole with BrC.tplbond.CCO2Me to form the azabicyclic ring, and subsequent amidation reaction of tert-Bu (1S,2R,4R)-2-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate with 3-methylfuro[2,3-c]pyridine-5-carboxylic acid. The prepared amides were assayed for human α7-5HT3 receptor binding activity.

IT

501899-60-1P	501899-61-2P	501899-62-3P	501899-63-4P	501899-64-5P
501899-65-6P	501899-66-7P	501899-67-8P	501899-68-9P	501899-69-0P
501899-70-3P	501899-71-4P	501899-72-5P	501899-73-6P	501899-74-7P
501899-75-8P	501899-76-9P	501899-77-0P	501899-78-1P	501899-79-2P
501899-80-5P	501899-81-6P	501899-82-7P	501899-83-8P	501899-84-9P
501899-85-0P	501899-86-1P	501899-87-2P	501899-88-3P	501899-89-4P
501899-90-7P	501899-91-8P	501899-92-9P	501899-93-0P	501899-94-1P
501899-95-2P	501899-96-3P	501899-97-4P	501899-98-5P	501899-99-6P
501900-00-1P	501900-01-2P	501900-02-3P	501900-03-4P	501900-04-5P
501900-05-6P	501900-06-7P	501900-07-8P	501900-08-9P	501900-09-0P
501900-10-3P	501900-11-4P	501900-12-5P	501900-13-6P	501900-14-7P
501900-15-8P	501900-16-9P	501900-17-0P	501900-18-1P	501900-19-2P
501900-20-5P	501900-21-6P	501900-22-7P	501900-23-8P	501900-24-9P
501900-25-0P	501900-26-1P	501900-27-2P	501900-28-3P	501900-29-4P
501900-30-7P	501900-31-8P	501900-32-9P	501900-33-0P	501900-34-1P
501900-35-2P	501900-36-3P	501900-37-4P	501900-38-5P	501900-39-6P
501900-40-9P	501900-41-0P	501900-42-1P	501900-43-2P	501900-44-3P
501900-45-4P	501900-46-5P	501900-47-6P	501900-48-7P	501900-49-8P
501900-50-1P	501900-51-2P	501900-52-3P	501900-53-4P	501900-54-5P
501900-55-6P	501900-56-7P	501900-57-8P	501900-58-9P	501900-59-0P
501900-60-3P	501900-61-4P	501900-62-5P	501900-63-6P	501900-64-7P
501900-65-8P	501900-66-9P	501900-67-0P	501900-68-1P	501900-69-2P
501900-70-5P	501900-71-6P	501900-72-7P	501900-73-8P	501900-74-9P
501900-75-0P	501900-76-1P	501900-77-2P	501900-78-3P	501900-79-4P
501900-80-7P	501900-81-8P	501900-82-9P	501900-83-0P	501900-84-1P
501900-85-2P	501900-86-3P	501900-87-4P	501900-88-5P	501900-89-6P
501900-90-9P	501900-91-0P	501900-92-1P	501900-93-2P	501900-94-3P

501900-95-4P 501900-96-5P 501900-97-6P 501900-98-7P 501900-99-8P
501901-00-4P 501901-01-5P 501901-02-6P 501901-03-7P
501901-04-8P 501901-05-9P 501901-06-0P 501901-07-1P
501901-08-2P 501901-09-3P 501901-10-6P 501901-11-7P 501901-12-8P
501901-13-9P 501901-14-0P 501901-15-1P 501901-16-2P 501901-17-3P
501901-18-4P 501901-19-5P 501901-20-8P 501901-21-9P 501901-22-0P
501901-23-1P 501901-24-2P 501901-25-3P 501901-26-4P 501901-27-5P
501901-28-6P 501901-29-7P 501901-30-0P 501901-31-1P 501901-32-2P
501901-33-3P 501901-34-4P 501901-35-5P 501901-36-6P 501901-37-7P
501901-38-8P 501901-39-9P 501901-40-2P 501901-41-3P 501901-42-4P
501901-43-5P 501901-44-6P 501901-45-7P 501901-46-8P 501901-47-9P
501901-48-0P 501901-49-1P 501901-50-4P 501901-51-5P 501901-52-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-[7-aza[2.2.1]bicycloheptanyl]arylamides for therapeutic use as nicotinic acetylcholine receptor agonists)

IT **501901-04-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-[7-aza[2.2.1]bicycloheptanyl]arylamides for therapeutic use as nicotinic acetylcholine receptor agonists)

RN 501901-04-8 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine-6-carboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:964354 CAPLUS
DN 138:24866
TI Preparation and formulation of N-quinuclidinyl-heteroaryls as nicotinic acetylcholinergic receptor modulators for the treatment of a variety of central nervous system disorders
IN Walker, Daniel P.; Wishka, Donn G.; Corbett, Jeffrey W.; Rauckhorst, Mark R.; Piotrowski, David W.; Groppi, Vincent E., Jr.
PA Pharmacia & Upjohn Company, USA
SO PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002100858	A2	20021219	WO 2002-US16570	20020606
	WO 2002100858	A3	20030220		
	WO 2002100858	C1	20031224		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2445471	AA	20021219	CA 2002-2445471	20020606
US 2003073707	A1	20030417	US 2002-163565	20020606
US 6828330	B2	20041207		
EP 1404674	A2	20040407	EP 2002-778934	20020606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004534065	T2	20041111	JP 2003-503625	20020606
US 2004224977	A1	20041111	US 2004-865149	20040610
PRAI US 2001-297629P	P	20010612		
US 2001-297630P	P	20010612		
US 2001-297631P	P	20010612		
US 2001-297632P	P	20010612		
US 2001-297633P	P	20010612		
US 2001-328548P	P	20011011		
US 2002-373496P	P	20020418		
US 2002-163565	A3	20020606		
WO 2002-US16570	W	20020606		

OS MARPAT 138:24866

AB N-quinuclidinyl-heteroaryls, such as amides I [R1 = H, alkyl, cycloalkyl, haloalkyl, aryl; R2 = H, benzyl, alkyl, haloalkyl, cycloalkyl, aryl; W = aryl, heteroaryl; X = O, S], were prepared for therapeutic use in the treatment of central **nervous** system disorders, such as cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain **injury**, behavioral and cognitive problems associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, depression, general anxiety disorder, age-related macular degeneration, Parkinson's disease, tardive dyskinesia, Pick's disease, post traumatic stress disorder, dysregulation of food intake including bulimia and anorexia **nervosa**, withdrawal symptoms associated with smoking cessation and dependent drug cessation, Gilles de la Tourette's Syndrome, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain. Thus, the fumarate salt of (3R)-N-quinuclidinyl amide II was prepared via the formation of 6-benzoxazolecarboxylic acid in 89% yield by cyclization of 4-amino-3-hydroxybenzoic acid and (MeO)3C at 100° for 2 h followed by amide formation of the acid with (R)-(+)-3-aminoquinuclidine dihydrochloride using DIEA in a 5:1 mixture of THF/DMF and subsequent fumarate salt formation. The prepared quinuclidine derivs. were assayed for nicotinic acetylcholinergic receptor binding activity using brain cell membrane prepared from male Sprague-Dawley rats.

IT 478169-36-7P 478169-37-8P, N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-1,3-benzoxazole-6-carboxamide fumarate 478169-39-0P 478169-40-3P
478169-41-4P 478169-42-5P 478169-43-6P 478169-44-7P 478169-45-8P
478169-46-9P 478169-47-0P 478169-48-1P 478169-49-2P 478169-50-5P
478169-51-6P 478169-57-2P 478169-60-7P 478169-61-8P 478169-66-3P
478169-67-4P 478169-73-2P 478169-75-4P 478169-76-5P 478169-78-7P
478169-79-8P 478169-80-1P 478169-81-2P 478169-82-3P 478169-83-4P
478169-84-5P 478169-85-6P 478169-86-7P 478169-87-8P 478169-88-9P

478169-89-0P 478169-90-3P 478169-91-4P 478169-92-5P 478169-93-6P
478169-94-7P 478169-95-8P 478169-96-9P 478169-97-0P 478169-98-1P
478169-99-2P 478170-00-2P 478170-01-3P 478170-02-4P 478170-03-5P
478170-04-6P 478170-05-7P 478170-06-8P 478170-07-9P 478170-08-0P
478170-09-1P 478170-10-4P 478170-11-5P 478170-12-6P 478170-13-7P
478170-14-8P 478170-15-9P 478170-16-0P 478170-17-1P 478170-18-2P
478170-19-3P 478170-20-6P 478170-21-7P 478170-22-8P 478170-23-9P
478170-24-0P 478170-25-1P 478170-26-2P 478170-27-3P 478170-28-4P
478170-29-5P **478170-30-8P** 478170-31-9P 478170-32-0P
478170-33-1P 478170-34-2P 478170-35-3P 478170-36-4P 478170-37-5P
478170-38-6P 478170-39-7P 478170-40-0P 478170-41-1P 478170-42-2P
478170-43-3P 478170-44-4P 478170-45-5P 478170-46-6P 478170-47-7P
478170-48-8P 478170-49-9P 478170-50-2P 478170-51-3P 478170-52-4P
478170-53-5P 478170-54-6P 478170-55-7P 478170-56-8P 478170-57-9P
478170-58-0P 478170-59-1P **478170-60-4P** 478170-61-5P
478170-62-6P 478170-63-7P 478170-64-8P 478170-65-9P 478170-66-0P
478170-67-1P 478170-68-2P 478170-69-3P 478170-70-6P 478170-71-7P
478170-72-8P 478170-73-9P 478170-74-0P 478170-75-1P 478170-76-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and formulation of N-quinuclidinyl-heteroaryls as nicotinic acetylcholinergic receptor modulators for treatment of a variety of central nervous system disorders)

IT **478170-30-8P 478170-60-4P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and formulation of N-quinuclidinyl-heteroaryls as nicotinic acetylcholinergic receptor modulators for treatment of a variety of central nervous system disorders)

RN 478170-30-8 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-6-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478170-60-4 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-6-carboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d bib hit hitstr 1-10

L11 ANSWER 1 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:216610 CAPLUS
DN 142:291412
TI Compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic-mediated central nervous system disorders or injury
IN Arneric, Stephen P.
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 155 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005020910	A2	20050310	WO 2004-US27600	20040826
	WO 2005020910	A3	20050609		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005085479	A1	20050421	US 2004-926751	20040826
PRAI	US 2003-498148P	P	20030827		

OS MARPAT 142:291412
IT 71125-38-7, Meloxicam 71125-38-7D, Meloxicam, isomers, esters, or salts 90880-23-2 123653-11-2 157284-96-3, Antalarmin 157286-86-7, CP 154526 162011-90-7, Rofecoxib 162011-90-7D, Rofecoxib, isomers, esters, or salts 169590-41-4, Deracoxib 169590-41-4D, Deracoxib, isomers, esters, or salts 169590-42-5, Celecoxib 169590-42-5D, Celecoxib, isomers, esters, or salts 170809-51-5, Astressin 180200-68-4 181695-72-7, Valdecoxib 181695-72-7D, Valdecoxib, isomers, esters, or salts 184241-44-9, NBI 27914 **195055-01-7**, R121920 **195055-03-9**, R121919 198470-84-7, Parecoxib 198470-84-7D, Parecoxib, isomers, esters, or salts 202409-33-4, Etoricoxib 202409-33-4D, Etoricoxib, isomers, esters, or salts 202578-52-7, DMP 696 212126-32-4 215123-80-1 215123-80-1D, esters or salts 220673-95-0, Antisauvagine-30 220991-20-8, Lumiracoxib 220991-20-8D, Lumiracoxib, isomers, esters, or salts 220991-33-3 220991-33-3D, esters or salts 259523-81-4 265114-23-6, Cimicoxib 265114-23-6D, Cimicoxib, isomers, esters, or salts 266320-83-6 266320-83-6D, salts 286936-37-6 286936-37-6D, isomers 354994-31-3, DMP 695 847449-04-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclooxygenase-2 selective inhibitor combination with corticotropin releasing factor antagonist for treatment of ischemic-mediated central **nervous** system disorders or **injury**)

IT **195055-01-7**, R121920 **195055-03-9**, R121919
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclooxygenase-2 selective inhibitor combination with corticotropin releasing factor antagonist for treatment of ischemic-mediated central **nervous** system disorders or **injury**)

RN 195055-01-7 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-3-pyridinyl]-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 195055-03-9 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)



L11 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:513486 CAPLUS
DN 141:47362
TI Pyridines for treating injured mammalian nerve tissue
IN Borgens, Richard B.; Shi, Riyi; Byrn, Stephen R.; Smith, Daniel T.
PA Purdue Research Foundation, USA
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004052291	A2	20040624	WO 2003-US38834	20031205
	WO 2004052291	A3	20041014		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2508165	AA	20040624	CA 2003-2508165	20031205
	US 2004171587	A1	20040902	US 2003-730495	20031205
	EP 1567497	A2	20050831	EP 2003-796756	20031205
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	US 2002-431637P	P	20021206		

WO 2003-US38834 W 20031205
OS MARPAT 141:47362
IT **54287-92-2P** 79546-31-9P **98400-69-2P**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pyridines for treating **injured** mammalian **nerve** tissue)
IT **5221-42-1P**, N-(4-Pyridyl)Acetamide **5221-44-3P**, N-(4-Pyridyl)Benzamide 7397-68-4P 21915-82-2P 22236-93-7P 39642-87-0P **70298-89-4P** 97999-83-2P 125329-97-7P 260262-86-0P **705925-39-9P**
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pyridines for treating **injured** mammalian **nerve** tissue)
IT **54-96-6**, 3,4-Diaminopyridine 79-03-8, Propionyl chloride 79-22-1, Methyl chloroformate 98-88-4, Benzoyl chloride 108-23-6, Isopropyl chloroformate 108-24-7, Acetic acid anhydride 121-44-8, Triethylamine, reactions 501-53-1, Benzyl chloroformate 530-62-1 541-41-3, Ethyl chloroformate 691-64-5 1499-21-4 2524-64-3 3282-30-2, Pivaloyl chloride 14794-31-1 24460-74-0, Dodecyl chloroformate
RL: RCT (Reactant); RACT (Reactant or reagent)
(pyridines for treating **injured** mammalian **nerve** tissue)
IT **54287-92-2P 98400-69-2P**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pyridines for treating **injured** mammalian **nerve** tissue)
RN 54287-92-2 CAPLUS
CN Carbamic acid, 4-pyridinyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 98400-69-2 CAPLUS
CN Carbamic acid, 4-pyridinyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **5221-42-1P**, N-(4-Pyridyl)Acetamide **5221-44-3P**, N-(4-Pyridyl)Benzamide **70298-89-4P 705925-39-9P**
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)
(pyridines for treating **injured** mammalian **nerve** tissue)

RN 5221-42-1 CAPLUS
CN Acetamide, N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 5221-44-3 CAPLUS
CN Benzamide, N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 70298-89-4 CAPLUS
CN Propanamide, 2,2-dimethyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 705925-39-9 CAPLUS
CN Butanoic acid, 4-oxo-4-(4-pyridinylamino)-, ethyl ester (9CI) (CA INDEX NAME)



IT **54-96-6**, 3,4-Diaminopyridine
RL: RCT (Reactant); RACT (Reactant or reagent)
(pyridines for treating **injured** mammalian **nerve** tissue)

RN 54-96-6 CAPLUS
CN 3,4-Pyridinediamine (9CI) (CA INDEX NAME)



L11 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:510790 CAPLUS
DN 141:76698
TI Methods for making and delivering rho-antagonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof
IN McKerracher, Lisa
PA Can.
SO U.S. Pat. Appl. Publ., 27 pp., Division of U.S. Ser. No. 725,906.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004121011	A1	20040624	US 2003-718598	20031124
	CA 2325765	AA	20020502	CA 2000-2325765	20001102
	CA 2325842	AA	20020502	CA 2000-2325842	20001129
PRAI	CA 2000-2325765	A	20001102		
	CA 2000-2325842	A	20001129		
	US 2000-725906	A3	20001130		

IT 9002-04-4, Thrombin **146986-50-7**, y-27632 199433-55-1, Y 30141
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods for making and delivering rho-antagonist tissue adhesive formulations to **injured** mammalian central and peripheral **nervous** systems and uses thereof)
IT **146986-50-7**, y-27632
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods for making and delivering rho-antagonist tissue adhesive formulations to **injured** mammalian central and peripheral **nervous** systems and uses thereof)
RN 146986-50-7 CAPLUS
CN Cyclohexanecarboxamide, 4-[(1R)-1-aminoethyl]-N-4-pyridinyl-, trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L11 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:220317 CAPLUS
DN 140:270562

TI Preparation of allyl- or hydrazino-containing 1,4-substituted cyclohexane carboxamides as Rho kinase inhibitors for repairing damaged nerves and as antiproliferative agents

IN McKerracher, Lisa; Thouin, Eryk; Lubell, William D.

PA Can.

SO PCT Int. Appl., 191 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004022541	A1	20040318	WO 2003-CA1338	20030829
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2400996	AA	20040303	CA 2002-2400996	20020903
	CA 2438909	AA	20040303	CA 2003-2438909	20030829
	AU 2003264207	A1	20040329	AU 2003-264207	20030829
	US 2004138272	A1	20040715	US 2003-651283	20030829
	EP 1546108	A1	20050629	EP 2003-793533	20030829
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	CA 2002-2400996	A	20020903		
	WO 2003-CA1338	W	20030829		

OS MARPAT 140:270562

IT **129830-38-2P**, trans-4-((R)-1-Aminoethyl)-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride **129830-39-3P**, trans-4-((S)-1-Aminoethyl)-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride **671816-24-3P**, trans-4-((R)-1-Aminobutyl)-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride **671816-25-4P**, trans-4-((S)-1-Aminobutyl)-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride 671816-26-5P, trans-4-[1-(Methylamino)but-3-enyl]-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride **671816-27-6P**, trans-4-[1-(Benzylamino)but-3-enyl]-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride **671816-28-7P**, trans-4-(1-Aminobut-3-enyl)-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride **671816-29-8P**, trans-4-((R)-1-Aminobut-3-enyl)-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride **671816-30-1P**, trans-4-((S)-1-Aminobut-3-enyl)-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride 671816-31-2P, trans-4-(1-Aminobut-3-enyl)-N-[2-(3-indolyl)ethyl]cyclohexanecarboxamide dihydrochloride **671816-32-3P**, trans-4-(1-Aminobut-3-enyl)-N-[(3-pyridyl)methyl]cyclohexanecarboxamide dihydrochloride **671816-33-4P**, trans-4-(1-Aminobut-3-enyl)-N-[2-(2-pyridyl)ethyl]cyclohexanecarboxamide dihydrochloride 671816-34-5P, trans-4-(1-Aminobut-3-enyl)-N-(1-benzylpiperidin-4-yl)cyclohexanecarboxamide dihydrochloride **671816-35-6P**, trans-4-(1-Aminobut-3-enyl)-N-(3-pyridyl)cyclohexanecarboxamide dihydrochloride 671816-36-7P, trans-4-(1-Aminobut-3-enyl)-N-(3-quinolyl)cyclohexanecarboxamide dihydrochloride 671816-37-8P, trans-4-(1-Aminobut-3-enyl)-N-(5-isoquinolyl)cyclohexanecarboxamide dihydrochloride 671816-38-9P, trans-4-(1-Aminobut-3-enyl)-N-(6-quinolyl)cyclohexanecarboxamide dihydrochloride 671816-39-0P, trans-4-(1-Aminobut-3-enyl)-N-[4-(dimethylamino)benzyl]cyclohexanecarboxamide dihydrochloride 671816-40-3P, trans-4-(1-Aminobut-3-enyl)-N-(4-

quinaldyl)cyclohexanecarboxamide dihydrochloride 671816-41-4P, trans-4-(1-Aminobut-3-enyl)-N-(5-indolyl)cyclohexanecarboxamide dihydrochloride **671816-42-5P**, trans-4-(1-Aminobut-3-enyl)-N-[(4-pyridyl)methyl]cyclohexanecarboxamide dihydrochloride 671816-43-6P, trans-4-(1-Aminobut-3-enyl)-N-(9H-purin-6-yl)cyclohexanecarboxamide dihydrochloride 671816-83-4P, cis-4-(1-Methylhydrazino)-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride 671816-84-5P, trans-4-(1-Methylhydrazino)-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride 671816-85-6P, cis-4-[1-(Propyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride 671816-86-7P, trans-4-[1-(Propyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride 671816-87-8P, cis-4-[1-(3-Methylbutyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride 671816-88-9P, trans-4-[1-(3-Methylbutyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride 671816-89-0P, cis-4-[1-(1-Methylethyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride 671816-90-3P, trans-4-[1-(1-Methylethyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride 671816-91-4P, cis-4-(1-Benzylhydrazino)-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride 671816-92-5P, trans-4-(1-Benzylhydrazino)-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride 671816-93-6P, trans-4-[1-(2-Phenylethyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride 671816-94-7P, trans-4-[1-(2,2-Diphenylethyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride 671816-95-8P, trans-4-[1-[4-(Benzyloxy)benzyl]hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride 671816-96-9P, trans-4-[1-(Cyclohexylmethyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride 671816-98-1P, trans-4-[1-((E)-3-Phenylprop-2-enyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride 671816-99-2P, trans-4-(1-Octylhydrazino)-N-(4-pyridyl)cyclohexanecarboxamide **671817-00-8P** 671817-01-9P **671817-02-0P** **671817-03-1P** 671817-04-2P **671817-05-3P** 671817-06-4P 671817-07-5P, 4-(1-Aminobut-3-enyl)-N-(5-isoquinolyl)cyclohexanecarboxamide 671817-08-6P 671817-09-7P 671817-10-0P 671817-11-1P **671817-12-2P** 671817-13-3P **671817-14-4P** 671817-15-5P, 4-(1-Aminobut-3-enyl)-N-(9H-purin-6-yl)cyclohexanecarboxamide **671817-16-6P**, trans-4-(1-Aminobut-3-enyl)-N-(4-pyridyl)cyclohexanecarboxamide 671817-17-7P, trans-4-(1-Aminobut-3-enyl)-N-[2-(3-indolyl)ethyl]cyclohexanecarboxamide **671817-18-8P**, trans-4-(1-Aminobut-3-enyl)-N-[(3-pyridyl)methyl]cyclohexanecarboxamide **671817-19-9P**, trans-4-(1-Aminobut-3-enyl)-N-[2-(2-pyridyl)ethyl]cyclohexanecarboxamide 671817-20-2P, trans-4-(1-Aminobut-3-enyl)-N-(1-benzylpiperidin-4-yl)cyclohexanecarboxamide **671817-21-3P**, trans-4-(1-Aminobut-3-enyl)-N-(3-pyridyl)cyclohexanecarboxamide 671817-22-4P, trans-4-(1-Aminobut-3-enyl)-N-(3-quinolyl)cyclohexanecarboxamide 671817-23-5P, trans-4-(1-Aminobut-3-enyl)-N-(5-isoquinolyl)cyclohexanecarboxamide 671817-24-6P, trans-4-(1-Aminobut-3-enyl)-N-(6-quinolyl)cyclohexanecarboxamide 671817-25-7P, trans-4-(1-Aminobut-3-enyl)-N-[4-(dimethylamino)benzyl]cyclohexanecarboxamide 671817-26-8P, trans-4-(1-Aminobut-3-enyl)-N-(4-quinaldyl)cyclohexanecarboxamide 671817-27-9P, trans-4-(1-Aminobut-3-enyl)-N-(5-indolyl)cyclohexanecarboxamide **671817-28-0P**, trans-4-(1-Aminobut-3-enyl)-N-[(4-pyridyl)methyl]cyclohexanecarboxamide **671817-29-1P**, (R)-trans-4-(1-Aminobut-3-enyl)-N-(4-pyridyl)cyclohexanecarboxamide **671817-30-4P**, (S)-trans-4-(1-Aminobut-3-enyl)-N-(4-pyridyl)cyclohexanecarboxamide 671817-31-5P, trans-4-[1-(Methylamino)but-3-enyl]-N-(4-pyridyl)cyclohexanecarboxamide **671817-32-6P**, trans-4-[1-(Benzylamino)but-3-enyl]-N-(4-pyridyl)cyclohexanecarboxamide 671817-33-7P, trans-4-(1-Aminobut-3-enyl)-N-(9H-purin-6-yl)cyclohexanecarboxamide 671817-36-0P, 4-(1-Methylhydrazino)-N-(4-

pyridyl)cyclohexanecarboxamide 671817-38-2P, 4-[1-(Propyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide 671817-40-6P, 4-[1-(3-Methylbutyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide 671817-42-8P, 4-[1-(1-Methylethyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide 671817-44-0P, 4-(1-Benzylhydrazino)-N-(4-pyridyl)cyclohexanecarboxamide 671817-46-2P, 4-[1-(2-Phenylethyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide 671817-48-4P, 4-[1-(2,2-Diphenylethyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide 671817-49-5P, 4-[1-[4-(Benzyloxy)benzyl]hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide 671817-50-8P, 4-[1-(Cyclohexylmethyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide 671817-51-9P, 4-(1-Octylhydrazino)-N-(4-pyridyl)cyclohexanecarboxamide 671817-52-0P, 4-[1-(3-Phenylprop-2-enyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide 671817-53-1P, cis-4-(1-Methylhydrazino)-N-(4-pyridyl)cyclohexanecarboxamide 671817-54-2P, trans-4-(1-Methylhydrazino)-N-(4-pyridyl)cyclohexanecarboxamide 671817-55-3P, trans-4-[1-(Propyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide 671817-56-4P, trans-4-[1-(3-Methylbutyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide 671817-57-5P, trans-4-(1-Benzylhydrazino)-N-(4-pyridyl)cyclohexanecarboxamide 671817-58-6P, cis-4-[1-(Propyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide 671817-59-7P, cis-4-[1-(3-Methylbutyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide 671817-60-0P, cis-4-[1-(1-Methylethyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide 671817-61-1P, cis-4-(1-Benzylhydrazino)-N-(4-pyridyl)cyclohexanecarboxamide 671817-62-2P, trans-4-[1-(2-Phenylethyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide 671817-63-3P, trans-4-[1-(2,2-Diphenylethyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide 671817-64-4P, trans-4-[1-[4-(Benzyloxy)benzyl]hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide 671817-65-5P, trans-4-[1-(Cyclohexylmethyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide 671817-66-6P, trans-4-[1-((E)-3-Phenylprop-2-enyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of allyl- or hydrazino-containing 1,4-substituted
cyclohexane carboxamides as Rho kinase inhibitors for repairing **damaged nerves** and as antiproliferative agents)

IT 17159-79-4P, Ethyl 4-oxocyclohexanecarboxylate 141836-47-7P, 4-[(tert-Butyldimethylsilyloxy)methyl]cyclohexanecarboxaldehyde 141836-50-2P, [4-[(tert-Butyldimethylsilyloxy)methyl]cyclohexyl]methanol 671815-85-3P, N-[[4-[(tert-Butyldimethylsilyloxy)methyl]cyclohexyl]methylidene]benzylamine 671815-86-4P, N-[[4-[(tert-Butyldimethylsilyloxy)methyl]cyclohexyl]methylidene]methylamine 671815-87-5P, N-Benzyl-1-[4-[(tert-butyldimethylsilyloxy)methyl]cyclohexyl]but-3-en-1-amine 671815-88-6P, N-(tert-Butyloxycarbonyl)-N-methyl-1-[4-[(tert-butyldimethylsilyloxy)methyl]cyclohexyl]but-3-en-1-amine 671815-89-7P, N-(tert-Butyloxycarbonyl)-N-benzyl-1-[4-[(tert-butyldimethylsilyloxy)methyl]cyclohexyl]but-3-en-1-amine 671815-90-0P, N-(Methyloxycarbonyl)-N-benzyl-1-[4-[(tert-butyldimethylsilyloxy)methyl]cyclohexyl]but-3-en-1-amine 671815-91-1P, N-(Methyloxycarbonyl)-1-[4-[(tert-butyldimethylsilyloxy)methyl]cyclohexyl]but-3-en-1-amine 671815-92-2P, N-(Methyloxycarbonyl)-1-[4-(hydroxymethyl)cyclohexyl]but-3-en-1-amine 671815-93-3P, N-(tert-Butyloxycarbonyl)-N-methyl-1-[4-(hydroxymethyl)cyclohexyl]but-3-en-1-amine 671815-94-4P, N-(tert-Butyloxycarbonyl)-N-benzyl-1-[4-(hydroxymethyl)cyclohexyl]but-3-en-1-amine 671815-96-6P, 4-[1-[[(Methyloxy)carbonyl]amino]but-3-enyl]cyclohexanecarboxylic acid 671815-97-7P, 4-[1-[(tert-Butyloxycarbonyl)(methyl)amino]but-3-enyl]cyclohexanecarboxylic acid 671815-98-8P, 4-[1-[(tert-Butyloxycarbonyl)(benzyl)amino]but-3-enyl]cyclohexanecarboxylic acid 671815-99-9P, trans-4-[(R)-1-[(tert-

Butyloxycarbonyl)amino]ethyl]cyclohexanecarboxylic acid 671816-00-5P, trans-4-[(R)-1-[(tert-Butyloxycarbonyl)amino]ethyl]cyclohexanecarboxaldehyde 671816-01-6P, trans-4-[(S)-1-[(tert-Butyloxycarbonyl)amino]ethyl]cyclohexanecarboxylic acid **671816-02-7P**, trans-4-[(R)-1-[(tert-Butyloxycarbonyl)amino]butyl]-N-(4-pyridyl)cyclohexanecarboxamide **671816-03-8P**, trans-4-[(S)-1-[(tert-Butyloxycarbonyl)amino]butyl]-N-(4-pyridyl)cyclohexanecarboxamide **671816-04-9P**, trans-4-[(R)-1-[(tert-Butyloxycarbonyl)amino]ethyl]-N-(4-pyridyl)cyclohexanecarboxamide **671816-05-0P**, trans-4-[(S)-1-[(tert-Butyloxycarbonyl)amino]ethyl]-N-(4-pyridyl)cyclohexanecarboxamide **671816-06-1P**, trans-4-[1-[[(Methyloxy)carbonyl]amino]but-3-enyl]-N-(4-pyridyl)cyclohexanecarboxamide **671816-07-2P**, trans-4-[(R)-1-[[(Methyloxy)carbonyl]amino]but-3-enyl]-N-(4-pyridyl)cyclohexanecarboxamide **671816-08-3P**, trans-4-[(S)-1-[[(Methyloxy)carbonyl]amino]but-3-enyl]-N-(4-pyridyl)cyclohexanecarboxamide 671816-09-4P, trans-4-[1-[(tert-Butyloxycarbonyl)(methyl)amino]but-3-enyl]cyclohexanecarboxamide 671816-10-7P, trans-4-[1-[(tert-Butyloxycarbonyl)(benzyl)amino]but-3-enyl]cyclohexanecarboxamide 671816-11-8P, trans-4-[1-[[(Methyloxy)carbonyl]amino]but-3-enyl]-N-[2-(3-indolyl)ethyl]cyclohexanecarboxamide **671816-12-9P**, trans-4-[1-[[(Methyloxy)carbonyl]amino]but-3-enyl]-N-[(3-pyridyl)methyl]cyclohexanecarboxamide **671816-13-0P**, trans-4-[1-[[(Methyloxy)carbonyl]amino]but-3-enyl]-N-[2-(2-pyridyl)ethyl]cyclohexanecarboxamide 671816-14-1P, trans-4-[1-[[(Methyloxy)carbonyl]amino]but-3-enyl]-N-(1-benzylpiperidin-4-yl)cyclohexanecarboxamide **671816-15-2P**, trans-4-[1-[[(Methyloxy)carbonyl]amino]but-3-enyl]-N-(3-pyridyl)cyclohexanecarboxamide 671816-16-3P, trans-4-[1-[[(Methyloxy)carbonyl]amino]but-3-enyl]-N-(3-quinolyl)cyclohexanecarboxamide 671816-17-4P, trans-4-[1-[[(Methyloxy)carbonyl]amino]but-3-enyl]-N-(5-isoquinolyl)cyclohexanecarboxamide 671816-18-5P, trans-4-[1-[[(Methyloxy)carbonyl]amino]but-3-enyl]-N-(6-quinolyl)cyclohexanecarboxamide 671816-19-6P, trans-4-[1-[[(Methyloxy)carbonyl]amino]but-3-enyl]-N-[4-(dimethylamino)benzyl]cyclohexanecarboxamide 671816-20-9P, trans-4-[1-[[(Methyloxy)carbonyl]amino]but-3-enyl]-N-(4-quinaldyl)cyclohexanecarboxamide 671816-21-0P, trans-4-[1-[[(Methyloxy)carbonyl]amino]but-3-enyl]-N-(5-indolyl)cyclohexanecarboxamide **671816-22-1P**, trans-4-[1-[[(Methyloxy)carbonyl]amino]but-3-enyl]-N-[(4-pyridyl)methyl]cyclohexanecarboxamide 671816-23-2P, trans-4-[1-[[(Methyloxy)carbonyl]amino]but-3-enyl]-N-(9H-purin-6-yl)cyclohexanecarboxamide 671816-44-7P, Ethyl 4-[N'-(tert-butyloxycarbonyl)hydrazono]cyclohexanecarboxylate 671816-45-8P, cis-Ethyl 4-[2-(tert-butyloxycarbonyl)hydrazino]cyclohexanecarboxylate 671816-46-9P, trans-Ethyl 4-[2-(tert-butyloxycarbonyl)hydrazino]cyclohexanecarboxylate 671816-47-0P, cis-Ethyl 4-[2-(tert-butyloxycarbonyl)-1-methylhydrazino]cyclohexanecarboxylate 671816-48-1P, trans-Ethyl 4-[2-(tert-butyloxycarbonyl)-1-methylhydrazino]cyclohexanecarboxylate 671816-49-2P, cis-Ethyl 4-[2-(tert-butyloxycarbonyl)-1-(propyl)hydrazino]cyclohexanecarboxylate 671816-50-5P, trans-Ethyl 4-[2-(tert-butyloxycarbonyl)-1-(propyl)hydrazino]cyclohexanecarboxylate 671816-51-6P, cis-Ethyl 4-[2-(tert-butyloxycarbonyl)-1-(3-methylbutyl)hydrazino]cyclohexanecarboxylate 671816-52-7P, trans-Ethyl 4-[2-(tert-butyloxycarbonyl)-1-(3-methylbutyl)hydrazino]cyclohexanecarboxylate 671816-53-8P, cis-Ethyl 4-[2-(tert-butyloxycarbonyl)-1-(1-methylethyl)hydrazino]cyclohexanecarboxylate 671816-54-9P, trans-Ethyl 4-[2-(tert-butyloxycarbonyl)-1-(1-methylethyl)hydrazino]cyclohexanecarboxylate 671816-55-0P, cis-Ethyl 4-[2-(tert-butyloxycarbonyl)-1-benzylhydrazino]cyclohexanecarboxylate 671816-56-1P, trans-Ethyl 4-[2-(tert-butyloxycarbonyl)-1-benzylhydrazino]cyclohexanecarboxylate 671816-57-2P, trans-Ethyl 4-[2-(tert-butyloxycarbonyl)-1-(2-

phenylethyl)hydrazino]cyclohexanecarboxylate 671816-58-3P, trans-Ethyl 4-[2-(tert-butyloxycarbonyl)-1-(2,2-diphenylethyl)hydrazino]cyclohexanecarboxylate 671816-59-4P, trans-Ethyl 4-[2-(tert-butyloxycarbonyl)-1-[4-(benzyloxy)benzyl]hydrazino]cyclohexanecarboxylate 671816-60-7P, trans-Ethyl 4-[2-(tert-butyloxycarbonyl)-1-(cyclohexylmethyl)hydrazino]cyclohexanecarboxylate 671816-61-8P, trans-Ethyl 4-[2-(tert-butyloxycarbonyl)-1-octylhydrazino]cyclohexanecarboxylate 671816-62-9P, trans-Ethyl 4-[2-(tert-butyloxycarbonyl)-1-((E)-3-phenylprop-2-enyl)hydrazino]cyclohexanecarboxylate 671816-63-0P, trans-4-[2-(tert-Butyloxycarbonyl)-1-(propyl)hydrazino]cyclohexanecarboxylic acid 671816-64-1P, trans-4-[2-(tert-Butyloxycarbonyl)-1-(3-methylbutyl)hydrazino]cyclohexanecarboxylic acid 671816-65-2P, trans-4-[2-(tert-Butyloxycarbonyl)-1-(1-methylethyl)hydrazino]cyclohexanecarboxylic acid 671816-66-3P, trans-4-[2-(tert-Butyloxycarbonyl)-1-benzylhydrazino]cyclohexanecarboxylic acid **671816-67-4P**, cis-4-[2-(tert-Butyloxycarbonyl)-1-methylhydrazino]-N-(4-pyridyl)cyclohexanecarboxamide **671816-68-5P**, trans-4-[2-(tert-Butyloxycarbonyl)-1-methylhydrazino]-N-(4-pyridyl)cyclohexanecarboxamide **671816-69-6P**, cis-4-[2-(tert-Butyloxycarbonyl)-1-(propyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide **671816-70-9P**, trans-4-[2-(tert-Butyloxycarbonyl)-1-(propyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide **671816-71-0P**, cis-4-[2-(tert-Butyloxycarbonyl)-1-(3-methylbutyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide **671816-72-1P**, trans-4-[2-(tert-Butyloxycarbonyl)-1-(3-methylbutyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide **671816-73-2P**, cis-4-[2-(tert-Butyloxycarbonyl)-1-(1-methylethyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide **671816-74-3P**, trans-4-[2-(tert-Butyloxycarbonyl)-1-(1-methylethyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide **671816-75-4P**, cis-4-[2-(tert-Butyloxycarbonyl)-1-benzylhydrazino]-N-(4-pyridyl)cyclohexanecarboxamide **671816-76-5P**, trans-4-[2-(tert-Butyloxycarbonyl)-1-benzylhydrazino]-N-(4-pyridyl)cyclohexanecarboxamide **671816-77-6P**, trans-4-[2-(tert-Butyloxycarbonyl)-1-(2-phenylethyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide **671816-78-7P**, Trans-4-[2-(tert-Butyloxycarbonyl)-1-(2,2-diphenylethyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide **671816-79-8P**, trans-4-[2-(tert-Butyloxycarbonyl)-1-[4-(benzyloxy)benzyl]hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide **671816-80-1P**, trans-4-[2-(tert-Butyloxycarbonyl)-1-(cyclohexylmethyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide **671816-81-2P**, trans-4-[2-(tert-Butyloxycarbonyl)-1-octylhydrazino]-N-(4-pyridyl)cyclohexanecarboxamide **671816-82-3P**, trans-4-[2-(tert-Butyloxycarbonyl)-1-((E)-3-phenylprop-2-enyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide 672314-40-8P, (R)-N-[[4-[(tert-Butyldimethylsilyloxy)methyl]cyclohexyl]methylidene]-1-phenylethanamine 672314-41-9P, (S)-N-[[4-[(tert-Butyldimethylsilyloxy)methyl]cyclohexyl]methylidene]-1-phenylethanamine 672314-42-0P, (S)-1-[[[4-[(tert-Butyldimethylsilyloxy)methyl]cyclohexyl]methylidene]amino]-2-(methoxymethyl)pyrrolidine 672314-43-1P, (1R)-N-((1R)-1-Phenylethyl)-1-[4-[(tert-Butyldimethylsilyloxy)methyl]cyclohexyl]but-3-en-1-amine 672314-44-2P, (1S)-N-((1S)-1-Phenylethyl)-1-[4-[(tert-butyldimethylsilyloxy)methyl]cyclohexyl]but-3-en-1-amine 672314-45-3P, (1R)-N-((1R)-1-Phenylethyl)-1-[4-[(tert-butyldimethylsilyloxy)methyl]cyclohexyl]ethan-1-amine 672314-46-4P, (1R)-N-(Methyloxycarbonyl)-N-[(S)-2-(methoxymethyl)pyrrolidino]-1-[4-[(tert-butyldimethylsilyloxy)methyl]cyclohexyl]but-3-en-1-amine 672314-47-5P, (1S)-N-(Methyloxycarbonyl)-N-[(R)-2-(methoxymethyl)pyrrolidino]-1-[4-[(tert-butyldimethylsilyloxy)methyl]cyclohexyl]but-3-en-1-amine 672314-48-6P, (R)-1-[[[4-[(tert-Butyldimethylsilyloxy)methyl]cyclohexyl]methylidene]amino]-2-

(methoxymethyl)pyrrolidine 672314-49-7P, (R)-1-[4-[(tert-Butyldimethylsilyloxy)methyl]cyclohexyl]butan-1-amine 672314-50-0P, (S)-1-[4-[(tert-Butyldimethylsilyloxy)methyl]cyclohexyl]butan-1-amine 672314-51-1P, (R)-1-[4-[(tert-Butyldimethylsilyloxy)methyl]cyclohexyl]ethan-1-amine 672314-52-2P, (S)-1-[4-[(tert-Butyldimethylsilyloxy)methyl]cyclohexyl]ethan-1-amine 672314-54-4P, (1R)-N-(Methyloxycarbonyl)-1-[4-[(tert-butyldimethylsilyloxy)methyl]cyclohexyl]but-3-en-1-amine 672314-55-5P, (1S)-N-(Methyloxycarbonyl)-1-[4-[(tert-butyldimethylsilyloxy)methyl]cyclohexyl]but-3-en-1-amine 672314-56-6P, (R)-N-(tert-Butyloxycarbonyl)-1-[4-[(tert-butyldimethylsilyloxy)methyl]cyclohexyl]butan-1-amine 672314-57-7P, (S)-N-(tert-Butyloxycarbonyl)-1-[4-[(tert-butyldimethylsilyloxy)methyl]cyclohexyl]butan-1-amine 672314-58-8P, (R)-N-(tert-Butyloxycarbonyl)-1-[4-[(tert-butyldimethylsilyloxy)methyl]cyclohexyl]ethan-1-amine 672314-59-9P, (S)-N-(tert-Butyloxycarbonyl)-1-[4-[(tert-butyldimethylsilyloxy)methyl]cyclohexyl]ethan-1-amine 672314-60-2P, (R)-N-(tert-Butyloxycarbonyl)-1-[4-(hydroxymethyl)cyclohexyl]butan-1-amine 672314-61-3P, (S)-N-(tert-Butyloxycarbonyl)-1-[4-(hydroxymethyl)cyclohexyl]butan-1-amine 672314-62-4P, (1R)-N-(tert-Butyloxycarbonyl)-1-[4-(hydroxymethyl)cyclohexyl]ethan-1-amine 672314-63-5P, (S)-N-(tert-Butyloxycarbonyl)-1-[4-(hydroxymethyl)cyclohexyl]ethan-1-amine 672314-64-6P, (R)-N-(Methyloxycarbonyl)-1-[4-(hydroxymethyl)cyclohexyl]but-3-en-1-amine 672314-65-7P, (S)-N-(Methyloxycarbonyl)-1-[4-(hydroxymethyl)cyclohexyl]but-3-en-1-amine 672314-66-8P, (R)-4-[1-[(tert-Butyloxycarbonyl)amino]butyl]cyclohexanecarboxylic acid 672314-67-9P, (S)-4-[1-[(tert-Butyloxycarbonyl)amino]butyl]cyclohexanecarboxylic acid 672314-68-0P, (R)-4-[1-[[(Methyloxy)carbonyl]amino]but-3-enyl]cyclohexanecarboxylic acid 672314-69-1P, (S)-4-[1-[[(Methyloxy)carbonyl]amino]but-3-enyl]cyclohexanecarboxylic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of allyl- or hydrazino-containing 1,4-substituted cyclohexane carboxamides as Rho kinase inhibitors for repairing **damaged nerves** and as antiproliferative agents)

IT **129830-38-2P**, trans-4-((R)-1-Aminoethyl)-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride **129830-39-3P**, trans-4-((S)-1-Aminoethyl)-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride **671816-24-3P**, trans-4-((R)-1-Aminobutyl)-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride **671816-25-4P**, trans-4-((S)-1-Aminobutyl)-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride **671816-27-6P**, trans-4-[1-(Benzylamino)but-3-enyl]-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride **671816-28-7P**, trans-4-(1-Aminobut-3-enyl)-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride **671816-29-8P**, trans-4-((R)-1-Aminobut-3-enyl)-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride **671816-30-1P**, trans-4-((S)-1-Aminobut-3-enyl)-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride **671816-32-3P**, trans-4-(1-Aminobut-3-enyl)-N-[(3-pyridyl)methyl]cyclohexanecarboxamide dihydrochloride **671816-33-4P**, trans-4-(1-Aminobut-3-enyl)-N-[2-(2-pyridyl)ethyl]cyclohexanecarboxamide dihydrochloride **671816-35-6P**, trans-4-(1-Aminobut-3-enyl)-N-(3-pyridyl)cyclohexanecarboxamide dihydrochloride **671816-42-5P**, trans-4-(1-Aminobut-3-enyl)-N-[(4-pyridyl)methyl]cyclohexanecarboxamide dihydrochloride **671817-00-8P 671817-02-0P 671817-03-1P 671817-05-3P 671817-12-2P 671817-14-4P 671817-16-6P**, trans-4-(1-Aminobut-3-enyl)-N-(4-pyridyl)cyclohexanecarboxamide **671817-18-8P**, trans-4-(1-Aminobut-3-enyl)-N-[(3-pyridyl)methyl]cyclohexanecarboxamide **671817-19-9P**, trans-4-(1-Aminobut-3-enyl)-N-[2-(2-pyridyl)ethyl]cyclohexanecarboxamide **671817-21-3P**, trans-4-(1-Aminobut-3-enyl)-N-(3-pyridyl)cyclohexanecarboxamide **671817-28-0P**, trans-4-(1-Aminobut-3-enyl)-N-[(4-

pyridyl)methyl]cyclohexanecarboxamide **671817-29-1P**, (R)-trans-4-(1-Aminobut-3-enyl)-N-(4-pyridyl)cyclohexanecarboxamide **671817-30-4P**, (S)-trans-4-(1-Aminobut-3-enyl)-N-(4-pyridyl)cyclohexanecarboxamide **671817-32-6P**, trans-4-[1-(Benzylamino)but-3-enyl]-N-(4-pyridyl)cyclohexanecarboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of allyl- or hydrazino-containing 1,4-substituted
cyclohexane carboxamides as Rho kinase inhibitors for repairing **damaged nerves** and as antiproliferative agents)

RN 129830-38-2 CAPLUS
CN Cyclohexanecarboxamide, 4-[(1R)-1-aminoethyl]-N-4-pyridinyl-, dihydrochloride, trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



●2 HCl

RN 129830-39-3 CAPLUS
CN Cyclohexanecarboxamide, 4-[(1S)-1-aminoethyl]-N-4-pyridinyl-, dihydrochloride, trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 671816-24-3 CAPLUS
CN Cyclohexanecarboxamide, 4-[(1R)-1-aminobutyl]-N-4-pyridinyl-, dihydrochloride, trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 671816-25-4 CAPLUS
CN Cyclohexanecarboxamide, 4-[(1S)-1-aminobutyl]-N-4-pyridinyl-, dihydrochloride, trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 671816-27-6 CAPLUS
CN Cyclohexanecarboxamide, 4-[1-[(phenylmethyl)amino]-3-butenyl]-N-4-pyridinyl-, dihydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 671816-28-7 CAPLUS

CN Cyclohexanecarboxamide, 4-(1-amino-3-butenyl)-N-4-pyridinyl-, dihydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 671816-29-8 CAPLUS
CN Cyclohexanecarboxamide, 4-[(1R)-1-amino-3-butenyl]-N-4-pyridinyl-, dihydrochloride, trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 671816-30-1 CAPLUS
CN Cyclohexanecarboxamide, 4-[(1S)-1-amino-3-butenyl]-N-4-pyridinyl-, dihydrochloride, trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 671816-32-3 CAPLUS
CN Cyclohexanecarboxamide, 4-(1-amino-3-butenyl)-N-(3-pyridinylmethyl)-, dihydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 671816-33-4 CAPLUS
CN Cyclohexanecarboxamide, 4-(1-amino-3-butenyl)-N-[2-(2-pyridinyl)ethyl]-, dihydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 671816-35-6 CAPLUS
CN Cyclohexanecarboxamide, 4-(1-amino-3-butenyl)-N-3-pyridinyl-, dihydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 671816-42-5 CAPLUS
CN Cyclohexanecarboxamide, 4-(1-amino-3-butenyl)-N-(4-pyridinylmethyl)-, dihydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 671817-00-8 CAPLUS
CN Cyclohexanecarboxamide, 4-(1-amino-3-butenyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 671817-02-0 CAPLUS
CN Cyclohexanecarboxamide, 4-(1-amino-3-butenyl)-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 671817-03-1 CAPLUS
CN Cyclohexanecarboxamide, 4-(1-amino-3-butenyl)-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 671817-05-3 CAPLUS
CN Cyclohexanecarboxamide, 4-(1-amino-3-butenyl)-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 671817-12-2 CAPLUS
CN Cyclohexanecarboxamide, 4-(1-amino-3-butenyl)-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 671817-14-4 CAPLUS
CN Cyclohexanecarboxamide, 4-[1-[(phenylmethyl)amino]-3-butenyl]-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 671817-16-6 CAPLUS

CN Cyclohexanecarboxamide, 4-(1-amino-3-butenyl)-N-4-pyridinyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 671817-18-8 CAPLUS
CN Cyclohexanecarboxamide, 4-(1-amino-3-butenyl)-N-(3-pyridinylmethyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 671817-19-9 CAPLUS
CN Cyclohexanecarboxamide, 4-(1-amino-3-butenyl)-N-[2-(2-pyridinyl)ethyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 671817-21-3 CAPLUS
CN Cyclohexanecarboxamide, 4-(1-amino-3-butenyl)-N-3-pyridinyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 671817-28-0 CAPLUS
CN Cyclohexanecarboxamide, 4-(1-amino-3-butenyl)-N-(4-pyridinylmethyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 671817-29-1 CAPLUS
CN Cyclohexanecarboxamide, 4-[(1R)-1-amino-3-butenyl]-N-4-pyridinyl-, trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 671817-30-4 CAPLUS
CN Cyclohexanecarboxamide, 4-[(1S)-1-amino-3-butenyl]-N-4-pyridinyl-, trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 671817-32-6 CAPLUS
CN Cyclohexanecarboxamide, 4-[1-[(phenylmethyl)amino]-3-butenyl]-N-4-pyridinyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **671816-02-7P,** trans-4-[(R)-1-[(tert-Butyloxycarbonyl)amino]butyl]-N-(4-pyridyl)cyclohexanecarboxamide **671816-03-8P,** trans-4-[(S)-1-[(tert-Butyloxycarbonyl)amino]butyl]-N-(4-pyridyl)cyclohexanecarboxamide **671816-04-9P,** trans-4-[(R)-1-[(tert-Butyloxycarbonyl)amino]ethyl]-N-(4-pyridyl)cyclohexanecarboxamide **671816-05-0P,** trans-4-[(S)-1-[(tert-Butyloxycarbonyl)amino]ethyl]-N-(4-pyridyl)cyclohexanecarboxamide **671816-06-1P,** trans-4-[1-[[(Methyloxy)carbonyl]amino]but-3-enyl]-N-(4-pyridyl)cyclohexanecarboxamide **671816-07-2P,** trans-4-[(R)-1-[[(Methyloxy)carbonyl]amino]but-3-enyl]-N-(4-pyridyl)cyclohexanecarboxamide **671816-08-3P,** trans-4-[(S)-1-[[(Methyloxy)carbonyl]amino]but-3-enyl]-N-(4-pyridyl)cyclohexanecarboxamide **671816-12-9P,** trans-4-[1-[[(Methyloxy)carbonyl]amino]but-3-enyl]-N-[(3-pyridyl)methyl]cyclohexanecarboxamide **671816-13-0P,** trans-4-[1-[[(Methyloxy)carbonyl]amino]but-3-enyl]-N-[2-(2-pyridyl)ethyl]cyclohexanecarboxamide **671816-15-2P,** trans-4-[1-[[(Methyloxy)carbonyl]amino]but-3-enyl]-N-(3-pyridyl)cyclohexanecarboxamide **671816-22-1P,** trans-4-[1-[[(Methyloxy)carbonyl]amino]but-3-enyl]-N-[(4-pyridyl)methyl]cyclohexanecarboxamide **671816-67-4P,** cis-4-[2-(tert-Butyloxycarbonyl)-1-methylhydrazino]-N-(4-pyridyl)cyclohexanecarboxamide **671816-68-5P,** trans-4-[2-(tert-Butyloxycarbonyl)-1-methylhydrazino]-N-(4-pyridyl)cyclohexanecarboxamide **671816-69-6P,** cis-4-[2-(tert-Butyloxycarbonyl)-1-(propyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide **671816-70-9P,** trans-4-[2-(tert-Butyloxycarbonyl)-1-(propyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide **671816-71-0P,** cis-4-[2-(tert-Butyloxycarbonyl)-1-(3-methylbutyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide **671816-72-1P,**

trans-4-[2-(tert-Butyloxycarbonyl)-1-(3-methylbutyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide **671816-73-2P**,
cis-4-[2-(tert-Butyloxycarbonyl)-1-(1-methylethyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide **671816-74-3P**,
trans-4-[2-(tert-Butyloxycarbonyl)-1-(1-methylethyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide **671816-75-4P**,
cis-4-[2-(tert-Butyloxycarbonyl)-1-benzylhydrazino]-N-(4-pyridyl)cyclohexanecarboxamide **671816-76-5P**,
trans-4-[2-(tert-Butyloxycarbonyl)-1-benzylhydrazino]-N-(4-pyridyl)cyclohexanecarboxamide **671816-77-6P**,
trans-4-[2-(tert-Butyloxycarbonyl)-1-(2-phenylethyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide **671816-78-7P**,
Trans-4-[2-(tert-Butyloxycarbonyl)-1-(2,2-diphenylethyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide **671816-79-8P**,
trans-4-[2-(tert-Butyloxycarbonyl)-1-[4-(benzyloxy)benzyl]hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide **671816-80-1P**,
trans-4-[2-(tert-Butyloxycarbonyl)-1-(cyclohexylmethyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide **671816-81-2P**,
trans-4-[2-(tert-Butyloxycarbonyl)-1-octylhydrazino]-N-(4-pyridyl)cyclohexanecarboxamide **671816-82-3P**,
trans-4-[2-(tert-Butyloxycarbonyl)-1-((E)-3-phenylprop-2-enyl)hydrazino]-N-(4-pyridyl)cyclohexanecarboxamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of allyl- or hydrazino-containing 1,4-substituted cyclohexane carboxamides as Rho kinase inhibitors for repairing **damaged nerves** and as antiproliferative agents)

RN 671816-02-7 CAPLUS
CN Carbamic acid, [(1R)-1-[trans-4-[(4-pyridinylamino)carbonyl]cyclohexyl]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 671816-03-8 CAPLUS
CN Carbamic acid, [(1S)-1-[trans-4-[(4-pyridinylamino)carbonyl]cyclohexyl]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 671816-04-9 CAPLUS
CN Carbamic acid, [(1R)-1-[trans-4-[(4-pyridinylamino)carbonyl]cyclohexyl]eth
yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 671816-05-0 CAPLUS
CN Carbamic acid, [(1S)-1-[trans-4-[(4-pyridinylamino)carbonyl]cyclohexyl]eth
yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 671816-06-1 CAPLUS
CN Carbamic acid, [1-[trans-4-[(4-pyridinylamino)carbonyl]cyclohexyl]-3-
butenyl]-, methyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 671816-07-2 CAPLUS
CN Carbamic acid, [(1R)-1-[trans-4-[(4-pyridinylamino)carbonyl]cyclohexyl]-3-butenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 671816-08-3 CAPLUS
CN Carbamic acid, [(1S)-1-[trans-4-[(4-pyridinylamino)carbonyl]cyclohexyl]-3-butenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 671816-12-9 CAPLUS
CN Carbamic acid, [1-[trans-4-[[(3-pyridinylmethyl)amino]carbonyl]cyclohexyl]-3-butenyl]-, methyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 671816-13-0 CAPLUS
CN Carbamic acid, [1-[trans-4-[[[2-(2-pyridinyl)ethyl]amino]carbonyl]cyclohexyl]-3-butenyl]-, methyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 671816-15-2 CAPLUS
CN Carbamic acid, [1-[trans-4-[(3-pyridinylamino)carbonyl]cyclohexyl]-3-butenyl]-, methyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 671816-22-1 CAPLUS
CN Carbamic acid, [1-[trans-4-[[(4-pyridinylmethyl)amino]carbonyl]cyclohexyl]-3-butenyl]-, methyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 671816-67-4 CAPLUS
CN Hydrazinecarboxylic acid, 2-methyl-2-[cis-4-[(4-pyridinylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 671816-68-5 CAPLUS
CN Hydrazinecarboxylic acid, 2-methyl-2-[trans-4-[(4-pyridinylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 671816-69-6 CAPLUS
CN Hydrazinecarboxylic acid, 2-propyl-2-[cis-4-[(4-

pyridinylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 671816-70-9 CAPLUS
CN Hydrazinecarboxylic acid, 2-propyl-2-[trans-4-[(4-pyridinylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 671816-71-0 CAPLUS
CN Hydrazinecarboxylic acid, 2-(3-methylbutyl)-2-[cis-4-[(4-pyridinylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 671816-72-1 CAPLUS
CN Hydrazinecarboxylic acid, 2-(3-methylbutyl)-2-[trans-4-[(4-pyridinylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 671816-73-2 CAPLUS
CN Hydrazinecarboxylic acid, 2-(1-methylethyl)-2-[cis-4-[(4-pyridinylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 671816-74-3 CAPLUS
CN Hydrazinecarboxylic acid, 2-(1-methylethyl)-2-[trans-4-[(4-pyridinylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 671816-75-4 CAPLUS
CN Hydrazinecarboxylic acid, 2-(phenylmethyl)-2-[cis-4-[(4-pyridinylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 671816-76-5 CAPLUS
CN Hydrazinecarboxylic acid, 2-(phenylmethyl)-2-[trans-4-[(4-pyridinylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 671816-77-6 CAPLUS
CN Hydrazinecarboxylic acid, 2-(2-phenylethyl)-2-[trans-4-[(4-pyridinylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA

INDEX NAME)

Relative stereochemistry.



RN 671816-78-7 CAPLUS
CN Hydrazinecarboxylic acid, 2-(2,2-diphenylethyl)-2-[trans-4-[(4-pyridinylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 671816-79-8 CAPLUS
CN Hydrazinecarboxylic acid, 2-[[4-(phenylmethoxy)phenyl]methyl]-2-[trans-4-[(4-pyridinylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 671816-80-1 CAPLUS
CN Hydrazinecarboxylic acid, 2-(cyclohexylmethyl)-2-[trans-4-[(4-pyridinylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 671816-81-2 CAPLUS
CN Hydrazinecarboxylic acid, 2-octyl-2-[trans-4-[(4-pyridinylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 671816-82-3 CAPLUS
CN Hydrazinecarboxylic acid, 2-[(2E)-3-phenyl-2-propenyl]-2-[trans-4-[(4-pyridinylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:282706 CAPLUS
DN 138:292804
TI Nutrient medium for maintaining neural cells in injured nervous system
IN Brewer, Gregory J.
PA Southern Illinois University, USA
SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003029417	A2	20030410	WO 2002-US31137	20021001
	WO 2003029417	A3	20031204		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US	2003077564	A1	20030424	US 2002-261462	20020930
CA	2462802	AA	20030410	CA 2002-2462802	20021001
EP	1451294	A2	20040901	EP 2002-766430	20021001

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

US	2005208028	A1	20050922	US 2005-115479	20050427
PRAI US	2001-326658P	P	20011002		
US	2002-261462	B1	20020930		
WO	2002-US31137	W	20021001		

IT 50-23-7, Cortisol 50-99-7, D Glucose, biological studies 52-90-4, Cysteine, biological studies 56-40-6, Glycine, biological studies 56-41-7, Alanine, biological studies 56-45-1, Serine, biological studies 56-85-9, Glutamine, biological studies 56-87-1, Lysine, biological studies 57-83-0, Progesterone, biological studies 58-85-5, Biotin 59-23-4, D(+)-Galactose, biological studies 59-30-3, Folic acid, biological studies 59-43-8, Thiamine, biological studies 60-18-4, Tyrosine, biological studies 60-33-3, Linoleic acid, biological studies 61-90-5, Leucine, biological studies 63-68-3, Methionine, biological studies 63-91-2, Phenylalanine, biological studies 66-72-8, Pyridoxal 67-48-1, Choline chloride 68-19-9, Vitamin b12 70-18-8, Reduced glutathione, biological studies 70-47-3, Asparagine, biological studies 71-00-1, Histidine, biological studies 72-18-4, Valine, biological studies 72-19-5, Threonine, biological studies 73-22-3, Tryptophan, biological studies 73-32-5, Isoleucine, biological studies 74-79-3, Arginine, biological studies 83-88-5, Riboflavin, biological studies 87-89-8, myo-Inositol **98-92-0**, Niacinamide 110-60-1, Putrescine 113-24-6, Sodium pyruvate 127-47-9, Retinyl acetate 137-08-6, Calcium D-pantothenate 141-43-5, Ethanolamine, biological studies 144-55-8, Sodium hydrogen carbonate, biological studies 147-85-3, Proline, biological studies 463-40-1, Linolenic acid 541-15-1, L-Carnitine 651-48-9, Dehydroepiandrosterone sulfate 6893-02-3, 3,3'[,5-Triiodo-L-thyronine 7447-40-7, Potassium chloride, biological studies 7558-80-7, Sodium dihydrogen phosphate 7647-14-5, Sodium chloride, biological studies 7733-02-0, Zinc sulfate 7786-30-3, Magnesium chloride, biological studies 9001-05-2, Catalase 9004-10-8, Insulin, biological studies 9054-89-1, Superoxide dismutase 10043-52-4, Calcium chloride, biological studies 10102-18-8, Sodium selenite 10191-41-0, DL-α-Tocopherol 10421-48-4, Ferric nitrate 52225-20-4, DLα Tocopherol acetate 106096-93-9, Fgf2
RL: FFD (Food or feed use); PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(nutrient medium for maintaining neural cells in **injured nervous** system)

IT **98-92-0**, Niacinamide
RL: FFD (Food or feed use); PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(nutrient medium for maintaining neural cells in **injured nervous** system)

RN 98-92-0 CAPLUS
CN 3-Pyridinecarboxamide (9CI) (CA INDEX NAME)



L11 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:57902 CAPLUS
DN 138:117662
TI Use of NK-1 receptor antagonists for the treatment of brain, spinal or nerve injury
IN Hoffmann, Torsten; Nimmo, Alan John; Sleight, Andrew; Vankan, Pierre; Vink, Robert
PA F. Hoffmann-La Roche A.-G., Switz.
SO PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003006016	A2	20030123	WO 2002-EP7323	20020703
	WO 2003006016	A3	20030731		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003083345	A1	20030501	US 2002-187587	20020702
	CA 2451566	AA	20030123	CA 2002-2451566	20020703
	EP 1406618	A2	20040414	EP 2002-764617	20020703
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002010893	A	20040622	BR 2002-10893	20020703
	CN 1523988	A	20040825	CN 2002-813542	20020703
	JP 2004536119	T2	20041202	JP 2003-511822	20020703
	EP 1621195	A2	20060201	EP 2005-17203	20020703
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, CY, TR, BG, CZ, EE, SK				
	ZA 2004000138	A	20050408	ZA 2004-138	20040108
PRAI	EP 2001-116812	A	20010710		
	EP 2002-764617	A3	20020703		
	WO 2002-EP7323	W	20020703		

OS MARPAT 138:117662
IT 290296-41-2 290296-42-3 290296-43-4 290296-44-5 290296-45-6
290296-46-7 290296-47-8 290296-49-0 290296-50-3 290296-51-4
290296-59-2 **290296-66-1** 290296-67-2 290296-68-3
290296-72-9 290296-73-0 290296-74-1 290296-75-2 290296-84-3
290296-85-4 290296-86-5 **290296-87-6** 290296-88-7
290296-89-8 290296-90-1 290296-91-2 290296-92-3 290296-93-4
290296-94-5 290296-95-6 290296-96-7 290296-98-9 290296-99-0
290297-00-6 290297-01-7 290297-05-1 290297-18-6 290297-26-6
290297-30-2 290297-57-3 290297-58-4 290297-59-5 290297-61-9
290297-62-0 290297-63-1 290297-64-2 290297-65-3 290297-66-4

290298-21-4 391674-73-0 391674-74-1 391674-75-2
391674-76-3 **391674-77-4** **391674-78-5** 391674-79-6
391674-80-9 391674-81-0 391674-82-1 391674-83-2
391674-84-3 391674-85-4 391674-86-5 **391674-87-6**
391674-89-8 391674-90-1 391674-91-2 391674-92-3 391674-93-4
391674-94-5 391674-95-6 391674-97-8 391674-98-9 391674-99-0
391675-00-6 391675-01-7 391675-02-8 393508-70-8 393508-71-9
393508-72-0 393508-73-1 393508-74-2 393508-75-3 **393508-76-4**
393508-77-5 393508-78-6 **393508-79-7**
393508-80-0 **393508-81-1** **393508-82-2**
393508-84-4 393508-91-3 401891-32-5 401891-33-6 401891-34-7
401891-35-8 401891-36-9 401891-37-0 **401891-38-1**
401891-39-2 401891-40-5 **401891-42-7**
401891-43-8 401891-44-9 **401891-45-0** 401891-55-2
401891-63-2 401891-67-6 401891-70-1 401891-87-0 **401891-90-5**
401891-91-6 401891-94-9 401892-00-0 401892-10-2 401892-12-4
401892-24-8 401892-25-9 401892-29-3 401892-38-4 401892-63-5
474026-07-8 474026-11-4 474026-12-5 474026-13-6 **488780-92-3**
488780-93-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NK-1 receptor antagonist for treatment of brain, spinal or **nerve injury**)

IT **290296-66-1** **290296-87-6** **290298-21-4**
391674-77-4 **391674-78-5** **391674-80-9**
391674-87-6 **393508-76-4** **393508-77-5**
393508-79-7 **393508-80-0** **393508-81-1**
393508-82-2 **401891-38-1** **401891-39-2**
401891-42-7 **401891-43-8** **401891-45-0**
401891-90-5 **488780-92-3** **488780-93-4**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NK-1 receptor antagonist for treatment of brain, spinal or **nerve injury**)

RN 290296-66-1 CAPLUS
CN Benzeneacetamide, N,α,α-trimethyl-N-[6-[methyl[2-(4-morpholinyl)ethyl]amino]-4-(2-methylphenyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 290296-87-6 CAPLUS
CN 3-Pyridinecarboxamide, 6-[3-(acetylmethylamino)-1-pyrrolidinyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 290298-21-4 CAPLUS
CN Benzeneacetamide, N-[6-[(2-hydroxyethyl)methylamino]-4-(2-methylphenyl)-3-pyridinyl]-N,α,α-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 391674-77-4 CAPLUS
CN Benzeneacetamide, N-[6-(dimethyloxidoamino)-4-(2-methylphenyl)-3-pyridinyl]-N,α,α-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 391674-78-5 CAPLUS
CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(dimethyloxidoamino)-3-pyridinyl]-N,α,α-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 391674-80-9 CAPLUS
CN Benzeneacetamide, N-[6-[(2-hydroxyethyl)methyloxidoamino]-4-(2-methylphenyl)-3-pyridinyl]-N,α,α-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 391674-87-6 CAPLUS
CN 3-Pyridinecarboxamide, 6-[3-(acetylmethylamino)-1-oxido-1-pyrrolidinyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 393508-76-4 CAPLUS
CN Benzeneacetamide, N-[6-[(2-hydroxyethyl)amino]-4-(2-methylphenyl)-3-pyridinyl]-N,α,α-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 393508-77-5 CAPLUS
CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-[(2-hydroxyethyl)amino]-3-pyridinyl]-N,α,α-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 393508-79-7 CAPLUS
CN Benzeneacetamide, N-[6-(acetylamino)-4-(2-methylphenyl)-3-pyridinyl]-N,α,α-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 393508-80-0 CAPLUS
CN Benzeneacetamide, N-[6-(acetylmethylamino)-4-(2-methylphenyl)-3-pyridinyl]-N,α,α-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 393508-81-1 CAPLUS
CN Benzeneacetamide, N-[6-[(cyclopropylcarbonyl)amino]-4-(2-methylphenyl)-3-pyridinyl]-N,α,α-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 393508-82-2 CAPLUS
CN Benzeneacetamide, N-[6-[(cyclopropylcarbonyl)methylamino]-4-(2-methylphenyl)-3-pyridinyl]-N,α,α-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 401891-38-1 CAPLUS
CN Benzeneacetamide, N-[6-[hydroxy(2-hydroxyethyl)amino]-4-(2-methylphenyl)-3-pyridinyl]-N,α,α-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 401891-39-2 CAPLUS
CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-[hydroxy(2-hydroxyethyl)amino]-3-pyridinyl]-N,α,α-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 401891-42-7 CAPLUS
CN Benzeneacetamide, N-[6-[(hydroxyacetyl)amino]-4-(2-methylphenyl)-3-pyridinyl]-N,α,α-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 401891-43-8 CAPLUS
CN Benzeneacetamide, N-[6-[(hydroxyacetyl)methylamino]-4-(2-methylphenyl)-3-pyridinyl]-N,α,α-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 401891-45-0 CAPLUS
CN Benzeneacetamide, N-[6-[bis(cyclopropylcarbonyl)amino]-4-(2-methylphenyl)-3-pyridinyl]-N,α,α-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 401891-90-5 CAPLUS
CN 3-Pyridinecarboxamide, 6-(3-amino-1-propynyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 488780-92-3 CAPLUS
CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(dimethylamino)-3-pyridinyl]-α,α-dimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 488780-93-4 CAPLUS
CN Glycine, N-[5-[[2-[3,5-bis(trifluoromethyl)phenyl]-2-methyl-1-oxopropyl]methylamino]-4-(2-methylphenyl)-2-pyridinyl]-N-(methoxycarbonyl)- (9CI) (CA INDEX NAME)



L11 ANSWER 7 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:927244 CAPLUS
DN 138:11433
TI Method for treating nerve injury caused as a result of surgery
IN Steiner, Joseph P.; Snyder, Solomon; Burnett, Arthur L.
PA Guilford Pharmaceuticals Inc., USA; The Johns Hopkins University School of Medicine
SO PCT Int. Appl., 349 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002096420	A2	20021205	WO 2002-US16806	20020529
	WO 2002096420	A3	20030206		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2449019	AA	20021205	CA 2002-2449019	20020529
	US 2003203890	A1	20031030	US 2002-156735	20020529
	EP 1404325	A2	20040407	EP 2002-774120	20020529
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2005500270	T2	20050106	JP 2002-592930	20020529
PRAI	US 2001-293544P	P	20010529		
	WO 2002-US16806	W	20020529		

IT 186268-50-8P 186268-51-9P 186268-52-0P 186268-53-1P 186268-54-2P
186268-56-4P 186268-58-6P 186268-63-3P 186268-64-4P 186268-65-5P
186268-66-6P 186268-68-8P 186452-05-1P 186452-06-2P 186452-07-3P
186452-08-4P 186452-09-5P 186452-10-8P 186452-11-9P 186452-12-0P
186452-13-1P 186452-14-2P 186452-16-4P 186452-17-5P 186452-18-6P
186452-19-7P 186452-20-0P 205388-13-2P 205388-14-3P 205388-15-4P
210048-13-8P 210048-24-1P **210103-55-2P** 210103-60-9P
212762-79-3P 222171-28-0P **244245-25-8P** 353288-37-6P
353288-39-8P 477319-22-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(neurotrophic agents for treating **nerve injury** caused as a result of surgery)

IT 141084-63-1 152754-42-2 155668-51-2 155668-52-3 155668-86-3

157757-22-7 186268-57-5 186268-67-7 186452-15-3 186834-62-8
186834-66-2 186834-69-5 186834-70-8 186834-71-9 186834-72-0
186834-73-1 186834-74-2 186834-75-3 186834-76-4 186834-77-5
186834-80-0 186834-81-1 186834-84-4 186834-85-5 186834-86-6
186834-87-7 205388-16-5 205388-20-1 205388-21-2 205388-22-3
205388-23-4 205388-24-5 205388-25-6 205388-26-7 205388-27-8
205388-28-9 205388-29-0 205388-30-3 205388-31-4 205388-32-5
205388-33-6 205388-34-7 205388-35-8 205388-36-9 205388-37-0
205388-38-1 205388-39-2 205388-42-7 205388-43-8 205388-44-9
205388-47-2 205388-48-3 205388-49-4 205388-50-7 205388-51-8
205388-53-0 205388-54-1 205388-55-2 205388-56-3 205388-57-4
205388-58-5 205388-59-6 205388-61-0 205388-62-1 205388-63-2
205388-80-3 210048-17-2 210048-19-4 210048-20-7 210048-21-8
210048-22-9 210103-56-3 210103-57-4 210103-58-5 **210103-59-6**
210103-61-0 210103-62-1 210103-63-2 217178-10-4
217180-44-4 217180-57-9 217180-59-1 217180-90-0 217186-52-2
217186-53-3 217186-54-4 217186-55-5 217186-56-6 217186-57-7
222171-24-6 222171-25-7 222171-27-9 222171-29-1 222171-30-4
222171-31-5 222171-32-6 250636-40-9 251948-47-7 252720-21-1
259231-75-9 261928-53-4 354114-37-7 354114-40-2 354114-43-5
354114-45-7 354114-47-9 354114-49-1 354114-51-5 477319-18-9
477319-24-7 477319-25-8 477319-26-9 477319-27-0 477319-35-0
477319-37-2 477319-38-3 477319-39-4 477319-41-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neurotrophic agents for treating **nerve injury** caused as a result of surgery)

IT **210103-55-2P 244245-25-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(neurotrophic agents for treating **nerve injury** caused as a result of surgery)

RN 210103-55-2 CAPLUS
CN 2-Pyrrolidinecarbothioic acid, 1-[[(1,1-dimethylpropyl)amino]carbonyl]-, S-[3-(3-pyridinyl)propyl] ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244245-25-8 CAPLUS
CN 2-Pyrrolidinecarbothioic acid, 1-[[(3-methylbutyl)amino]carbonyl]-, S-[3-(3-pyridinyl)propyl] ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **210103-59-6 210103-61-0 210103-62-1**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neurotrophic agents for treating **nerve injury** caused as a result of surgery)
RN 210103-59-6 CAPLUS
CN 2-Pyrrolidinecarbothioic acid, 1-[(cyclohexylamino)carbonyl]-, S-[3-(3-pyridinyl)propyl] ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 210103-61-0 CAPLUS
CN 2-Pyrrolidinecarbothioic acid, 1-[thioxo(tricyclo[3.3.1.13,7]dec-1-ylamino)methyl]-, S-[3-(3-pyridinyl)propyl] ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 210103-62-1 CAPLUS
CN 2-Pyrrolidinecarbothioic acid, 1-[[(1,1-dimethylpropyl)amino]thioxomethyl]-, S-[3-(3-pyridinyl)propyl] ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 8 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:750523 CAPLUS
DN 137:273218
TI Combination preparation for prophylaxis and/or therapy of nerve cell damage and/or glial cell damage
IN Sendtner, Michael; Sedlacek, Hans-Harald
PA Medinnova Gesellschaft fur Medizinische Innovationen aus Akademischer Forschung m.b.H., Germany
SO Ger. Offen., 10 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 10113513	A1	20021002	DE 2001-10113513	20010320
WO 2002089779	A2	20021114	WO 2002-DE1049	20020319
WO 2002089779	A3	20030821		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI DE 2001-10113513 A 20010320
IT 51-83-2, Carbachol 54-11-5, Nicotine 56-03-1D, Biguanide, derivs. 58-00-4, Apomorphine 64-77-7, Tolbutamide 89-00-9, 2,3-Pyridinedicarboxylic acid 92-13-7, Pilocarpine 96-48-0, Butyrolactone 108-88-3, Toluene, biological studies 110-86-1D, Pyridine, 2,6-di-Ph derivs. 154-23-4, Catechol 154-23-4D, Catechol, derivs. 302-79-4, Retinoic acid 452-86-8, 4-Methylcatechol 487-79-6, Kainic acid 491-38-3D, 4H-1-Benzopyran-4-one, derivs. 518-82-1, Emodin 657-24-9, Metformin 1132-49-6D, derivs. 1335-05-3D, Pyrimidone, derivs. 6384-92-5, NMDA 7683-59-2, Isoproterenol 9004-10-8, Insulin, biological studies 9061-61-4, Nerve growth factor 10238-21-8, Glibenclamide 21187-98-4, Gliclazide 25046-79-1, Glisoxepide 26444-09-7D, Corrole, 5,10,15-triaryl derivs. 26944-48-9, Glibornuride 33342-05-1, Gliquidone 33507-63-0, Substance P 36791-04-5, Ribavirin 36791-04-5D, Ribavirin, derivs. 50913-82-1, Org 2766 52809-07-1 61912-98-9, Insulin-like growth factor 66575-29-9, Forskolin 77521-29-0, AMPA 81627-83-0, M-CSF 83869-56-1, GM-CSF 93479-97-1, Glimepiride 109511-58-2 111025-46-8, Pioglitazone 112953-11-4, 7-Hydroxystaurosporine 112953-11-4D, 7-Hydroxystaurosporine, derivs. 124620-88-8 124620-88-8D, optical isomers 128908-32-7, Melanocortin 130939-66-1, Neurotrophin 3 138605-00-2, NKH 477 142273-18-5 142273-18-5D, derivs. 143375-33-1, Neurotrophin 4 143375-33-1,

Neurotrophin 5 146426-40-6, Flavopiridol 146426-40-6D, Flavopiridol, analogs 146426-40-6D, Flavopiridol, derivs. 152121-47-6 **155141-29-0**, Rosiglitazone maleate 167869-21-8 167869-21-8D, derivs. 177345-94-7, Neurotrophin 6 180132-69-8, Cardiotrophin-1 185857-51-6, Neurturin 186692-46-6, Roscovitine 212631-79-3 212844-53-6, Purvalanol A 213010-45-8, Scabronine A 214980-75-3, Scabronine B 251445-63-3, Growth differentiation factor 15
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination preparation for prophylaxis and/or therapy of **nerve** cell **damage** and/or glial cell **damage**)

IT **155141-29-0**, Rosiglitazone maleate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination preparation for prophylaxis and/or therapy of **nerve** cell **damage** and/or glial cell **damage**)

RN 155141-29-0 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4
CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 9 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:936030 CAPLUS
DN 136:48467
TI Use of TNF-α inhibitors for treating nerve root injury
IN Olmarker, Kjell; Rydevik, Bjorn
PA Swed.
SO U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S. Ser. No. 743,852.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2001055594	A1	20011227	US 2001-826893	20010406
	SE 9803710	A	20000326	SE 1998-3710	19981029
	WO 2000018409	A1	20000406	WO 1999-SE1671	19990923
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6649589	B1	20031118	US 2001-743852	20010117
	US 2003039651	A1	20030227	US 2002-225237	20020822
PRAI	SE 1998-3276	A	19980925		
	SE 1998-3710	A	19981029		
	WO 1999-SE1671	W	19990923		
	US 2001-743852	A2	20010117		
	US 2001-826893	A2	20010406		

IT 71-58-9, CBP 1011 132173-07-0, SR-31747 137945-48-3, CT 3
158978-98-4, PMS 601 170277-31-3, Infliximab 179024-48-7, PD 168787
185243-69-0, Etanercept 189940-24-7, SH 636 199657-29-9
226072-63-5 287096-87-1, RDP 58 316350-99-9, AGT-1
331731-18-1, D 2E7 336128-48-4, CDP-571 383198-14-9, Sch 23863
383198-15-0, RIP 3 383198-16-1, NR 58-3.14.3 383198-17-2, CH 3697
383198-18-3, TNF 484A 383198-19-4, NCS 700 383198-20-7, M-PGA
383198-21-8, CLX 1100 428863-50-7, CDP-870
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as TNF-α inhibitor; use of TNF-α inhibitors for treating **nerve** root **injury**)
IT **226072-63-5**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as TNF-α inhibitor; use of TNF-α inhibitors for treating **nerve** root **injury**)

RN 226072-63-5 CAPLUS

CN Butanediamide, N4-[(1S)-2,2-dimethyl-1-[(2-pyridinylamino)carbonyl]propyl]-N1-hydroxy-2-methoxy-3-(2-methylpropyl)-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 10 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:798047 CAPLUS

DN 135:339277

TI Lipoic acid-containing pharmaceutical compositions for treatment, prevention or inhibition of central nervous system injuries and diseases

IN Meyerhoff, James L.; Yoorick, Debra L.; Koenig, Michael L.

PA United States Army Medical Research and Material Command, USA

SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001080851	A1	20011101	WO 2001-US13043	20010420
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001053767	A5	20011107	AU 2001-53767	20010420
	US 6469049	B2	20021022	US 2001-839905	20010420
	US 2002177558	A1	20021128		
PRAI	US 2000-198958P	P	20000421		
	WO 2001-US13043	W	20010420		

IT 50-81-7, Vitamin C, biological studies 70-18-8, GSH, biological studies 73-31-4, Melatonin 75-17-2, Nitrone **98-92-0**, Niacinamide 127-17-3, biological studies 462-20-4, Dihydrolipoic acid 616-91-1, N-Acetylcysteine 1077-27-6 1200-22-2, α-Lipoic acid 1200-22-2D, α-Lipoic acid, metabolites and analogs 1406-18-4, Vitamin E 98441-85-1 113443-50-8 119365-69-4 211174-88-8 243138-49-0 371112-46-8 371112-47-9

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lipoic acid-containing pharmaceutical compns. for treatment, prevention or inhibition of central **nervous** system **injuries** and diseases)

IT **98-92-0**, Niacinamide
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lipoic acid-containing pharmaceutical compns. for treatment, prevention or inhibition of central **nervous** system **injuries** and diseases)

RN 98-92-0 CAPLUS
CN 3-Pyridinecarboxamide (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

d bib hitstr hit 11-21

L11 ANSWER 11 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:693264 CAPLUS
DN 135:257269
TI Preparation of N-heterocyclyl amide compounds as 5-HT antagonists
IN Yamada, Akira; Tomishima, Masaki; Hayashida, Hisashi; Imanishi, Masashi; Spears, Glen W.; Ito, Kiyotaka; Takahashi, Fumie; Miyake, Hiroshi
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 239 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001068585	A1	20010920	WO 2001-JP1993	20010313
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001041128	A5	20010924	AU 2001-41128	20010313
EP 1264820	A1	20021211	EP 2001-912338	20010313
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004087798	A1	20040506	US 2002-221554	20021227
PRAI JP 2000-70127	A	20000314		
JP 2000-305947	A	20001005		
WO 2001-JP1993	W	20010313		

OS CASREACT 135:257269; MARPAT 135:257269
IT **361550-59-6P 361550-90-5P 361551-04-4P**
361551-05-5P 361551-09-9P 361551-10-2P
361551-13-5P 361551-34-0P 361551-35-1P
361551-36-2P 361551-37-3P 361551-39-5P
361551-40-8P 361551-41-9P 361551-44-2P
361551-47-5P 361551-48-6P 361551-50-0P
361551-55-5P 361551-56-6P 361551-57-7P
361551-85-1P 361551-86-2P 361551-87-3P
361551-88-4P 361551-89-5P 361551-90-8P
361551-91-9P 361551-92-0P 361551-93-1P
361551-94-2P 361552-17-2P 361552-24-1P
361552-34-3P 361552-35-4P 361552-36-5P
361552-37-6P 361552-44-5P 361552-48-9P
361552-51-4P 361552-54-7P 361552-57-0P
361552-58-1P 361552-59-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-heterocyclyl amide compds. as 5-HT antagonists for treatment of 5-HT-mediated diseases such as central **nervous** system disorders, drug withdrawal symptom, schizophrenia, spinal code **injury**, and head **injury**)
RN 361550-59-6 CAPLUS
CN 2-Propenamide, N-[3-[[(2-chloro-4-pyridinyl)amino]methyl]phenyl]-3-[2-(trifluoromethyl)phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 361550-90-5 CAPLUS
CN 2-Propenamide, 3-(2-chlorophenyl)-N-[6-[(2-pyridinylmethyl)amino]-3-pyridinyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 361551-04-4 CAPLUS
CN 2-Propenamide, N-[3-chloro-5-[[imino[4-[(2-methyl-3-pyridinyl)oxy]phenyl]methyl]amino]phenyl]-3-(2-chlorophenyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 361551-05-5 CAPLUS
CN 2-Propenamide, N-[3-chloro-5-[[imino[4-[(2-pyridinylmethyl)amino]phenyl]methyl]amino]phenyl]-3-(2-chlorophenyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 361551-09-9 CAPLUS
CN 2-Propenamide, N-[3-chloro-5-[[imino[4-[(2-methyl-3-pyridinyl)oxy]phenyl]methyl]amino]phenyl]-3-[2-(trifluoromethyl)phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 361551-10-2 CAPLUS
CN 2-Propenamide, N-[3-chloro-5-[[imino[4-[(1-oxido-3-pyridinyl)oxy]phenyl]methyl]amino]phenyl]-3-(2-chlorophenyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 361551-13-5 CAPLUS
CN 2-Propenamide, N-[3-fluoro-5-[(iminophenylmethyl)amino]phenyl]-3-(2-pyridinyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 361551-34-0 CAPLUS
CN 1H-Indole-7-carboxamide, N-[5-chloro-6-[(2-pyridinylmethyl)amino]-3-pyridinyl]-2,3-dimethyl- (9CI) (CA INDEX NAME)



RN 361551-35-1 CAPLUS
CN [1,1'-Biphenyl]-3-carboxamide, N-[5-chloro-6-[(2-pyridinylmethyl)amino]-3-pyridinyl]-4'-fluoro- (9CI) (CA INDEX NAME)



RN 361551-36-2 CAPLUS
CN Benzamide, N-[5-chloro-6-[(2-pyridinylmethyl)amino]-3-pyridinyl]-3-(2-

thienyl)- (9CI) (CA INDEX NAME)



RN 361551-37-3 CAPLUS
CN 2-Thiophenecarboxamide, N-[5-chloro-6-[(2-pyridinylmethyl)amino]-3-pyridinyl]-5-phenyl- (9CI) (CA INDEX NAME)



RN 361551-39-5 CAPLUS
CN 2-Thiophenecarboxamide, N-[5-chloro-6-[(2-pyridinylmethyl)amino]-3-pyridinyl]-5-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 361551-40-8 CAPLUS
CN 9H-Carbazole-1-carboxamide, N-[5-chloro-6-[(2-pyridinylmethyl)amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 361551-41-9 CAPLUS
CN 9H-Carbazole-1-carboxamide, N-[5-chloro-6-[(2-pyridinylmethyl)amino]-3-pyridinyl]-6-fluoro- (9CI) (CA INDEX NAME)



RN 361551-44-2 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[4-[(2-pyridinylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 361551-47-5 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[6-[(2-pyridinylmethyl)amino]-3-pyridinyl]-
(9CI) (CA INDEX NAME)



RN 361551-48-6 CAPLUS
CN 9H-Carbazole-1-carboxamide, N-[6-[(2-pyridinylmethyl)amino]-3-pyridinyl]-
(9CI) (CA INDEX NAME)



RN 361551-50-0 CAPLUS
CN 1H-Indole-7-carboxamide, 3-methyl-N-[6-[(2-pyridinylmethyl)amino]-3-pyridinyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 361551-55-5 CAPLUS
CN 3-Pyridinecarboxamide, 5-[(9H-fluoren-1-ylcarbonyl)amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 361551-56-6 CAPLUS
CN 3-Pyridinecarboxamide, 5-[(9H-fluoren-1-ylcarbonyl)amino]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 361551-57-7 CAPLUS
CN Benzamide, N-[6-[(2-pyridinylmethyl)amino]-3-pyridinyl]-3-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 361551-85-1 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[5-methyl-6-[(2-pyridinylmethyl)amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 361551-86-2 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[6-[(2-pyridinylmethyl)amino]-5-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 361551-87-3 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[6-[methyl(2-pyridinylmethyl)amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 361551-88-4 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[5-chloro-6-[methyl(2-pyridinylmethyl)amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 361551-89-5 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[6-[[(4-methyl-2-pyridinyl)methyl]amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 361551-90-8 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[6-[[(3-methyl-2-pyridinyl)methyl]amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 361551-91-9 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[6-[[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 361551-92-0 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[6-[(3-pyridinylmethyl)amino]-3-pyridinyl]-(9CI) (CA INDEX NAME)



RN 361551-93-1 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[6-[[2-(2-pyridinyl)ethyl]amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 361551-94-2 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[6-[(phenylmethyl)amino]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 361552-17-2 CAPLUS
CN 1-Benzoxepin-4-carboxamide, N-[5-chloro-6-[(2-pyridinylmethyl)amino]-3-pyridinyl]-7-fluoro-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 361552-24-1 CAPLUS
CN 1-Benzoxepin-4-carboxamide, 7-fluoro-2,3-dihydro-N-[6-[(2-pyridinylmethyl)amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 361552-34-3 CAPLUS
CN 9H-Carbazole-1-carboxamide, N-[2-[(2-pyridinylmethyl)amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 361552-35-4 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[2-[(2-pyridinylmethyl)amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 361552-36-5 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[5-chloro-6-[(2-pyridinylmethyl)amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 361552-37-6 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[5-chloro-6-[(pyrazinylmethyl)amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 361552-44-5 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[6-[(pyrazinylmethyl)amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 361552-48-9 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[3-[(4-pyridinylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 361552-51-4 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[3-[[(4,6-dimethyl-2-pyridinyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 361552-54-7 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[3-[[[5-(3-pyridinyl)-1H-1,2,4-triazol-3-yl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 361552-57-0 CAPLUS
CN 9H-Fluorene-1-carboxamide, N-[3-[[(2-chloro-4-pyridinyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 361552-58-1 CAPLUS
CN 9H-Carbazole-1-carboxamide, N-[3-[[(2-chloro-4-pyridinyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 361552-59-2 CAPLUS
CN 9H-Carbazole-1-carboxamide, N-[3-[(4-pyridinylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



IT **462-08-8**, 3-Aminopyridine **2706-56-1**, 2-(2-Pyridyl)ethylamine **3731-52-0**, 3-Pyridinemethanamine **21035-59-6 21630-48-8 36052-25-2**, 5-Aminonicotinic acid methyl ester **181633-42-1**, 3-Amino-6-(2-methyl-3-pyridyloxy)pyridine
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-heterocyclyl amide compds. as 5-HT antagonists for treatment of 5-HT-mediated diseases such as central **nervous** system disorders, drug withdrawal symptom, schizophrenia, spinal code **injury**, and head **injury**)

RN 462-08-8 CAPLUS
CN 3-Pyridinamine (9CI) (CA INDEX NAME)



RN 2706-56-1 CAPLUS
CN 2-Pyridineethanamine (9CI) (CA INDEX NAME)



RN 3731-52-0 CAPLUS
CN 3-Pyridinemethanamine (9CI) (CA INDEX NAME)



RN 21035-59-6 CAPLUS
CN 2-Pyridinemethanamine, N-methyl- (9CI) (CA INDEX NAME)



RN 21630-48-8 CAPLUS
CN 2,5-Pyridinediamine, N2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 36052-25-2 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-amino-, methyl ester (9CI) (CA INDEX NAME)



RN 181633-42-1 CAPLUS
CN 3-Pyridinamine, 6-[(2-methyl-3-pyridinyl)oxy]- (9CI) (CA INDEX NAME)



IT **21626-42-6P 21630-51-3P 361549-96-4P**
361550-45-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-heterocyclyl amide compds. as 5-HT antagonists for treatment of 5-HT-mediated diseases such as central **nervous** system disorders, drug withdrawal symptom, schizophrenia, spinal code **injury**, and head **injury**)

RN 21626-42-6 CAPLUS
CN 2-Pyridinemethanamine, N-(5-nitro-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 21630-51-3 CAPLUS
CN 2,5-Pyridinediamine, N2-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 361549-96-4 CAPLUS
CN 4-Pyridinamine, N-[(3-aminophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 361550-45-0 CAPLUS
CN [3,3'-Bipyridin]-5-amine, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

IT **3731-51-9**, 2-(Aminomethyl)pyridine
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-heterocyclyl amide compds. as 5-HT antagonists for treatment of 5-HT-mediated diseases such as central **nervous** system disorders, drug withdrawal symptom, schizophrenia, spinal cord **injury**, and head **injury**)
RN 3731-51-9 CAPLUS
CN 2-Pyridinemethanamine (9CI) (CA INDEX NAME)



IT **361548-85-8P 361549-28-2P 361549-29-3P**
361549-31-7P 361549-55-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-heterocyclyl amide compds. as 5-HT antagonists for treatment of 5-HT-mediated diseases such as central **nervous** system disorders, drug withdrawal symptom, schizophrenia, spinal cord **injury**, and head **injury**)
RN 361548-85-8 CAPLUS
CN 4-Pyridinamine, N-[(3-aminophenyl)methyl]-2-chloro- (9CI) (CA INDEX NAME)



RN 361549-28-2 CAPLUS
CN Benzonitrile, 4-[(2-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 361549-29-3 CAPLUS
CN Benzenecarbothioamide, 4-[(2-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 361549-31-7 CAPLUS
CN Benzenecarboximidothioic acid, 4-[(2-pyridinylmethyl)amino]-, methyl ester, monohydriodide (9CI) (CA INDEX NAME)



● HI

RN 361549-55-5 CAPLUS
CN 2-Propenamide, N-(3-amino-5-chlorophenyl)-3-(2-pyridinyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT 361550-47-2P 361550-48-3P 361550-49-4P 361550-50-7P 361550-51-8P
361550-52-9P 361550-53-0P 361550-54-1P 361550-55-2P 361550-56-3P
361550-57-4P 361550-58-5P **361550-59-6P** 361550-62-1P
361550-63-2P 361550-64-3P 361550-65-4P 361550-66-5P 361550-67-6P
361550-68-7P 361550-69-8P 361550-70-1P 361550-71-2P 361550-72-3P
361550-73-4P 361550-74-5P 361550-75-6P 361550-76-7P 361550-77-8P
361550-78-9P 361550-79-0P 361550-80-3P 361550-81-4P 361550-82-5P
361550-83-6P 361550-84-7P 361550-85-8P 361550-86-9P 361550-87-0P
361550-88-1P 361550-89-2P **361550-90-5P** 361550-91-6P
361550-92-7P 361550-93-8P 361550-94-9P 361550-95-0P 361550-96-1P
361550-97-2P 361550-98-3P 361550-99-4P 361551-00-0P 361551-01-1P
361551-02-2P 361551-03-3P **361551-04-4P** **361551-05-5P**
361551-06-6P 361551-07-7P 361551-08-8P **361551-09-9P**
361551-10-2P 361551-11-3P 361551-12-4P **361551-13-5P**
361551-14-6P 361551-15-7P 361551-16-8P 361551-17-9P 361551-18-0P
361551-19-1P 361551-20-4P 361551-21-5P 361551-22-6P 361551-24-8P
361551-27-1P 361551-30-6P 361551-31-7P 361551-32-8P 361551-33-9P

361551-34-0P 361551-35-1P 361551-36-2P
361551-37-3P 361551-39-5P 361551-40-8P
361551-41-9P 361551-43-1P **361551-44-2P** 361551-45-3P
361551-46-4P **361551-47-5P 361551-48-6P** 361551-49-7P
361551-50-0P 361551-51-1P 361551-52-2P 361551-54-4P
361551-55-5P 361551-56-6P 361551-57-7P
361551-58-8P 361551-59-9P 361551-61-3P 361551-62-4P 361551-63-5P
361551-65-7P 361551-66-8P 361551-67-9P 361551-68-0P 361551-69-1P
361551-70-4P 361551-71-5P 361551-72-6P 361551-73-7P 361551-74-8P
361551-75-9P 361551-76-0P 361551-77-1P 361551-78-2P 361551-79-3P
361551-80-6P 361551-81-7P 361551-82-8P 361551-83-9P
361551-85-1P 361551-86-2P 361551-87-3P
361551-88-4P 361551-89-5P 361551-90-8P
361551-91-9P 361551-92-0P 361551-93-1P
361551-94-2P 361551-96-4P 361551-97-5P 361551-99-7P
361552-01-4P 361552-02-5P 361552-03-6P 361552-04-7P 361552-05-8P
361552-06-9P 361552-07-0P 361552-09-2P 361552-11-6P 361552-13-8P
361552-14-9P 361552-16-1P **361552-17-2P** 361552-18-3P
361552-19-4P 361552-20-7P 361552-21-8P 361552-22-9P 361552-23-0P
361552-24-1P 361552-25-2P 361552-26-3P 361552-27-4P
361552-28-5P 361552-29-6P 361552-30-9P 361552-31-0P 361552-33-2P
361552-34-3P 361552-35-4P 361552-36-5P
361552-37-6P 361552-38-7P 361552-39-8P 361552-40-1P
361552-41-2P 361552-42-3P 361552-43-4P **361552-44-5P**
361552-45-6P 361552-46-7P 361552-47-8P **361552-48-9P**
361552-49-0P 361552-50-3P **361552-51-4P** 361552-52-5P
361552-53-6P **361552-54-7P** 361552-55-8P 361552-56-9P
361552-57-0P 361552-58-1P 361552-59-2P
361552-60-5P 361552-61-6P 361552-63-8P 361552-65-0P 361552-67-2P
361552-68-3P 361552-69-4P 361552-70-7P 361552-71-8P 361552-72-9P
361552-73-0P 361552-75-2P 361552-77-4P 361552-79-6P 361552-81-0P
361552-83-2P 361575-58-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-heterocyclyl amide compds. as 5-HT antagonists for treatment of 5-HT-mediated diseases such as central **nervous** system disorders, drug withdrawal symptom, schizophrenia, spinal code **injury**, and head **injury**)

IT 75-65-0, tert-Butyl alcohol, reactions 110-91-8, Morpholine, reactions 367-31-7, 4-Fluoro-1,2-benzenediamine **462-08-8**, 3-Aminopyridine 504-24-5, 4-Aminopyridine 591-54-8, 4-Aminopyrimidine 624-83-9, Methyl isocyanate 814-75-5, 2-Bromo-3-butanone 939-58-2, trans-2-Chlorocinnamic acid 940-62-5, (E)-3-(4-Chlorophenyl)acrylic acid 1068-57-1, Acetylhydrazine 1121-60-4, 2-Formylpyridine 1722-12-9, 2-Chloropyrimidine 1914-58-5, (E)-4-Phenyl-3-butenoic acid 2062-25-1, 3-[2-(Trifluoromethyl)phenyl]acrylic acid **2706-56-1**, 2-(2-Pyridyl)ethylamine 2759-28-6, 1-Benzylpiperazine 3529-82-6, 3-Nitrophenyl isothiocyanate **3731-52-0**, 3-Pyridinemethanamine 4110-35-4, 3,5-Dinitrobenzonitrile 4595-59-9, 5-Bromopyrimidine 5327-44-6, 3,5-Dinitroanisole 5720-06-9, 2-Methoxyphenylboronic acid 5873-89-2 6276-03-5, 9H-Fluorene-1-carboxylic acid 6952-67-6, 2-(3-Nitrophenyl)-1,3-dioxolane 13026-12-5, 3-(Naphthalen-1-yl)acrylic acid 13026-23-8, 3-(1,1'-Biphenyl-4-yl)acrylic acid 13331-27-6, 3-Nitrophenylboronic acid 14473-90-6, (E)-3-(3-Chlorophenyl)acrylic acid 16263-52-8, 3-Chloro-1,2-benzisoxazole 16642-92-5, (E)-3-(4-Trifluoromethylphenyl)acrylic acid 20010-99-5, 2-Aminomethylpyrazine 20595-44-2, (E)-3-(2,3-Dichlorophenyl)acrylic acid 20595-45-3, (E)-3-(2,4-Dichlorophenyl)acrylic acid 20826-04-4, 5-Bromonicotinic acid **21035-59-6 21630-48-8** 22280-56-4, 2-Chloro-3-methyl-5-nitropyridine 26177-43-5, 3-Nitrobenzylamine hydrochloride 33786-89-9, 3,5-Diaminochlorobenzene **36052-25-2**, 5-Aminonicotinic acid

methyl ester 59002-79-8, 6-Fluoro-9H-carbazole-1-carboxylic acid 63413-91-2, 3-Phenylthioacrylic acid 69491-59-4, 3-(5-Pyrimidinyl)aniline 83823-06-7, 6-Chloro-2H-chromene-3-carboxylic acid 89260-48-0 89640-55-1, 3-Iodo-4-methoxypyridine 89878-14-8, Diethyl(3-pyridyl)borane 99368-67-9, 2-Chloro-5-nitro-3-(trifluoromethyl)pyridine 112677-67-5, 3-(Imidazol-1-yl)aniline 112898-33-6, (E)-3-(2,5-Difluorophenyl)acrylic acid 123947-73-9, 7-Methoxy-2,3-dihydrobenz[b]oxepin-4-carboxylic acid 123947-74-0, 8-Methoxy-2,3-dihydrobenz[b]oxepin-4-carboxylic acid 129768-95-2 135616-29-4, 8,9-Dihydro-7H-benzocycloheptene-6-carboxylic acid 138830-47-4, 4-Methyl-1-(3-nitrophenyl)-1H-imidazole 147700-58-1, (E)-3-(3,4-Difluorophenyl)acrylic acid 153936-26-6 174603-37-3, (E)-3-(2-Chloro-4-fluorophenyl)acrylic acid 176032-78-3 **181633-42-1**, 3-Amino-6-(2-methyl-3-pyridyloxy)pyridine 206353-51-7, 2,3-Dihydrobenz[b]oxepin-4-carboxylic acid 312619-48-0, (E)-3-[2,5-Bis(trifluoromethyl)phenyl]acrylic acid 326476-49-7 333792-46-4, 3-(1,2-Dimethylimidazol-5-yl)aniline 333792-92-0, 3-Methyl-2-(trifluoromethyl)-1H-indole-7-carboxylic acid 333793-36-5, 3-(4,5-Dimethylimidazol-1-yl)aniline 361549-63-5 361549-97-5 361550-35-8 361550-60-9 361551-42-0 361551-53-3 361551-64-6 361551-84-0 361551-95-3 361551-98-6 361552-00-3 361552-08-1 361552-10-5 361552-12-7 361552-15-0 361552-32-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-heterocyclyl amide compds. as 5-HT antagonists for treatment of 5-HT-mediated diseases such as central **nervous** system disorders, drug withdrawal symptom, schizophrenia, spinal code **injury**, and head **injury**)

IT 6398-87-4P, 3-(1,3-Dioxolan-2-yl)aniline 10406-92-5P, 3-Cyano-5-nitroaniline **21626-42-6P 21630-51-3P** 55341-64-5P, 9H-Fluorene-1-carbonyl chloride 167897-26-9P 361549-59-9P 361549-62-4P 361549-64-6P 361549-65-7P 361549-66-8P 361549-67-9P 361549-68-0P 361549-69-1P 361549-70-4P 361549-71-5P 361549-72-6P 361549-73-7P 361549-74-8P 361549-75-9P 361549-76-0P 361549-80-6P 361549-81-7P 361549-82-8P 361549-83-9P 361549-84-0P 361549-85-1P 361549-86-2P 361549-87-3P 361549-88-4P 361549-89-5P 361549-90-8P 361549-91-9P 361549-92-0P 361549-93-1P 361549-94-2P 361549-95-3P **361549-96-4P** 361549-98-6P 361549-99-7P 361550-00-7P 361550-01-8P 361550-02-9P 361550-03-0P 361550-04-1P 361550-05-2P 361550-06-3P 361550-07-4P 361550-08-5P 361550-09-6P 361550-10-9P 361550-11-0P 361550-12-1P 361550-13-2P 361550-14-3P 361550-15-4P 361550-16-5P 361550-18-7P 361550-19-8P 361550-20-1P 361550-22-3P 361550-23-4P 361550-24-5P 361550-25-6P 361550-26-7P 361550-27-8P 361550-28-9P 361550-29-0P 361550-30-3P 361550-31-4P 361550-32-5P 361550-33-6P 361550-34-7P 361550-36-9P 361550-39-2P 361550-41-6P 361550-42-7P 361550-43-8P 361550-44-9P **361550-45-0P** 361550-46-1P 361551-84-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-heterocyclyl amide compds. as 5-HT antagonists for treatment of 5-HT-mediated diseases such as central **nervous** system disorders, drug withdrawal symptom, schizophrenia, spinal code **injury**, and head **injury**)

IT 62-55-5, Thioacetamide 74-88-4, Methyl iodide, reactions 99-09-2, 3-Nitroaniline 99-29-6, 2-Bromo-6-chloro-4-nitroaniline 99-61-6, 3-Nitrobenzaldehyde 99-81-0, 2-Bromo-1-(4-nitrophenyl)ethanone 103-82-2, Phenylacetic acid, reactions 288-13-1, Pyrazole 345-16-4, 5-Fluoro-2-hydroxybenzoic acid 350-46-9, 4-Fluoro-1-nitrobenzene 364-76-1, 4-Fluoro-3-nitroaniline 621-82-9, Cinnamic acid, reactions 1194-02-1, 4-Fluorobenzonitrile 1739-84-0, 1,2-Dimethylimidazole **3731-51-9**, 2-(Aminomethyl)pyridine 3752-25-8, 2-Chlorocinnamic acid 3819-88-3, 1-Fluoro-3-iodo-5-nitrobenzene 4548-45-2, 2-Chloro-5-nitropyridine 13889-98-0, 1-Acetylpiperazine 14432-12-3,

4-Amino-2-chloropyridine 18197-26-7 18437-64-4, tert-Butyl 3-nitrophenylcarbamate 24424-99-5, Di-tert-butyl dicarbonate 68621-88-5, tert-Butyl 3-aminophenylcarbamate
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-heterocyclyl amide compds. as 5-HT antagonists for treatment of 5-HT-mediated diseases such as central **nervous** system disorders, drug withdrawal symptom, schizophrenia, spinal cord **injury**, and head **injury**)

IT 704-04-1P, 5-Fluoro-2-methoxybenzamide 1008-95-3P, 4-(1,3-Oxazol-5-yl)aniline 1014-23-9P, 5-(4-Nitrophenyl)-1,3-oxazole 3463-30-7P, 1-(4-Nitrophenyl)-1H-pyrazole 3704-42-5P, 4-(4-Nitrophenyl)-1,3-thiazole 13140-76-6P, N-(3-Nitrophenyl)phenylacetamide 17635-45-9P, 4-(1H-Pyrazol-1-yl)aniline 23068-80-6P, 5-Chloro-2-methoxybenzamide 33786-93-5P, 3,5-Diaminobenzonitrile 33924-48-0P, Methyl 5-chloro-2-methoxybenzoate 38980-93-7P, 4-(4-Nitrophenyl)-1H-imidazole 55000-38-9P, N-(3-Nitrophenyl)cinnamide 55877-79-7P, 5-Chloro-2-methoxybenzonitrile 60759-10-6P, 4-(1,3-Thiazol-4-yl)aniline 85856-32-2P, N-(3-Aminophenyl)phenylacetamide 89250-16-8P, 4-(1-Methyl-1H-imidazol-4-yl)aniline 103298-41-5P, 1-Methyl-4-(4-nitrophenyl)-1H-imidazole 151793-20-3P, Methyl 5-fluoro-2-methoxybenzoate 186650-90-8P, 4-(4-Acetyl-1-piperazinyl)benzonitrile 189628-38-4P, 5-Fluoro-2-methoxybenzonitrile 219817-43-3P, 3-Bromo-5-chloronitrobenzene 332370-72-6P, tert-Butyl 4-fluoro-3-nitrophenylcarbamate 349433-63-2P, N-(4-Cyanophenyl)-2-chlorocinnamide 361548-78-9P 361548-79-0P 361548-80-3P, 5-(3-Methoxy-5-nitrophenyl)-1,2-dimethyl-1H-imidazole 361548-81-4P
361548-82-5P 361548-83-6P 361548-84-7P **361548-85-8P**
361548-86-9P 361548-87-0P 361548-88-1P 361548-89-2P 361548-90-5P
361548-91-6P 361548-92-7P 361548-93-8P 361548-94-9P 361548-95-0P
361548-96-1P 361548-97-2P 361548-98-3P 361548-99-4P 361549-00-0P
361549-01-1P 361549-02-2P 361549-03-3P 361549-04-4P 361549-05-5P
361549-06-6P 361549-07-7P 361549-08-8P 361549-09-9P 361549-10-2P
361549-11-3P 361549-12-4P 361549-13-5P 361549-14-6P 361549-15-7P
361549-16-8P 361549-17-9P 361549-18-0P 361549-19-1P 361549-20-4P
361549-21-5P 361549-22-6P 361549-23-7P 361549-24-8P 361549-25-9P
361549-26-0P **361549-28-2P 361549-29-3P**
361549-31-7P 361549-32-8P 361549-34-0P 361549-36-2P
361549-38-4P 361549-40-8P 361549-49-7P 361549-51-1P 361549-53-3P
361549-55-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-heterocyclyl amide compds. as 5-HT antagonists for treatment of 5-HT-mediated diseases such as central **nervous** system disorders, drug withdrawal symptom, schizophrenia, spinal cord **injury**, and head **injury**)

L11 ANSWER 12 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:668212 CAPLUS
DN 135:226999
TI Preparation of 2-azolylpyrrolidine or -piperidine derivatives having neurite outgrowth activity
IN Kato, Susumu; Ueno, Hiroshi; Kondo, Wataru
PA Japan Tobacco, Inc., Japan
SO Jpn. Kokai Tokkyo Koho, 81 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001247569	A2	20010911	JP 2000-236882	20000804
PRAI	JP 1999-228938	A	19990812		

JP 1999-375867 A 19991228

OS MARPAT 135:226999

IT **359802-97-4P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-azolylpyrrolidine or -piperidine derivs. having neurite outgrowth activity for treatment and/or prevention of **nerve injury** or neurodegenerative diseases)

RN 359802-97-4 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[1-[2-oxo-2-[[2-(3-pyridinyl)ethyl]amino]ethyl]-1H-benzimidazol-2-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **20173-24-4,** 3-(2-Aminoethyl)pyridine

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 2-azolylpyrrolidine or -piperidine derivs. having neurite outgrowth activity for treatment and/or prevention of **nerve injury** or neurodegenerative diseases)

RN 20173-24-4 CAPLUS

CN 3-Pyridineethanamine (9CI) (CA INDEX NAME)



IT **359804-16-3P 359804-17-4P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2-azolylpyrrolidine or -piperidine derivs. having neurite outgrowth activity for treatment and/or prevention of **nerve injury** or neurodegenerative diseases)

RN 359804-16-3 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[[2-hydroxy-5-(3-pyridinyl)pentyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 359804-17-4 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[[2-oxo-5-(3-pyridinyl)pentyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 359802-64-5P 359802-65-6P 359802-66-7P 359802-67-8P 359802-68-9P
359802-69-0P 359802-70-3P 359802-71-4P 359802-72-5P 359802-73-6P
359802-74-7P 359802-75-8P 359802-76-9P 359802-77-0P 359802-78-1P
359802-79-2P 359802-80-5P 359802-81-6P 359802-82-7P 359802-83-8P
359802-84-9P 359802-85-0P 359802-86-1P 359802-87-2P 359802-88-3P
359802-89-4P 359802-90-7P 359802-91-8P 359802-92-9P 359802-93-0P
359802-94-1P 359802-95-2P 359802-96-3P **359802-97-4P**
359802-98-5P 359802-99-6P 359803-00-2P 359803-01-3P 359803-02-4P
359803-03-5P 359803-04-6P 359803-05-7P 359803-06-8P 359803-07-9P
359803-08-0P 359803-09-1P 359803-10-4P 359803-11-5P 359803-13-7P
359803-14-8P 359803-16-0P 359803-17-1P 359803-19-3P 359803-20-6P
359803-22-8P 359803-23-9P 359803-25-1P 359803-26-2P 359803-28-4P
359803-29-5P 359803-30-8P 359803-31-9P 359803-33-1P 359803-34-2P
359803-37-5P 359803-39-7P 359803-40-0P 359803-42-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-azolylpyrrolidine or -piperidine derivs. having neurite outgrowth activity for treatment and/or prevention of **nerve injury** or neurodegenerative diseases)

IT 57-56-7, Semicarbazide 60-12-8, Phenethyl alcohol 61-54-1, Tryptamine 62-55-5, Thioacetamide 75-86-5, Acetone cyanohydrin 91-16-7, 1,2-Dimethoxybenzene 95-54-5, 1,2-Phenylenediamine, reactions 98-58-8, 4-Bromobenzenesulfonyl chloride 98-59-9, p-Toluenesulfonyl chloride 98-60-2, 4-Chlorobenzenesulfonyl chloride 98-74-8, 4-Nitrobenzenesulfonyl chloride 98-88-4, Benzoyl chloride 99-56-9, 4-Nitro-1,2-phenylenediamine 104-53-0, 3-Phenylpropionaldehyde 104-86-9, 4-Chlorobenzylamine 108-55-4, Glutaric anhydride 109-00-2, 3-Pyridinol 121-51-7, 3-Nitrobenzenesulfonyl chloride 137-07-5, 2-Aminothiophenol 143-33-9, Sodium cyanide 451-46-7, 4-Fluorobenzoic acid ethyl ester 501-53-1, Benzyloxycarbonyl chloride 535-75-1, DL-Pipecolic acid 609-36-9, Proline 637-59-2, 3-Phenylpropyl bromide 701-99-5, Phenoxyacetyl chloride 766-51-8, 2-Chloroanisole 779-89-5, 3-Trifluoromethylcinnamic acid 870-46-2, tert-Butoxycarbonylhydrazine 1123-25-7, 1-Methylcyclohexanecarboxylic acid 1138-80-3, N-Benzyloxycarbonylglycine 1467-70-5, 2-Oxo-2-(2-furanyl)acetic acid 1635-61-6, 5-Chloro-2-nitroaniline 1747-60-0, 2-Amino-6-methoxybenzothiazole 1802-16-0, 3-(3-Pyridyl)propionaldehyde 1939-99-7, Benzylsulfonyl chloride 2386-60-9, 1-Butanesulfonyl chloride 2859-67-8, 3-Pyridinepropanol 2955-88-6, 1-(2-Hydroxyethyl)pyrrolidine 3218-02-8, Cyclohexanemethanamine 5437-45-6, Bromoacetic acid benzyl ester 6555-30-2, 3-(4-Methoxyphenyl)butyric acid 7803-57-8, Hydrazine monohydrate 15542-27-5 18162-48-6, tert-Butyldimethylsilyl chloride **20173-24-4**, 3-(2-Aminoethyl)pyridine 20260-53-1, Nicotinoyl chloride hydrochloride 23095-31-0, 3,4-Dimethoxybenzenesulfonyl chloride 24424-99-5, Di-tert-butyl dicarbonate 32315-10-9, Triphosgene

34097-60-4, Methyl (phenylsulfonyl)acetate 43207-78-9 53440-12-3, 1,2,3,4-Tetrahydronaphthalene-2-carboxylic acid 61563-39-1 88755-16-2, 3,4,5-Trimethoxybenzoylformic acid 102153-64-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 2-azolylpyrrolidine or -piperidine derivs. having neurite outgrowth activity for treatment and/or prevention of **nerve injury** or neurodegenerative diseases)

IT 1145-15-9P 2270-20-4P, Benzenepentanoic acid 4378-55-6P 5680-83-1P 7021-11-6P 14064-13-2P, (1-Methylcyclohexyl)methanol 17270-50-7P, 3-Pyridinebutanoic acid 22952-43-8P 27678-09-7P, 3-Pyridinebutanenitrile 36107-06-9P 59433-50-0P 100618-82-4P
251096-94-3P 359803-43-3P 359803-45-5P 359803-46-6P 359803-48-8P
359803-51-3P 359803-55-7P 359803-58-0P 359803-61-5P 359803-69-3P
359803-71-7P 359803-73-9P 359803-75-1P 359803-81-9P 359803-84-2P
359803-86-4P 359803-88-6P 359803-89-7P 359803-91-1P 359803-93-3P
359803-94-4P 359803-96-6P 359803-97-7P 359803-99-9P 359804-00-5P
359804-03-8P 359804-04-9P 359804-05-0P 359804-06-1P 359804-07-2P
359804-08-3P 359804-09-4P 359804-10-7P 359804-11-8P 359804-12-9P
359804-13-0P 359804-14-1P 359804-15-2P **359804-16-3P**
359804-17-4P 359804-18-5P 359804-19-6P 359804-20-9P
359804-21-0P 359804-22-1P 359804-23-2P 359804-24-3P 359804-25-4P
359804-26-5P 359804-27-6P 359804-28-7P 359804-29-8P 359804-30-1P
359804-31-2P 359804-32-3P 359804-33-4P 359804-34-5P 359804-35-6P
359804-36-7P 359804-37-8P 359804-38-9P 359804-39-0P 359804-40-3P
359804-42-5P 359804-43-6P 359804-44-7P 359804-45-8P 359804-46-9P
359804-47-0P 359804-48-1P 359804-49-2P 359804-50-5P 359804-51-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2-azolylpyrrolidine or -piperidine derivs. having neurite outgrowth activity for treatment and/or prevention of **nerve injury** or neurodegenerative diseases)

L11 ANSWER 13 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:227511 CAPLUS
DN 132:260696
TI Use of TNF-α inhibitors for treating nerve root injury
IN Olmarker, Kjell; Rydevik, Bjorn
PA A+ Science Invest AB, Swed.
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000018409	A1	20000406	WO 1999-SE1671	19990923
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	SE 9803710	A	20000326	SE 1998-3710	19981029
	CA 2342200	AA	20000406	CA 1999-2342200	19990923
	AU 9964918	A1	20000417	AU 1999-64918	19990923
	AU 772036	B2	20040408		
	EP 1115405	A1	20010718	EP 1999-952857	19990923
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

	JP 2002525331	T2	20020813	JP 2000-571927	19990923
	NZ 510122	A	20030530	NZ 1999-510122	19990923
	RU 2234336	C2	20040820	RU 2001-111322	19990923
	US 2001027199	A1	20011004	US 2001-760810	20010117
	US 6635250	B2	20031021		
	US 2001027175	A1	20011004	US 2001-760811	20010117
	US 6649589	B1	20031118	US 2001-743852	20010117
	US 2001055594	A1	20011227	US 2001-826893	20010406
	US 2003039651	A1	20030227	US 2002-225237	20020822
PRAI	SE 1998-3276	A	19980925		
	SE 1998-3710	A	19981029		
	WO 1999-SE1671	W	19990923		
	US 2001-743852	A2	20010117		
	US 2001-826893	A2	20010406		

IT **60719-84-8**, Amrinone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TNF-α inhibitors for treating **nerve** root **injury**)
RN 60719-84-8 CAPLUS
CN [3,4'-Bipyridin]-6(1H)-one, 5-amino- (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT 50-35-1, Thalidomide 60-54-8, Tetracycline 60-54-8D, Tetracycline, derivs. 73-31-4, Melatonin 79-57-2, Oxytetracycline 564-25-0, Doxycycline 992-21-2, Lymecycline 2444-65-7 10118-90-8, Minocycline **60719-84-8**, Amrinone 70458-92-3, Pefloxacin 70458-96-7, Norfloxacin 74150-27-9, Pimobendan 81840-15-5, Vesnarinone 82419-36-1, Ofloxacin 85721-33-1, Ciprofloxacin 98079-51-7, Lomefloxacin 108319-06-8, Temafloxacin 112811-59-3, Gatifloxacin 170277-31-3, Infliximab 185243-69-0, Etanercept
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TNF-α inhibitors for treating **nerve** root **injury**)

L11 ANSWER 14 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1990:624878 CAPLUS
DN 113:224878
TI 21-Aminosteroids attenuate excitotoxic neuronal injury in cortical cell cultures
AU Monyer, Hannelore; Hartley, Dean M.; Choi, Dennis W.
CS Med. Cent., Stanford Univ., Stanford, CA, 94305, USA
SO Neuron (1990), 5(2), 121-6
CODEN: NERNET; ISSN: 0896-6273
DT Journal
LA English
IT **110101-65-0**, U 74500A **130590-09-9**, U 75412E
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(**nerve injury** induced by methylaspartate receptors

inhibition by)

RN 110101-65-0 CAPLUS

CN Pregna-1,4,9(11)-triene-3,20-dione, 21-[4-[3,6-bis(diethylamino)-2-pyridinyl]-1-piperazinyl]-16-methyl-, hydrochloride, (16α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 130590-09-9 CAPLUS

CN Pregna-1,4,9(11)-triene-3,20-dione, 21-[4-[3-(ethylamino)-2-pyridinyl]-1-piperazinyl]-16-methyl-, (16α)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 125173-73-1

CMF C33 H44 N4 O2

Absolute stereochemistry.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



IT **110101-65-0**, U 74500A 110101-67-2, U 74006F **130590-09-9**
, U 75412E
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(**nerve injury** induced by methylaspartate receptors inhibition by)

L11 ANSWER 15 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1989:567248 CAPLUS
DN 111:167248
TI 6-Aminonicotinamide selectivity causes necrosis in reactive astroglia cells in vivo. Preliminary morphological observations
AU Politis, M. J.
CS Dep. Biol., Univ. Saskatchewan, Saskatoon, SK, S7N 0W0, Can.
SO Journal of the Neurological Sciences (1989), 92(1), 71-9
CODEN: JNSCAG; ISSN: 0022-510X
DT Journal
LA English
IT **329-89-5**, 6-Aminonicotinamide
RL: BIOL (Biological study)
(astroglia toxicity from, in optic **nerve injury**)
RN 329-89-5 CAPLUS
CN 3-Pyridinecarboxamide, 6-amino- (9CI) (CA INDEX NAME)



IT **329-89-5**, 6-Aminonicotinamide
RL: BIOL (Biological study)
(astroglia toxicity from, in optic **nerve injury**)

L11 ANSWER 16 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1986:102388 CAPLUS
DN 104:102388
TI Neuromuscular toxicity of pyridostigmine bromide in the diaphragm, extensor digitorum longus, and soleus muscles of the rat
AU Hudson, C. Sue; Foster, Robert E.; Kahng, Myong W.
CS Dep. Pharmacol. Exp. Ther., Univ. Maryland, Baltimore, MD, 21201, USA
SO Fundamental and Applied Toxicology (1985), 5(6, Pt. 2), S260-S269
CODEN: FAATDF; ISSN: 0272-0590
DT Journal
LA English
AB The neuromuscular junctions from diaphragm, soleus, and extensor digitorum longus (EDL) muscles of male albino rats were assessed for morphol. alterations following acute (30-min) and subacute (2-day) exposure to pyridostigmine (I) [**155-97-5**]. These muscles were selected to compare the effects of the drug on muscles of different fiber type composition The diaphragm has approx. equal nos. of type I and type II fibers whereas the soleus and EDL possess primarily type I and type II fibers, resp. I was administered to each acute-exposure animal by a single s.c. injection of 0.36 mg/kg and to each subacute-exposure animal by a s.c. implanted osmotic minipump containing 10 mg/mL I. Both treatments resulted in whole blood cholinesterase (ChE) [9001-08-5] depression of .apprx.60-70%. Both acute and subacute exposures resulted in morphol. alteration of the neuromuscular junctions (NMJs) of all 3 muscles, although considerable variation in the extent of **damage** occurred even within individual NMJs. The most frequently observed presynaptic alterations were mitochondrial **damage** and partial withdrawal of **nerve** terminal branches (partial denervation). Postsynaptic changes included occasional rarefaction of mitochondrial matrices and disruption of the myofibrillar organization in small nos. of subjunctional sarcomeres. Evidently an acute or subacute exposure to I at a whole blood ChE depression of 60-70% results in similar alterations to the NMJs of 3 muscles with substantially different fiber type compns. Although the severity of the **damage** varies from fiber to fiber, the variability appears random and not related to a specific fiber type or dosage regimen.

L11 ANSWER 17 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1985:517629 CAPLUS
DN 103:117629
TI Comparison of the ultrastructural myopathy induced by anticholinesterase agents at the end plates of rat soleus and extensor muscles
AU Meshul, Charles K.; Boyne, Alan F.; Deshpande, Sharad S.; Albuquerque, Edson X.
CS Sch. Med., Univ. Maryland, Baltimore, MD, 21201, USA
SO Experimental Neurology (1985), 89(1), 96-114
CODEN: EXNEAC; ISSN: 0014-4886
DT Journal
LA English

AB Rats were treated with single s.c. injections of the irrerversible acetylcholinesterase (AChE) [9000-81-1] inhibitors, sarin [107-44-8] (90-100 μg/kg) or soman [96-64-0] (55 μ/kg), and with chronic doses of the reversible carbamate inhibitor, pyridostigmine [**155-97-5**]. In surviving animals with severe behavioral symptoms, the end-plate regions of the slow-twitch soleus and the fast-twitch extensor digitorum longus muscles were examined, using the electron microscope. Within 30 min, sarin administration caused a recognizable subjunctional myopathy. The progress of morphol. **damage** was followed for 7 days, during which time the occurrence of **damage** diminished. The initial swelling of subjunctional organelles and vacuole generation progressed to the point where **nerve** terminals and attached postjunctional folds were fited away from the muscle surface. This appeared to be caused by a combination of enlarging vacuoles and insertion of Schwann and macrophage cells into the legions, and was followed by degeneration of the postjunctional folds. A new component of anti-AChE myopathy was recognized: progressive swelling of chromatin in subjunctional muscle nuclei. The soleus muscle was considerably more sensitive to these effects than the extensor muscle. Soman had a much less prominent ultrastructural effect on the muscle end plates. Chronic pyridostigmine treatment had effects similar to those of a single sarin injection on the soleus as well as a pronounced effect on the extensor muscle.

L11 ANSWER 18 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1978:558115 CAPLUS
DN 89:158115
TI Experimental spongy degeneration of the white matter induced by 6-aminonicotinamide intoxication
AU Miyoshi, Koho; Takauchi, Shigeru; Hayashi, Saburo
CS Dep. Neuropsychiatry, Hyogo Med. Coll., Nishinomiya, Japan
SO Folia Psychiatrica et Neurologica Japonica (1978), 32(2), 253-61
CODEN: FPNJAG; ISSN: 0015-5721
DT Journal
LA English
IT **329-89-5**
RL: PRP (Properties)
(**nervous** system white matter **damage** by)
RN 329-89-5 CAPLUS
CN 3-Pyridinecarboxamide, 6-amino- (9CI) (CA INDEX NAME)



AB Neuropathol. examination of young rats treated with 6-aminonicotinamide (I) [**329-89-5**] (10 mg/kg, i.p.) showed spongy and degenerative change of white and gray matter of the central **nervous** system. Edematous and spongy degeneration was observed in the corpus callosum, cerebellar cortex, and optic **nerves**. Ultrastructural changes of myelin sheath were initially observed in the vicinity of severely **damaged** oligodendrocytes. Vacuoles in the myelin were formed by splitting between the innermost myelin lamellae and axon.
IT **329-89-5**
RL: PRP (Properties)
(**nervous** system white matter **damage** by)

L11 ANSWER 19 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1974:56229 CAPLUS
DN 80:56229
TI Ultrastructure of glial and axonal changes in the optic nerve of the rat induced by 6-aminonicotinamide
AU Meyer-Koenig, E.
CS Abt. Neuroanat., Univ. Krankenhaus Hamburg-Eppendorf, Hamburg, Fed. Rep. Ger.
SO Acta Neuropathologica (1973), 26(2), 115-26
CODEN: ANPTAL; ISSN: 0001-6322
DT Journal
LA German
IT **329-89-5**
RL: BIOL (Biological study)
(optic **nerve damage** from)
RN 329-89-5 CAPLUS
CN 3-Pyridinecarboxamide, 6-amino- (9CI) (CA INDEX NAME)



IT **98-92-0**
RL: BIOL (Biological study)
(optic **nerve damage** from aminonicotinamide in relation to)
RN 98-92-0 CAPLUS
CN 3-Pyridinecarboxamide (9CI) (CA INDEX NAME)



IT **329-89-5**
RL: BIOL (Biological study)
(optic **nerve damage** from)
IT **98-92-0**
RL: BIOL (Biological study)
(optic **nerve damage** from aminonicotinamide in relation to)

L11 ANSWER 20 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1971:96781 CAPLUS
DN 74:96781
TI Evidence against mediation of ocular lesion by exposure, histamine, or serotonin following fifth nerve injury in rats
AU Moses, Robert A.; Holekamp, Timothy L. R.
CS Sch. Med., Washington Univ., St. Louis, MO, USA
SO American Journal of Ophthalmology (1971), 71(2), 574-7
CODEN: AJOPAA; ISSN: 0002-9394
DT Journal
LA English
IT **91-81-6**

RL: BIOL (Biological study)
(eye lesions after fifth **nerve injury** in relation to)

RN 91-81-6 CAPLUS
CN 1,2-Ethanediamine, N,N-dimethyl-N'-(phenylmethyl)-N'-2-pyridinyl- (9CI) (CA INDEX NAME)



IT 50-67-9, biological studies 51-45-6, biological studies **91-81-6** 129-03-3 7424-00-2
RL: BIOL (Biological study)
(eye lesions after fifth **nerve injury** in relation to)

L11 ANSWER 21 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1959:46815 CAPLUS
DN 53:46815
OREF 53:8440e-f
TI 6-Aminonicotinamide and acute degenerative changes in the central nervous system
AU Sternberg, Stephen S.; Philips, Frederick S.
CS Sloan-Kettering Inst., New York, NY
SO Science (Washington, DC, United States) (1958), 127, 644-5
CODEN: SCIEAS; ISSN: 0036-8075
DT Journal
LA Unavailable
IT **329-89-5**, Nicotinamide, 6-amino-
(**nervous**-system **damage** by)
RN 329-89-5 CAPLUS
CN 3-Pyridinecarboxamide, 6-amino- (9CI) (CA INDEX NAME)



IT **329-89-5**, Nicotinamide, 6-amino-
(**nervous**-system **damage** by)